WO2004072031A2 - Phenylacetamides and their use as glucokinase modulators - Google Patents

Phenylacetamides and their use as glucokinase modulators Download PDF

Info

Publication number
WO2004072031A2
WO2004072031A2 PCT/US2004/003968 US2004003968W WO2004072031A2 WO 2004072031 A2 WO2004072031 A2 WO 2004072031A2 US 2004003968 W US2004003968 W US 2004003968W WO 2004072031 A2 WO2004072031 A2 WO 2004072031A2
Authority
WO
WIPO (PCT)
Prior art keywords
thiazol
tetrahydropyran
ylpropionamide
tefrahydropyran
methanesulfonylphenyl
Prior art date
Application number
PCT/US2004/003968
Other languages
French (fr)
Other versions
WO2004072031A3 (en
WO2004072031A8 (en
Inventor
Matthew Colin Thor Fyfe
Lisa Sarah Gardner
Masao Nawano
Martin James Procter
Chrystelle Marie Rasamison
Karen Lesley Schofield
Vilasben Kanji Shah
Kosuke Yasuda
Original Assignee
Prosidion Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN200480009651.1A priority Critical patent/CN1809561B/en
Priority to EA200501095A priority patent/EA012700B1/en
Priority to SI200430768T priority patent/SI1594867T1/en
Priority to NZ541759A priority patent/NZ541759A/en
Priority to JP2006503482A priority patent/JP4757188B2/en
Priority to DK04707845T priority patent/DK1594867T3/en
Priority to KR1020057014855A priority patent/KR101120916B1/en
Application filed by Prosidion Limited filed Critical Prosidion Limited
Priority to CA002515670A priority patent/CA2515670A1/en
Priority to DE602004012969T priority patent/DE602004012969T2/en
Priority to EP04707845A priority patent/EP1594867B1/en
Priority to MXPA05008406A priority patent/MXPA05008406A/en
Priority to BR0407139-5A priority patent/BRPI0407139A/en
Priority to AU2004212500A priority patent/AU2004212500B2/en
Publication of WO2004072031A2 publication Critical patent/WO2004072031A2/en
Publication of WO2004072031A3 publication Critical patent/WO2004072031A3/en
Priority to IL169954A priority patent/IL169954A/en
Priority to HR20050687A priority patent/HRP20050687A2/en
Priority to NO20053742A priority patent/NO20053742L/en
Publication of WO2004072031A8 publication Critical patent/WO2004072031A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Definitions

  • the present invention is directed to tri(cyclo) substituted amide compounds.
  • the present invention is directed to amide compounds substituted i) at the carbonyl carbon with an ethyl/ethenyl attached to a phenyl ring and an aryl/heteroaryl/heterocyclic ring, and ii) at the amino with a nitrogen bearing heteroaryl ring, which are modulators of glucokinase and are useful in the prophylactic or therapeutic treatment of hyperglycemia and type II diabetes.
  • GK Glucokinase
  • WO2003095438 published after the priority date ofthe present application, describes N-heteroaryl phenylacetamides and related compounds as GK activators for the treatment of type II diabetes.
  • U.S. Patent No. 6,610,846 describes the preparation of cycloalkylheteroaryl propionamides as GK activators.
  • International Patent Publication No. WO2003000262 describes vinyl phenyl GK activators, hitemational Patent Publication No. O2003000267 describes aminonicotinate derivatives as GK modulators.
  • International Patent Publication No. WO2003015774 published after the priority date ofthe present application, describes compounds as GK modulators.
  • WO2003047626 published after the priority date ofthe present application, describes the use of a GK activator in combination with a glucagon antagonist for treating type II diabetes
  • hitemational Patent Publication No. WO2003055482 published after the priority date ofthe present application
  • amide derivatives as GK activators
  • hitemational Patent Publication No. WO2003080585 published after the priority date ofthe present application
  • hitemational Patent Publication No. WO2003097824 published after the priority date ofthe present application, describes human liver GK crystals and their used for structure-based drug design.
  • International Patent Publication No. WO2004002481 published after the priority date ofthe present application, discloses arylcarbonyl derivatives as GK activators.
  • the present invention is directed to a compound of Formula (I):
  • Q is an aryl, a 5- or 6-membered heteroaryl, or a 4-8-membered heterocyclic ring;
  • R and R each independently are hydrogen, hydroxy, halogen, cyano, nitro, vinyl, ethynyl, methoxy, OCF n H 3 _ n , -N(C 0 - 4 alkyl)(C 0 - 4 alkyl), CHO, or C 1-2 alkyl optionally substituted with 1-5 independent halogen, hydroxy, cyano, methoxy, -N(C 0 - 2 alkyl)(Co_ 2 alkyl), SOCH 3 , or SO 2 CH 3 substituents; or R 1 andR 2 together form a carbocyclic or heterocyclic ring; or R 1 and R 2 may be taken together to represent an oxygen atom attached to the ring via a double bond;
  • R 3 and R 4 each independently are hydrogen, halogen, OCF n H _ n , methoxy, CO 2 R 77 , cyano, nitro, CHO, CONR 99 R 100 , CON(OCH 3 )CH 3 , or C 1-2 alkyl, heteroaryl, or C _ 7 cycloalkyl optionally substituted with 1-5 independent halogen, hydroxy, cyano, methoxy, -NHCO 2 CH 3 , or -N(C 0 - 2 alkyl)(Co_ 2 alkyl) substituents; or R 3 and R 4 together form a 5-8-membered aromatic, heteroaromatic, carbocyclic, or heterocyclic ring;
  • R 7 and R 77 each independently are hydrogen, or C 1-4 alkyl group, C 2-4 alkenyl group, C 2-4 alkynyl group, C -7 cycloalkyl group, aryl group, heteroaryl group, or 4—7- membered heterocyclic group, wherein any group optionally is substituted with 1-6 independent halogen, cyano, nitro, hydroxy, C ⁇ _ 2 alkoxy, -N(Co- 2 alkyl)(Co- 2 alkyl), C 1 _ 2 alkyl, C 3 - 7 cycloalkyl, 4-7 -membered heterocyclic ring, CF ⁇ H 3 _ n , aryl, heteroaryl, CO 2 H, -COC ⁇ alkyl, -CON(C 0 _ 2 alkyl)(Co- 2 alkyl), SOCH 3 , SO 2 CH 3 , or -S ⁇ 2N(Co-2alkyl)(C 0 - 2 alkyl) substituent
  • R 8 is C ⁇ ancyl group, C 2- alkenyl group, C 2 - alkynyl group, C 3- cycloalkyl group, aryl group, heteroaryl group, or 4-7-membered heterocyclic group, wherein any group optionally is substituted with 1-6 independent halogen, cyano, nitro, hydroxy, - ⁇ alkoxy, -N(Co_ 2 alkyl)(C 0 _ 2 a ⁇ kyl), C ⁇ _ 2 alkyl, C 3 _- 7 cycloalkyl, 4-7- membered heterocyclic ring, CF n H 3 _ n , aryl, heteroaryl, CO 2 H, CO - ⁇ alkyl, -CON(C 0 _ 2 alkyl)(C 0 _ 2 alkyl), SOCH 3 , SO 2 CH 3 , or -SO 2 N(Co- 2 alkyl)(C 0 _ 2 alkyl) substituents;
  • R 9 , R 10 , R 99 , and R 100 each independently are hydrogen, or C 1-4 alkyl group, C 3-7 cycloalkyl group, aryl group, heteroaryl group, or 4-7-membered heterocyclic group, wherein any group optionally is substituted with 1-6 independent halogen, cyano, nitro, hydroxy, C 1--2 alkoxy, -N(CQ- 2 alkyl)(Co- 2 alkyl), C 1--2 alkyl, C 3 _ 7 cycloalkyl, 4-7-membered heterocyclic ring, CF n H 3 _ n , aryl, heteroaryl, COC ⁇ alkyl, -CON(C 0 - 2 alkyl)(Co_ 2 alkyl), SOCH 3 , SO 2 CH 3 , or-SO 2 N(C 0 _ 2 alkyl)(C 0 _ 2 alkyl) substituents; or R 9 and R 10 or R 99 and R 100 together form a
  • the carbon atom linking the aryl ring and Q-bearing sidechain to the carbonyl carbon is a chiral centre. Accordingly, the compound may be present either as a racemate, or as a single enantiomer in the (R)- or (S)-configuration.
  • the (R)-enantiomers are prefe ⁇ ed.
  • T completes a 5- or 6-membered heteroaryl ring which is unsubstituted or monosubstituted by halogen, methoxy, CO 2 -Co -4 alkyl, cyano, nitro, CONH 2 , CONH- C 1-4 alkyl, or C 1-2 alkyl optionally monosubstituted with methoxy or -NH(C 0 - 2 alkyl);
  • R 5 and R 6 each independently are hydrogen, hydroxy, halogen, cyano, nitro, CO 2 -C 1-4 alkyl, S-C 1-4 alkyl, S-perfluoroC 1-4 alkyl, SO-C 1-4 alkyl, SO 2 -C 1-4 alkyl, SO 2 - perfluoroC 1- alkyl, SO 2 NH 2 , NH 2 , C 1- alkyl, perfluoroC 1- alkyl, C 1- alkoxy or perfluoroC 1-4 alkoxy; and m is 0; then the dotted line together with the solid line must form a double bond.
  • the present invention is directed to a compound represented by Formula (la):
  • the present invention is directed to a compound represented by Fonnula (la), or a pharmaceutically acceptable salt thereof, wherein: Q is an aryl.
  • the present invention is directed to a compound represented by Formula (la), or a pharmaceutically acceptable salt thereof, wherein Q is a 5- or 6-membered heteroaryl ring.
  • the present invention is directed to a compound represented by Formula (la), or a pharmaceutically acceptable salt thereof, wherein Q is a thienyl, furyl, thiazolyl, or pyridyl ring.
  • the present invention is directed to a compound represented by Formula (la), or a pharmaceutically acceptable salt thereof, wherein Q is a 4-8-membered heterocyclic ring.
  • the present invention is directed to a compound represented by Formula (la), or a pharmaceutically acceptable salt thereof, wherein Q is tetrahydropyranyl, piperidinyl, tetrahydrothiopyranyl, 1-oxo- tetrahydrothiopyranyl or 1,1-dioxo-tetrahydrothiopyranyl.
  • Q is tetrahydropyranyl, piperidinyl, tetrahydrothiopyranyl, 1-oxo- tetrahydrothiopyranyl or 1,1-dioxo-tetrahydrothiopyranyl.
  • the present invention is directed to a compound represented by Formula (lb):
  • the present invention is directed to a compound represented by Fonnula (lb), or a pharmaceutically acceptable salt thereof, wherein: Q is a thienyl, furyl, thiazolyl, or pyridyl ring.
  • the present invention is directed to a compound represented by Formula (lb), or a pharmaceutically acceptable salt thereof, wherein: Q is a 4-8-membered heterocyclic ring.
  • the present invention is directed to a compound represented by Formula (lb), or a pharmaceutically acceptable salt thereof, wherein: Q is tetrahydropyranyl, piperidinyl, tefrahydrothiopyranyl, 1-oxo- tetrahydrothiopyranyl, or 1,1-dioxo-tetrahydrothiopyranyl.
  • the molecular weight ofthe compounds of formula (I) is preferably less than 800, more preferably less than 600, most preferably less than 500.
  • Q is preferably 2-furyl, 2-thienyl, tetrahydropyranyl, tetrahydrothiopyranyl, 1-oxo-tetrahydrothiopyranyl, or 1,1-dioxo- tetrahydrothiopyranyl; more preferably 4-tetrahydropyranyl or 4- tetrahydrothiopyranyl; most preferably 4-tetrahydropyranyl.
  • Q When Q is a heteroaryl or heterocyclic group it is preferably linked to the - (CH 2 ) m - group through a carbon atom. When Q is a heteroaryl group it preferably does not have a substituent R 1 or R 2 other than hydrogen at a position adjacent to point of attachment to the -(CH 2 ) m - group.
  • 2-thiazolyl and R 3 is 5-fluoro and R 4 is hydrogen; or 2-pyrazinyl and R 3 and R 4 are hydrogen; especially preferred is 2-thiazolyl where R 3 is 5-fluoro and R 4 is hydrogen.
  • R 1 and R 9 are preferably hydrogen.
  • R 3 and R are preferably independently selected from hydrogen, halogen, and methyl, more preferably R 3 and R are independently selected from hydrogen, fluoro, and methyl.
  • R 3 is preferably hydrogen or halogen; more preferably hydrogen, fluoro, chloro or bromo; even more preferably hydrogen, fluoro, or chloro; most preferably hydrogen or fluoro.
  • R 4 is preferably hydrogen, halogen, or methyl; more preferably hydrogen or methyl.
  • R 5 and R 6 are preferably not both hydrogen.
  • R 5 is preferably CF 3 , SOR 8 , SO 2 R 8 , SO 2 NR 9 R 10 , NHSO 2 R 8 , or triazolyl; more preferably SOR 8 , SO 2 R 8 , or SO 2 NR 9 R 10 ; most preferably SO 2 R 8 or SO 2 NR 9 R 10 , especially SO 2 R 8 .
  • R 5 is SO 2 C 3 _ cycloalkyl, especially SO 2 cyclopropyl.
  • R 6 is preferably hydrogen, chloro, fluoro, or trifluoromethyl; more preferably hydrogen.
  • R 7 , R 77 , and R 8 are preferably C ⁇ -4 alkyl, C 3 _ 7 cycloalkyl, heteroaryl, or 4-7-membered heterocyclic group; more preferably Ci_ 3 alkyl, 4-6-membered heterocyclic group, or C 3 _ 5 cycloalkyl; most preferably methyl, ethyl, ra-propyl, cyclopropyl, cyclobutyl, oxetanyl, or tetrahydrofuryl, and especially methyl, ethyl, w-propyl, cyclopropyl, or cyclobutyl.
  • R is preferably C 1-3 alkyl, or C ⁇ cycloalkyl.
  • R is preferably C 3 - cycloalkyl, especially cyclopropyl.
  • R 7 is preferably not hydrogen.
  • R 9 and R 10 are preferably independently Co ⁇ alkyl e.g. one of R 9 and R 10 is hydrogen and the other is ethyl, or combine to form a 4-8- membered heterocyclic ring. R 9 and R 10 are preferably not both hydrogen.
  • R 99 and R 100 are preferably Co ⁇ alkyl.
  • m is preferably 0.
  • n is preferably 2 or 3.
  • a prefe ⁇ ed group of compounds are compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein:
  • Q is 4-tetrahydropyranyl
  • R and R are hydrogen
  • R 3 and R 4 each independently are hydrogen or fluoro
  • R 5 is SO 2 R 8 , or SO 2 NR 9 R 10 ;
  • R 6 is hydrogen;
  • R is a C -5 cycloalkyl group or a 4-6-membered heterocyclic group, and, in addition, when the dotted line together with the solid line forms a double bond R 8 may be a d-salkyl group;
  • R 9 and R 10 are independently C ⁇ ⁇ alkyl, provided that R 9 and R 10 are not both hydrogen; m is 0; and the dotted line together with the solid line forms an optional double bond, and ⁇ indicates that the double bond has the (E)-configuration.
  • a more preferred group of compounds are compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein:
  • Q is 4-tetrahydropyranyl
  • R and R are hydrogen
  • R 3 and R 4 each independently are hydrogen or fluoro
  • R 5 is SO 2 R 8 ;
  • R 6 is hydrogen
  • R is a C 3 _ 5 cycloalkyl group and, in addition, when the dotted line together with the solid line forms a double bond R 8 may be a C 1-3 alkyl group; m is 0; and the dotted line together with the solid line forms an optional double bond, and ⁇ indicates that the double bond has the (E)-configuration.
  • preferred compounds of this invention include those in which several or each variable in Formula (I) is selected from the preferred, more prefe ⁇ ed, most prefe ⁇ ed, especially or particularly listed groups for each variable. Therefore, this invention is intended to include all combinations of preferred, more prefe ⁇ ed, most prefe ⁇ ed, especially and particularly listed groups.
  • alkyl as well as other groups having the prefix “alk” such as, for example, alkoxy, alkanyl, alkenyl, alkynyl, and the like, means carbon chains which may be linear or branched or combinations thereof. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec- and tert-butyl, pentyl, hexyl, heptyl and the like. "Alkenyl”, “alkynyl” and other like terms include carbon chains having at least one unsaturated carbon-carbon bond.
  • Co -4 alkyl is used to mean an alkyl having 0-4 carbons - that is, 0, 1, 2, 3, or 4 carbons in a straight or branched configuration.
  • An alkyl having no carbon is hydrogen when the alkyl is a terminal group.
  • An alkyl having no carbon is a direct bond when the alkyl is a bridging (connecting) group.
  • cycloalkyl and “carbocyclic ring” mean carbocycles containing no heteroatoms, and include mono-, bi-, and tricyclic saturated carbocycles, as well as fused and bridged systems.
  • fused ring systems can include one ring that is partially or fully unsaturated, such as a benzene ring, to form fused ring systems, such as benzofused carbocycles.
  • Cycloalkyl includes such fused ring systems as spirofused ring systems.
  • cycloalkyl and carbocyclic rings include C 3-8 cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and decahydronaphthalene, adamantane, indanyl, 1,2,3,4-tetrahydronaphthalene and the like.
  • halogen includes fluorine, chlorine, bromine, and iodine atoms.
  • aryl includes, for example, phenyl and naphthyl.
  • heterocyclic ring includes 4-8-membered saturated rings containing one or two heteroatoms chosen from oxygen, sulfur, and nitrogen. The heteroatoms are not directly attached to one another.
  • heterocyclic rings include oxetane, tetrahydrofuran, tetrahydropyran, oxepane, oxocane, thietane, tetrahydrothiophene, tetrahydrotliiopyran, thiepane, thiocane, azetidine, pyrrolidine, piperidine, azepane, azocane, [l,3]dioxane, oxazolidine, piperazine, and the like.
  • heterocyclic rings include the oxidised forms ofthe sulfur-containing rings.
  • tetrahydrothiophene 1-oxide, tetrahydrothiophene 1,1 -dioxide, tetrahydrothiopyran 1-oxide, and tetrahydrothiopyran 1,1-dioxide are also considered to be heterocyclic rings.
  • heteroaryl includes 5- or 6-membered heteroaryl rings containing 1-4 heteroatoms chosen from oxygen, sulfur, and nitrogen.
  • heteroaryl rings are furyl, thienyl, py ⁇ olyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl.
  • the above formulas are shown without a definitive stereochemistry at certain positions.
  • the present invention includes all stereoisomers (e.g. geometric isomers, optical isomers, diastereoisomers, etc.) and pharmaceutically acceptable salts thereof, except where specifically drawn or stated otherwise. Further, mixtures of stereoisomers as well as isolated specific stereoisomers are also included, except where specifically drawn or stated otherwise.
  • stereoisomers e.g. geometric isomers, optical isomers, diastereoisomers, etc.
  • pharmaceutically acceptable salts thereof e.g. geometric isomers, optical isomers, diastereoisomers, etc.
  • mixtures of stereoisomers as well as isolated specific stereoisomers are also included, except where specifically drawn or stated otherwise.
  • the products of such procedures can be a mixture of stereoisomers.
  • the present invention includes any possible tautomers and pharmaceutically acceptable salts thereof, and mixtures thereof, except where specifically drawn or stated otherwise.
  • the compound ofthe above formulas and pharmaceutically acceptable salts thereof exist in the form of solvates or polymorphic forms
  • the present invention includes any possible solvates and polymorphic forms.
  • a type of a solvent that forms the solvate is not particularly limited so long as the solvent is pharmacologically acceptable. For example, water, ethanol, propanol, acetone or the like can be used.
  • the compounds of Formula (I) are intended for pharmaceutical use they are preferably provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure, especially at least 98% pure (% are on a weight for weight basis).
  • the invention also encompasses a pharmaceutical composition that is comprised of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.
  • composition is comprised of a pharmaceutically acceptable ca ⁇ ier and a non-toxic therapeutically effective amount of a compound of Formula (I) as described above, or a pharmaceutically acceptable salt thereof.
  • the invention encompasses a pharmaceutical composition for the prophylaxis or treatment of hyperglycemia and diabetes by the activation of GK, comprising a phannaceutically acceptable carrier and a non-toxic therapeutically effective amount of compound of Formula (I) as described above, or a pharmaceutically acceptable salt thereof.
  • the invention also provides the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof as a pharmaceutical.
  • the compounds and compositions ofthe present invention are effective for treating hyperglycemia in mammals such as, for example, humans.
  • the invention also provides a method of prophylactic or therapeutic treatment of a condition where activation of GK is desirable comprising a step of administering an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
  • the invention also provides a method of prophylactic or therapeutic treatment of hyperglycemia or diabetes comprising a step of administering an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
  • the invention also provides a method of prevention of diabetes in a human demonstrating pre-diabetic hyperglycemia or impaired glucose tolerance comprising a step of administering an effective prophylactic amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
  • the invention also provides the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as a GK activator.
  • the invention also provides the use of a compound of Fonnula (I), or a pharmaceutically acceptable salt thereof, for the prophylactic or therapeutic treatment of hyperglycemia or diabetes.
  • the invention also provides the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the prevention of diabetes in a human demonstrating pre-diabetic hyperglycemia or impaired glucose tolerance.
  • the invention also provides the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the activation of GK.
  • the invention also provides the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prophylactic or therapeutic treatment of hyperglycemia or diabetes.
  • the invention also provides the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention of diabetes in a human demonstrating pre-diabetic hyperglycemia or impaired glucose tolerance.
  • the compounds and compositions ofthe present invention may be optionally employed in combination with one or more other anti-diabetic agents or anti- hyperglycemic agents, which include, for example, sulfonylureas (e.g. glyburide, glirnepiride, glipyride, glipizide, chlorpropamide, gliclazide, glisoxepid, acetohexamide, glibornuride, tolbutamide, tolazamide, carbutamide, gliquidone, glyhexamide, phenbutamide, tolcyclamide, etc.), biguanides (e.g.
  • sulfonylureas e.g. glyburide, glirnepiride, glipyride, glipizide, chlorpropamide, gliclazide, glisoxepid, acetohexamide, glibornuride, tolbutamide, tolazamide, carbutamide, gliquid
  • glucagon antagonists e.g. a peptide or non-peptide glucagon antagonist
  • glucosidase inhibitors e.g. acarbose, miglitol, etc.
  • insulin secetagogues e.g. insulin sensitizers (e.g. troglitazone, rosightazone, pioglitazone, etc.) and the like; or anti-obesity agents (e.g. sibutramine, orlistat, etc.) and the like.
  • anti-obesity agents e.g. sibutramine, orlistat, etc.
  • the compounds and compositions ofthe present invention and the other anti-diabetic agents or anti-hyperglycemic agents may be administered simultaneously, sequentially or separately.
  • salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids.
  • pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases.
  • Salts derived from such inorganic bases include aluminum, ammonium, calcium, cupric, cuprous, ferric, fe ⁇ ous, lithium, magnesium, manganic, manganous, potassium, sodium, zinc and the like salts. Particularly prefe ⁇ ed are the ammonium, calcium, magnesium, potassium and sodium salts.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, as well as cyclic amines and substituted amines such as naturally occurring and synthetic amines.
  • Other phannaceutically acceptable organic non-toxic bases from which salts can be formed include, for example, arginine, betaine, caffeine, choline, N',N'-dibenzylethylenediamine, diethylamine, 2- diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N- ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the
  • the compound ofthe present invention When the compound ofthe present invention is basic, its co ⁇ esponding salt can be conveniently prepared from phannaceutically acceptable non-toxic acids, including inorganic and organic acids.
  • Such acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like.
  • Particularly prefe ⁇ ed are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, methanesulfonic, and tartaric acids.
  • compositions ofthe present invention comprise a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as an active ingredient, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants.
  • the compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, as well as administration through inhaling, although the most suitable route in any given case will depend on the particular host, and nature and severity ofthe conditions for which the active ingredient is being administered.
  • the pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any ofthe methods well known in the art of pharmacy.
  • the pharmaceutical compositions according to the invention are preferably adapted for oral administration.
  • the compounds of Formula (I), or pharmaceutically acceptable salts thereof, of this invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional phannaceutical compounding techniques.
  • the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g. oral or parenteral (including intravenous).
  • the pharmaceutical compositions ofthe present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount ofthe active ingredient.
  • compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion, or as a water-in-oil liquid emulsion.
  • the compound represented by Fonnula (I), or a phannaceutically acceptable salt thereof may also be administered by controlled release means and/or delivery devices.
  • the compositions may be prepared by any ofthe methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.
  • compositions of this invention may include a pharmaceutically acceptable carrier and a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
  • the compounds of Formula (I), or pharmaceutically acceptable salts thereof, can also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds.
  • compositions of this invention include a phannaceutically acceptable liposomal formulation containing a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • the pharmaceutical carrier employed can be, for example, a solid, liquid, or gas.
  • solid carriers include lactose, te ⁇ a alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid.
  • liquid ca ⁇ iers are sugar syrup, peanut oil, olive oil, and water.
  • gaseous carriers include carbon dioxide and nitrogen.
  • any convenient phannaceutical media may be employed.
  • water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like may be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used to form oral solid preparations such as powders, capsules and tablets.
  • carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used to form oral solid preparations such as powders, capsules and tablets.
  • tablets and capsules are the prefe ⁇ ed oral dosage units whereby solid phannaceutical ca ⁇ iers are employed.
  • tablets may be coated by standard aqueous or nonaqueous techniques.
  • a tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants.
  • Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent or other such excipient.
  • excipients may be, for example, inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, com starch, or alginic acid; binding agents, for example, starch, gelatin or acacia; and lubricating agents, for example, magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer time.
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be used.
  • the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin.
  • the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
  • Molded tablets may be made by molding in a suitable machine, a mixture ofthe powdered compound moistened with an inert liquid diluent.
  • Each tablet preferably contains from about 0.05mg to about 5g ofthe active ingredient and each cachet or capsule preferably containing from about 0.05mg to about 5g ofthe active ingredient.
  • a formulation intended for the oral administration to humans may contain from about 0.5mg to about 5g of active agent, compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent ofthe total composition.
  • Unit dosage forms will generally contain between from about lmg to about 2g ofthe active ingredient, typically 25mg, 50mg, lOOmg, 200mg, 300mg, 400mg, 500mg, 600mg, 800mg, or lOOOmg.
  • compositions ofthe present invention suitable for parenteral administration may be prepared as solutions or suspensions ofthe active compounds in water.
  • a suitable surfactant can be included such as, for example, hydroxypropylcellulose.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.
  • compositions ofthe present invention suitable for injectable use include sterile aqueous solutions or dispersions.
  • the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions.
  • the final injectable form must be sterile and must be effectively fluid for easy syringability.
  • the pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.
  • compositions ofthe present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder, or the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a compound of Formula (I), or a pharmaceutically acceptable salt thereof, via conventional processing methods. As an example, a cream or ointment is prepared by admixing hydrophilic material and water, together with about 5wt% to about 10wt% ofthe compound, to produce a cream or ointment having a desired consistency.
  • a cream or ointment is prepared by admixing hydrophilic material and water, together with about 5wt% to about 10wt% ofthe compound, to produce a cream or ointment having a desired consistency.
  • compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by first admixing the composition with the softened or melted ca ⁇ ier(s) followed by chilling and shaping in molds.
  • compositions of this invention can be in a fonn suitable for inhaled administration.
  • Such administration can be in forms and utilizing carriers described in, for example, 1) Particulate Interactions in Dry Powder Formulations for Inhalation. Xian Zeng et al, 2000, Taylor and Francis, 2) Pharmaceutical Inhalation Aerosol Technology, Anthony Hickey, 1992, Marcel Dekker, 3) Respiratory Dmg Delivery, 1990, Editor: P.R. Byron, CRC Press.
  • compositions described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like.
  • additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like.
  • additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like.
  • additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like.
  • other adjuvants can be included to render the formulation isotonic with the blood ofthe intended recipient.
  • dosage levels on the order of from about O.Olmg/kg to about 150mg/kg of body weight per day are useful in the treatment ofthe above-indicated conditions, or alternatively about 0.5mg to about lOg per patient per day.
  • diabetes may be effectively treated by the administration of from about 0.01 to lOOmg ofthe compound per kilogram of body weight per day, or alternatively about 0.5mg to about 7g per patient per day.
  • the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity ofthe disease in the particular diabetic patient undergoing therapy. Further, it is understood that the compomids and salts thereof of this invention can be administered at subtherapeutic levels prophylactically in anticipation of a hyperglycemic condition.
  • the compounds of Formula (I) may exhibit advantageous properties compared to known glucokinase activators, e.g. as illustrated in the assays described herein.
  • the aldehydes II and phenylacetic acids or esters III are commercially available or are readily prepared using known techniques.
  • IV may be prepared by the Perkin reaction (G. Karminski-Zamola et al., Tetrahedron 1982, 38, 1329-1335).
  • a carboxylic acid anhydride e.g. acetic anhydride
  • a tertiary amine base e.g. triethylamine
  • an amine base such as piperidine
  • a strong base e.g. lithium diisopropylamide
  • T. Severin et al. Chem. Ber. 1985, 118, 4760-4773 that may be saponified using, for example, sodium hydroxide (W. L. Corbett et al., WO 01/44216), to produce IV.
  • the ,/5-unsaturated carboxylic acids IV may be condensed with heteroaromatic amines V, many ofwhich are commercially available, using a variety of coupling conditions, e.g. polymer supported carbodiimide- 1-hydroxybenzotriazole in N,N-dimethylformamide at 20°C (for representative procedures, see http://www.argotech.com/PDF/resins/ps_carbodiimide.pdfand available from Argonaut Technologies, hie, Foster City, California), to give (la).
  • heteroaromatic amines V many ofwhich are commercially available, using a variety of coupling conditions, e.g. polymer supported carbodiimide- 1-hydroxybenzotriazole in N,N-dimethylformamide at 20°C (for representative procedures, see http://www.argotech.com/PDF/resins/ps_carbodiimide.pdfand available from Argonaut Technologies, hie, Foster City, California), to give (la).
  • Q, T, R ⁇ R 6 and m are as described above, V is CO R ⁇ or CO CH 2 Ph, and X is chloro, bromo, iodo, or -OSO 2 R 12 ; wherein R 11 is as described above and R 12 is C 1-4 alkyl, optionally substituted with one or more fluorines, or optionally substituted aryl.
  • the halides and sulfonate esters VI are commercially available or are readily prepared using known techniques. These alkylating agents may be reacted with the dianions ofthe phenylacetic acids VII, generated at — 78°C in tetrahydrofuran with >2 equivalents of a strong base, such as lithium diisopropylamide, to generate VIII directly (F. T. Bizza ⁇ o et al., WO 00/58293). Alternatively, the ⁇ -carbanion of phenylacetic ester VII, generated at -78°C in tefrahydrofuraii by a strong base, such as lithium bis(trimethylsilyl)amide (L. Snyder et al., J. Org.
  • the carboxylic acids VIII may be condensed with heteroaromatic amines V using a variety of coupling conditions, e.g. polymer supported carbodiimide-1- hydroxybenzotriazole in N,N-dimethylformamide at 20°C (for representative procedures, see http://www.argotech.com/PDF/resins/ps_carbodiimide.pdf and available from Argonaut Technologies, Inc., Foster City, California), to give amides (lb).
  • the compound of Formula (lb) has an asymmetric carbon atom which interlinks the amide carbonyl carbon, the aryl ring, and the Q-containing sidechain.
  • the prefe ⁇ ed stereoconfiguration at the asymmetric centre is (R).
  • racemic VIII can be condensed with a chiral oxazolidinone derivative (see, for instance, F. T. Bizza ⁇ o et al. WO 00/58293) to generate a mixture of diastereoisomeric imides that are separable by any conventional method, e.g. column chromatography.
  • the compounds of Formula (I) may be prepared singly or as compound libraries comprising at least 2, for example 5 to 1,000, compounds and more preferably 10 to 100 compounds of Formula (I).
  • Compound libraries may be prepared by a combinatorial "split and mix” approach or by multiple parallel synthesis using either solution or solid phase chemistry, using procedures known to those skilled in the art.
  • labile functional groups in the intermediate compounds e.g. hydroxy, carboxy and amino groups
  • the protecting groups may be removed at any stage in the synthesis ofthe compounds of Formula (I) or may be present on the final compound of Formula (I).
  • a comprehensive discussion ofthe ways in which various labile functional groups may be protected and methods for cleaving the resulting protected derivatives is given in, for example, Protective Groups in Organic Chemistry, T.W. Greene and P.G.M. Wuts, (1991) Wiley-Interscience, New York, 2 nd edition.
  • Preferred compounds of formula (IV) are those wherein:
  • Q is 4-tetrahydropyranyl
  • R 1 and R 2 are hydrogen
  • R 5 is SO 2 R 8 , or SO 2 NR 9 R 10 ;
  • R 6 is hydrogen
  • R 8 is a C 1-3 alkyl group, a C 3-5 cycloalkyl group or a 4-6-membered heterocyclic group
  • R 9 and R 10 are independently C 0 - alkyl, provided that R 9 and R 10 are not both hydrogen; m is 0; and
  • Q is 4-tetrahydropyranyl
  • R 1 and R 2 are hydrogen
  • R 5 is SO 2 R 8 , or SO 2 NR 9 R 10 ;
  • R 6 is hydrogen
  • R 8 is a C 3-5 cycloalkyl group or a A- 6-membered heterocyclic group
  • R 9 and R 10 are independently Co ⁇ alkyl, provided that R 9 and R 10 are not both hydrogen; and m is 0.
  • 5- fluorothiazol-2-ylamine or an amide or acid addition salt thereof hi particular the invention provides the amides and acid addition salts of this compound.
  • Suitable acid addition salts include those formed with inorganic and organic acids.
  • Such acids include, for example, acetic, trifluoroacetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, hydrofluoric isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, triflic and the like.
  • Particularly prefe ⁇ ed are the hydrohalide salts especially the hydrochloride.
  • the amides and acid addition salts of 5-fluorothiazol-2-ylamine may be useful as intermediates for the synthesis of compounds of Formula (I) or may themeselves act as GK activators and hence be of use in the prophylactic or therapeutic treatment of hyperglycemia and type II diabetes.
  • a sti ⁇ ed suspension of A1C1 3 (12.90g, 96.8mmol) in anhydrous CH 2 C1 2 (135mL) was treated portionwise at 0°C with ethyl chlorooxoacetate (8.5mL, 76.0mmol).
  • Cyclopropyl phenyl sulfide (lO.OmL, 70.0mmol) was added to the mixture dropwise over lh while maintaining the reaction temperature below 10°C.
  • the mixure was allowed to warm to 20°C, before being sti ⁇ ed for an additional 70min. Ice cold H 2 O (35mL) was added on cooling to 0°C, then the mixture was sti ⁇ ed further for lOmin.
  • NEt 3 (1.3mL, 9.0mmol) and 4-iodotetrahydro ⁇ yran (1.93g, 9.0mmol) were added to a sti ⁇ ed solution of ethyl (4-mercaptophenyl)acetate (1.21g, ⁇ .Ommol) in anhydrous DMF (lOmL) at 0°C.
  • the mixture was allowed to warm to room temperature over 3d, then the solvents were removed under reduced pressure.
  • the residue was partitioned between Et 2 O (lOOmL) and saturated aqueous NH 4 C1 (50mL), the aqueous phase being extracted further with Et O (45mL).
  • NEt 3 (15.4mL, 1 lOmmol) was added to a sti ⁇ ed suspension of 2-(4- methanesulfonylphenyl)-3-(tefrahydropyran-4-yl)propanoic acid (Preparation 41, 30.0g, 96.0mmol) in anhydrous THF (300mL) at 0°C.
  • pivaloyl chloride (13.6mL, 1 lOmmol) was added dropwise over 20min and the mixture was sti ⁇ ed at 0°C for 2h.
  • NEt 3 (63.4mL, 455mmol) was added to a sti ⁇ ed suspension of 5- bromothiazol-2-ylamine hydrobromide (102.7g, 379mmol) in CH 2 C1 (1.5L). After lh, TFAA (64.2mL, 455mmol) was added dropwise at 0°C over 15min. The mixture was allowed to warm to 20°C over lh, before being sti ⁇ ed for an additional 2h. H 2 O (600mL) was added and the resulting precipitate was collected. The aqueous layer of the filtrate was separated and extracted with CHC1 3 (3 x 300mL). The combined organic extracts were washed with brine, dried (Na 2 SO 4 ), filtered and concentrated.
  • N-(5-bromothiazol-2-yl)-2,2,2-trifluoroacetamide ⁇ 5 (CDCI 3 ): 7.45 (IH, s), 13.05 (IH, br).
  • n-BuLi (253mL of a 1.58M solution in hexanes, 403mmol) was added dropwise over 50min to a sti ⁇ ed solution ofthe above amide (50.0g, 183mmol) in anhydrous THF (1.3L) at -78°C.
  • a solution of this compound (1.37g, 3.94mmol) in CH 2 C1 2 (5mL) was treated with TFA-CH 2 C1 2 (2:1, 15mL) at 0°C over lOmin.
  • Method B Racemic 2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)- N-thiazol-2-ylpropionamide (EXAMPLE 65) was separated by chiral stationary phase HPLC.
  • the aqueous phase was extracted with CH 2 C1 2 , then the CH 2 C1 2 extracts were dried (MgSO 4 ), filtered, and concenfrated. The residue was sti ⁇ ed with ⁇ a 2 S 2 O 5 solution. The solid produced was collected and triturated with EtOAc. This material was then suspended in EtOAc, then saturated aqueous NaHCO 3 was added with stirring. The layers were separated, then the aqueous phase was extracted with EtOAc and CH 2 C1 2 .
  • LiOH ⁇ 2 O (410mg, 9.8mmol) was added to a solution of this ester (1.44g, 3.1mmol) in THF-H 2 O (3:1, 30mL). The mixture was sti ⁇ ed at 20°C for 16h and then at 55°C for 24h. The solvents were removed in vacuo, then the residue was dissolved in H O (50mL). The aqueous solution was washed with EtOAc (20mL), before being acidified to pH 1 with 2M HCl and exfracted with EtOAc (2 x lOOmL).
  • NEt 3 (647 ⁇ L, 4.64mmol) and BOP (976mg, 2.21mmol) were added to a sti ⁇ ed solution of 2-[2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4- yl)propionylamino]tl ⁇ iazole-5-carboxylic acid (EXAMPLE 127, 968mg, 2.21mmol) in anhydrous DMF (30mL). After 5min, N,O-dimethylhydroxylamine hydrochloride (237mg, 2.43mmol) was added, then the mixture was sti ⁇ ed at 20°C for 18h.
  • DLBAL (2.45mL of a 1.5M solution in PhMe, 3.68mmol) was added dropwise to a sti ⁇ ed solution of ethyl 2-[2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4- yl)propionylamino]thiazole-5-carboxylate (see EXAMPLE 127, 1.72g, 3.68mmol) in anhydrous CH 2 C1 2 (50mL) at -78°C. After 50min, more DLBAL (2.0mL of a 1.5M solution in PhMe, 3.00mmol) was added.
  • NEt 3 (0.14mL, 1006 mol) and a solution of 4- iodomethyltetrahydropyran (151 mg, 668 mo ⁇ ) in anhydrous DMF (3mL) were added to a sti ⁇ ed solution of this benzenethiol (197mg, 565 ⁇ mol) in anhydrous DMF (7mL) at 0°C.
  • the mixture was warmed to 20°C, before being sti ⁇ ed for 16h.
  • the solvents were evaporated off under reduced pressure, then the residue was partitioned between CH 2 C1 2 (25mL) and 2% aqueous citric acid (lOmL).
  • GK activity was assayed by coupling the production of G6P by GST-GK to the generation of ⁇ ADPH with G6PDH as the coupling enzyme.
  • the GK assay was performed at 30°C in a flat bottom 96-well assay plate from Costar with a final incubation volume of 100 L.
  • the assay buffer contained: 25mM Hepes buffer (pH 7.4), 12.5mM KCI, 5mM D-Glc, 5mM ATP, 6.25mM NADP, 25mM MgCl 2 , ImM dithiothreitol, test compound or 5% DMSO, 3.0unit/mL G6PDH, and OA ⁇ UmL GST-GK, derived from human liver GK.
  • ATP, G6PDH, and NADP were purchased from Roche Diagnostics.
  • the other reagents were >98% pure and were purchased from Kanto Chemicals.
  • the test compounds were dissolved in DMSO, before being added to the assay buffer without ATP. This mix was preincubated in the temperature controlled chamber of a SPECTRAmax 250 microplate spectrophotometer (Molecular Devices Corporation, Sunnyvale, CA) for lOmin, then the reaction was started by the addition of 10 L ATP solution.
  • C57BL/6 J mice were dosed orally via gavage with GK activator at 50mg/kg body weight. Blood Glc determinations were made 5 times during the 6h post-dose study period.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Compounds of Formula (I): or pharmaceutically acceptable salts thereof, are useful in the prophylactic and therapeutic treatment of hyperglycemia and diabetes.

Description

TITLE OF THE INVENTION
TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS
BACKGROUND OF THE INVENTION
The present invention is directed to tri(cyclo) substituted amide compounds. In particular, the present invention is directed to amide compounds substituted i) at the carbonyl carbon with an ethyl/ethenyl attached to a phenyl ring and an aryl/heteroaryl/heterocyclic ring, and ii) at the amino with a nitrogen bearing heteroaryl ring, which are modulators of glucokinase and are useful in the prophylactic or therapeutic treatment of hyperglycemia and type II diabetes.
Glucokinase ("GK") is believed to be important in the body's regulation of its plasma glucose level. GK, found principally in the liver and pancreas, is one of four hexokinases that catalyze the initial metabolism of glucose. The GK pathway is saturated at higher glucose levels than the other hexokinase pathways (See RX. Printz et al., Annu. Rev. Nutr., 13:463-496(1993)). GK is critical to maintaining the glucose balance in mammals. Animals that do not express GK die soon after birth with diabetes, while animals that overexpress GK have improved glucose tolerance. Activation of GK can lead to hyperinsulinemic hypoglycemia. (See, for example, H.B.T. Christesen et al., Diabetes, 51:1240-1246(2002)). Additionally, type II maturity-onset diabetes ofthe young is caused by the loss of function mutations in the GK gene, suggesting that GK operates as a glucose sensor in humans. (Y. Liang et al., Biochem. J. 309: 167-173(1995)). Thus, compounds that activate GK increase the sensitivity ofthe GK sensory system and would be useful in the treatment of hyperglycemia - particularly the hyperglycemia associated with type II diabetes. It is therefore desirable to provide novel compounds that activate GK to treat diabetes.
International Patent Publication No. WO2001044216 and U.S. Patent No. 6,353,111 describe (E)-2,3-disubstituted-N-heteroarylacrylamides as GK activators. International Patent Publication No. WO2002014312 and U.S. Patent Nos. 6,369,232, 6,388,088, and 6,441,180 describe tetrazolylphenylacetamide GK activators. International Patent Publication No. WO2000058293, European Patent Application No. EP 1169312 and U.S. Patent No. 6,320,050 describe arylcycloalkylpropionamide GK activators, hiternational Patent Publication No. 2002008209 and U.S. Patent No. 6,486,184 describe alpha-acyl and alpha-heteroatom-substituted benzene acetamide GK activators as anti-diabetic agents. International Patent Publication No. WO2001083478 describes hydantoin-containing GK activators. International Patent Publication No. WO2001083465 and U.S. Patent No. 6,388,071 describe alkynylphenyl heteroaromatic GK activators. International Patent Publication No. WO2001085707 and U.S. Patent No. 6,489,485 describe para-amine substituted phenylamide GK activators. International Patent Publication No. O2002046173 and U.S. Patent Nos. 6,433,188, 6,441,184, and 6,448,399 describe fused heteroaromatic GK activators. International Patent Publication No. WO2002048106 and U.S. Patent No. 6,482,951 describe isoindolin-1-one GK activators. International Patent Publication No. WO2001085706 describes substituted phenylacetamide GK activators for treating type II diabetes. U.S. Patent No. 6,384,220 describes para-aryl or heteroaryl substituted phenyl GK activators. French Patent No. 2,834,295 describes methods for the purification and crystal structure of human GK. International Patent Publication No. WO2003095438, published after the priority date ofthe present application, describes N-heteroaryl phenylacetamides and related compounds as GK activators for the treatment of type II diabetes. U.S. Patent No. 6,610,846 describes the preparation of cycloalkylheteroaryl propionamides as GK activators. International Patent Publication No. WO2003000262 describes vinyl phenyl GK activators, hitemational Patent Publication No. O2003000267 describes aminonicotinate derivatives as GK modulators. International Patent Publication No. WO2003015774, published after the priority date ofthe present application, describes compounds as GK modulators. International Patent Publication No. WO2003047626, published after the priority date ofthe present application, describes the use of a GK activator in combination with a glucagon antagonist for treating type II diabetes, hitemational Patent Publication No. WO2003055482, published after the priority date ofthe present application, describes amide derivatives as GK activators, hitemational Patent Publication No. WO2003080585, published after the priority date ofthe present application, describes aminobenzamide derivatives with GK activity for the treatment of diabetes and obesity, hitemational Patent Publication No. WO2003097824, published after the priority date ofthe present application, describes human liver GK crystals and their used for structure-based drug design. International Patent Publication No. WO2004002481, published after the priority date ofthe present application, discloses arylcarbonyl derivatives as GK activators. SUMMARY OF THE INVENTION
Compounds represented by Formula (I):
Figure imgf000005_0001
(I) or phannaceutically acceptable salts thereof, are useful in the prophylactic or therapeutic treatment of hyperglycemia and type II diabetes.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is directed to a compound of Formula (I):
Figure imgf000005_0002
(I) or a pharmaceutically acceptable salt thereof, wherein:
Q is an aryl, a 5- or 6-membered heteroaryl, or a 4-8-membered heterocyclic ring;
T together with the -N=C- to which it is attached forms a heteroaryl ring, or a heterocyclic ring where the N=C bond is the only site of unsaturation; R and R each independently are hydrogen, hydroxy, halogen, cyano, nitro, vinyl, ethynyl, methoxy, OCFnH3_n, -N(C0-4alkyl)(C0-4alkyl), CHO, or C1-2alkyl optionally substituted with 1-5 independent halogen, hydroxy, cyano, methoxy, -N(C0-2alkyl)(Co_2alkyl), SOCH3, or SO2CH3 substituents; or R1 andR2 together form a carbocyclic or heterocyclic ring; or R1 and R2 may be taken together to represent an oxygen atom attached to the ring via a double bond;
R3 and R4 each independently are hydrogen, halogen, OCFnH _n, methoxy, CO2R77, cyano, nitro, CHO, CONR99R100, CON(OCH3)CH3, or C1-2alkyl, heteroaryl, or C _7cycloalkyl optionally substituted with 1-5 independent halogen, hydroxy, cyano, methoxy, -NHCO2CH3, or -N(C0-2alkyl)(Co_2alkyl) substituents; or R3 and R4 together form a 5-8-membered aromatic, heteroaromatic, carbocyclic, or heterocyclic ring;
R5 and R6 each independently are hydrogen, hydroxy, halogen, cyano, nitro, CO2R7, CHO, COR8, C(OH)R7R8, C(=NOR7)R8, CONR9R10, SR7, SOR8, SO2R8, SO2NR9R10, CH2NR9R10, NR9R10, N(C0^alkyl)SO2R8, NHCOR7, or Cι-4alkyl group, C2-4alkenyl group, C2-4alkynyl group, C1-4alkoxy group, aryl group, or heteroaryl group, wherein any group optionally is substituted with 1-6 independent halogen, cyano, nitro, hydroxy, C^alkoxy, -N(Co_2alkyl)(Co_2alkyl), -^alkyl, CFnH3_n, aryl, heteroaryl, -COC^alkyl, -CON(C0-2alkyl)(C0_2alkyl), SCH3, SOCH3, SO2CH3, or -SO2N(Co-2alkyl)(C0_2alkyl) substituents; or R5 and R6 together form a 5-8- membered carbocyclic or heterocyclic ring;
R7 and R77 each independently are hydrogen, or C1-4alkyl group, C2-4alkenyl group, C2-4alkynyl group, C -7cycloalkyl group, aryl group, heteroaryl group, or 4—7- membered heterocyclic group, wherein any group optionally is substituted with 1-6 independent halogen, cyano, nitro, hydroxy, Cι_2alkoxy, -N(Co-2alkyl)(Co-2alkyl), C1_2alkyl, C3-7cycloalkyl, 4-7 -membered heterocyclic ring, CFπH3_n, aryl, heteroaryl, CO2H, -COC^alkyl, -CON(C0_2alkyl)(Co-2alkyl), SOCH3, SO2CH3, or -Sθ2N(Co-2alkyl)(C0-2alkyl) substituents;
R8 is C^ancyl group, C2- alkenyl group, C2- alkynyl group, C3- cycloalkyl group, aryl group, heteroaryl group, or 4-7-membered heterocyclic group, wherein any group optionally is substituted with 1-6 independent halogen, cyano, nitro, hydroxy, -^alkoxy, -N(Co_2alkyl)(C0_2aιkyl), Cι_2alkyl, C3_-7cycloalkyl, 4-7- membered heterocyclic ring, CFnH3_n, aryl, heteroaryl, CO2H, CO -^alkyl, -CON(C0_2alkyl)(C0_2alkyl), SOCH3, SO2CH3, or -SO2N(Co-2alkyl)(C0_2alkyl) substituents;
R9, R10, R99, and R100 each independently are hydrogen, or C1-4alkyl group, C3-7cycloalkyl group, aryl group, heteroaryl group, or 4-7-membered heterocyclic group, wherein any group optionally is substituted with 1-6 independent halogen, cyano, nitro, hydroxy, C1--2alkoxy, -N(CQ-2alkyl)(Co-2alkyl), C1--2alkyl, C3_ 7cycloalkyl, 4-7-membered heterocyclic ring, CFnH3_n, aryl, heteroaryl, COC^alkyl, -CON(C0-2alkyl)(Co_2alkyl), SOCH3, SO2CH3, or-SO2N(C0_2alkyl)(C0_2alkyl) substituents; or R9 and R10 or R99 and R100 together form a 6-8-membered heterobicyclic ring system or a 4-8-membered heterocyclic ring which optionally is substituted with 1-2 independent C^alkyl, CH2OCH3, COCo-2alkyl, hydroxy, or SO2CH3 substituents; n is 1, 2 or 3; m is 0 or 1; and the dotted line together with the solid line forms an optional double bond, and Δ indicates that the double bond has the (E)-configuration.
If the dotted line together with the solid line forms a single bond, the carbon atom linking the aryl ring and Q-bearing sidechain to the carbonyl carbon is a chiral centre. Accordingly, the compound may be present either as a racemate, or as a single enantiomer in the (R)- or (S)-configuration. The (R)-enantiomers are prefeπed.
A particular group of compounds which may be mentioned are compounds of Formula (I), or pharmaceutically acceptable salts thereof, provided that when Q is an unsubstituted 5- or 6-membered heterocyclic ring containing one heteroatom selected from O, S and S=O;
T completes a 5- or 6-membered heteroaryl ring which is unsubstituted or monosubstituted by halogen, methoxy, CO2-Co-4alkyl, cyano, nitro, CONH2, CONH- C1-4alkyl,
Figure imgf000007_0001
or C1-2alkyl optionally monosubstituted with methoxy or -NH(C0-2alkyl);
R5 and R6 each independently are hydrogen, hydroxy, halogen, cyano, nitro, CO2-C1-4alkyl, S-C1-4alkyl, S-perfluoroC1-4alkyl, SO-C1-4alkyl, SO2-C1-4alkyl, SO2- perfluoroC1- alkyl, SO2NH2, NH2, C1- alkyl, perfluoroC1- alkyl, C1- alkoxy or perfluoroC1-4alkoxy; and m is 0; then the dotted line together with the solid line must form a double bond. In the first aspect, the present invention is directed to a compound represented by Formula (la):
Figure imgf000008_0001
(la) or a phannaceutically acceptable salt thereof, wherein Q, T, R^R6, m, and Δ are as defined above in Formula (I).
In an embodiment ofthe first aspect, the present invention is directed to a compound represented by Fonnula (la), or a pharmaceutically acceptable salt thereof, wherein: Q is an aryl. hi another embodiment ofthe first aspect, the present invention is directed to a compound represented by Formula (la), or a pharmaceutically acceptable salt thereof, wherein Q is a 5- or 6-membered heteroaryl ring. hi another embodiment ofthe first aspect, the present invention is directed to a compound represented by Formula (la), or a pharmaceutically acceptable salt thereof, wherein Q is a thienyl, furyl, thiazolyl, or pyridyl ring.
In another embodiment ofthe first aspect, the present invention is directed to a compound represented by Formula (la), or a pharmaceutically acceptable salt thereof, wherein Q is a 4-8-membered heterocyclic ring.
In another embodiment ofthe first aspect, the present invention is directed to a compound represented by Formula (la), or a pharmaceutically acceptable salt thereof, wherein Q is tetrahydropyranyl, piperidinyl, tetrahydrothiopyranyl, 1-oxo- tetrahydrothiopyranyl or 1,1-dioxo-tetrahydrothiopyranyl.
In the second aspect, the present invention is directed to a compound represented by Formula (lb):
Figure imgf000009_0001
(lb) or a pharmaceutically acceptable salt thereof, wherein Q, T, R^R6 and m are as defined above in Formula (I). hi an embodiment ofthe second aspect, the present invention is directed to a compound represented by Formula (lb), or a pharmaceutically acceptable salt thereof, wherein: Q is a 5- or 6-membered heteroaryl ring.
In another embodiment ofthe second aspect, the present invention is directed to a compound represented by Fonnula (lb), or a pharmaceutically acceptable salt thereof, wherein: Q is a thienyl, furyl, thiazolyl, or pyridyl ring. hi another embodiment ofthe second aspect, the present invention is directed to a compound represented by Formula (lb), or a pharmaceutically acceptable salt thereof, wherein: Q is a 4-8-membered heterocyclic ring.
In another embodiment ofthe second aspect, the present invention is directed to a compound represented by Formula (lb), or a pharmaceutically acceptable salt thereof, wherein: Q is tetrahydropyranyl, piperidinyl, tefrahydrothiopyranyl, 1-oxo- tetrahydrothiopyranyl, or 1,1-dioxo-tetrahydrothiopyranyl.
The molecular weight ofthe compounds of formula (I) is preferably less than 800, more preferably less than 600, most preferably less than 500.
In the present invention, Q is preferably 2-furyl, 2-thienyl, tetrahydropyranyl, tetrahydrothiopyranyl, 1-oxo-tetrahydrothiopyranyl, or 1,1-dioxo- tetrahydrothiopyranyl; more preferably 4-tetrahydropyranyl or 4- tetrahydrothiopyranyl; most preferably 4-tetrahydropyranyl.
When Q is a heteroaryl or heterocyclic group it is preferably linked to the - (CH2)m- group through a carbon atom. When Q is a heteroaryl group it preferably does not have a substituent R1 or R2 other than hydrogen at a position adjacent to point of attachment to the -(CH2)m- group.
In the present invention, the group of formula
Figure imgf000010_0001
is preferably a monocyclic heteroaryl group. More preferably it is thiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, pyrimidinyl, pyrazinyl, or pyridyl; more preferably 2-tbiazolyl, 5-[l,2,4]thiadiazolyl, 2-[l,3,4]thiadiazolyl, 4-pyrimidinyl, 2-pyrazinyl, 3- isoxazolyl, or 2-pyridyl; even more preferably 2-thiazolyl, 5-[l,2,4]thiadiazolyl, 4- pyrimidinyl, 2-pyrazinyl, or 2-pyridyl; most preferably 2-thiazolyl, 2-pyrazinyl, or 2- pyridyl.
More preferably the group of fonnula
Figure imgf000010_0002
is 2-thiazolyl, or 2-pyrazinyl.
Most preferably the group of formula
Figure imgf000010_0003
is 2-thiazolyl and R3 is 5-fluoro and R4 is hydrogen; or 2-pyrazinyl and R3 and R4 are hydrogen; especially preferred is 2-thiazolyl where R3 is 5-fluoro and R4 is hydrogen.
In the present invention, R 1 and R 9 are preferably hydrogen.
In the present invention R3 and R are preferably independently selected from hydrogen, halogen, and methyl, more preferably R3 and R are independently selected from hydrogen, fluoro, and methyl. hi the present invention, R3 is preferably hydrogen or halogen; more preferably hydrogen, fluoro, chloro or bromo; even more preferably hydrogen, fluoro, or chloro; most preferably hydrogen or fluoro. In the present invention, R4 is preferably hydrogen, halogen, or methyl; more preferably hydrogen or methyl.
In the present invention, R5 and R6 are preferably not both hydrogen.
In the present invention, R5 is preferably CF3, SOR8, SO2R8, SO2NR9R10, NHSO2R8, or triazolyl; more preferably SOR8, SO2R8, or SO2NR9R10; most preferably SO2R8 or SO2NR9R10, especially SO2R8.
In particular R5 is SO2C3_ cycloalkyl, especially SO2cyclopropyl.
In the present invention, R6 is preferably hydrogen, chloro, fluoro, or trifluoromethyl; more preferably hydrogen.
In the present invention, R7, R77, and R8 are preferably Cι-4alkyl, C3_ 7cycloalkyl, heteroaryl, or 4-7-membered heterocyclic group; more preferably Ci_ 3alkyl, 4-6-membered heterocyclic group, or C3_5cycloalkyl; most preferably methyl, ethyl, ra-propyl, cyclopropyl, cyclobutyl, oxetanyl, or tetrahydrofuryl, and especially methyl, ethyl, w-propyl, cyclopropyl, or cyclobutyl. o
When the dotted line together with the solid line forms a double bond R is preferably C1-3alkyl, or C^cycloalkyl.
When the dotted line together with the solid line fonns a single bond R is preferably C3- cycloalkyl, especially cyclopropyl.
When R5 and/or R6 are CO2R7 or SR7, R7 is preferably not hydrogen.
In the present invention, R9 and R10 are preferably independently Co^alkyl e.g. one of R9 and R10 is hydrogen and the other is ethyl, or combine to form a 4-8- membered heterocyclic ring. R9 and R10 are preferably not both hydrogen.
In the present invention, R99 and R100 are preferably Co^alkyl.
In the present invention, m is preferably 0.
In the present invention, n is preferably 2 or 3.
A prefeπed group of compounds are compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein:
Q is 4-tetrahydropyranyl;
T together with the -N=C— to which it is attached forms a 2-pyrazinyl or 2- thiazolyl ring;
1 9
R and R are hydrogen;
R3 and R4 each independently are hydrogen or fluoro;
R5 is SO2R8, or SO2NR9R10;
R6 is hydrogen; R is a C -5cycloalkyl group or a 4-6-membered heterocyclic group, and, in addition, when the dotted line together with the solid line forms a double bond R8 may be a d-salkyl group;
R9 and R10 are independently Cϋ^alkyl, provided that R9 and R10 are not both hydrogen; m is 0; and the dotted line together with the solid line forms an optional double bond, and Δ indicates that the double bond has the (E)-configuration.
A more preferred group of compounds are compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein:
Q is 4-tetrahydropyranyl;
T together with the -N=C- to which it is attached forms a 2-pyrazinyl or 2- thiazolyl ring;
1 9
R and R are hydrogen;
R3 and R4 each independently are hydrogen or fluoro;
R5 is SO2R8;
R6 is hydrogen;
R is a C3_5cycloalkyl group and, in addition, when the dotted line together with the solid line forms a double bond R8 may be a C1-3 alkyl group; m is 0; and the dotted line together with the solid line forms an optional double bond, and Δ indicates that the double bond has the (E)-configuration.
Specific compounds ofthe invention which may be mentioned are those described in the Examples, in particular Examples 1 to 201, and pharmaceutically acceptable salts thereof.
Specific compounds ofthe invention which may be mentioned are:
(2R)-2-(4-Cyclopropanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3- (tetrahydropyran-4-yl)propionamide;
(2R)-2-(4-Cyclopropanesulfonylphenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4- yι)propionamide;
(2R)-2-(4-Cyclobutanesulfonylphenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4- yi)propionamide; (2R)-2-(4-Cyclobutanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3- (tetrahydropyran-4-yl)propionamide; and
(E)-N-(5-Fluorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3- (tetrahydropyran-4-yl)acrylamide; or a pharmaceutically acceptable salt thereof.
In particular the compounds:
(2R)-2-(4-Cyclopropanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3- (tetrahydropyran-4-yl)propionamide;
(2R)-2-(4-Cyclopropanesulfonylphenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4- yl)propionamide; and
(E)-N-(5-Fluorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3- (tetrahydropyran-4-yl)acrylamide; or a phannaceutically acceptable salt thereof.
While the prefeπed groups for each variable have generally been listed above separately for each variable, preferred compounds of this invention include those in which several or each variable in Formula (I) is selected from the preferred, more prefeπed, most prefeπed, especially or particularly listed groups for each variable. Therefore, this invention is intended to include all combinations of preferred, more prefeπed, most prefeπed, especially and particularly listed groups.
As used herein, unless stated otherwise, "alkyl" as well as other groups having the prefix "alk" such as, for example, alkoxy, alkanyl, alkenyl, alkynyl, and the like, means carbon chains which may be linear or branched or combinations thereof. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec- and tert-butyl, pentyl, hexyl, heptyl and the like. "Alkenyl", "alkynyl" and other like terms include carbon chains having at least one unsaturated carbon-carbon bond.
As used herein, for example, "Co-4alkyl" is used to mean an alkyl having 0-4 carbons - that is, 0, 1, 2, 3, or 4 carbons in a straight or branched configuration. An alkyl having no carbon is hydrogen when the alkyl is a terminal group. An alkyl having no carbon is a direct bond when the alkyl is a bridging (connecting) group.
The terms "cycloalkyl" and "carbocyclic ring" mean carbocycles containing no heteroatoms, and include mono-, bi-, and tricyclic saturated carbocycles, as well as fused and bridged systems. Such fused ring systems can include one ring that is partially or fully unsaturated, such as a benzene ring, to form fused ring systems, such as benzofused carbocycles. Cycloalkyl includes such fused ring systems as spirofused ring systems. Examples of cycloalkyl and carbocyclic rings include C3-8cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and decahydronaphthalene, adamantane, indanyl, 1,2,3,4-tetrahydronaphthalene and the like.
The term "halogen" includes fluorine, chlorine, bromine, and iodine atoms.
The term "aryl" includes, for example, phenyl and naphthyl.
Unless otherwise stated, the term "heterocyclic ring" includes 4-8-membered saturated rings containing one or two heteroatoms chosen from oxygen, sulfur, and nitrogen. The heteroatoms are not directly attached to one another. Examples of heterocyclic rings include oxetane, tetrahydrofuran, tetrahydropyran, oxepane, oxocane, thietane, tetrahydrothiophene, tetrahydrotliiopyran, thiepane, thiocane, azetidine, pyrrolidine, piperidine, azepane, azocane, [l,3]dioxane, oxazolidine, piperazine, and the like. Other examples of heterocyclic rings include the oxidised forms ofthe sulfur-containing rings. Thus, tetrahydrothiophene 1-oxide, tetrahydrothiophene 1,1 -dioxide, tetrahydrothiopyran 1-oxide, and tetrahydrothiopyran 1,1-dioxide are also considered to be heterocyclic rings.
Unless otherwise stated, the term "heteroaryl" includes 5- or 6-membered heteroaryl rings containing 1-4 heteroatoms chosen from oxygen, sulfur, and nitrogen. Examples of such heteroaryl rings are furyl, thienyl, pyπolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl.
The above formulas are shown without a definitive stereochemistry at certain positions. The present invention includes all stereoisomers (e.g. geometric isomers, optical isomers, diastereoisomers, etc.) and pharmaceutically acceptable salts thereof, except where specifically drawn or stated otherwise. Further, mixtures of stereoisomers as well as isolated specific stereoisomers are also included, except where specifically drawn or stated otherwise. During the course ofthe synthetic procedures used to prepare such compounds, or in using racemization or epimerization procedures known to those skilled in the art, the products of such procedures can be a mixture of stereoisomers. When a tautomer ofthe compound of the above formulas exists, the present invention includes any possible tautomers and pharmaceutically acceptable salts thereof, and mixtures thereof, except where specifically drawn or stated otherwise. When the compound ofthe above formulas and pharmaceutically acceptable salts thereof exist in the form of solvates or polymorphic forms, the present invention includes any possible solvates and polymorphic forms. A type of a solvent that forms the solvate is not particularly limited so long as the solvent is pharmacologically acceptable. For example, water, ethanol, propanol, acetone or the like can be used.
Since the compounds of Formula (I) are intended for pharmaceutical use they are preferably provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure, especially at least 98% pure (% are on a weight for weight basis).
The invention also encompasses a pharmaceutical composition that is comprised of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.
Preferably the composition is comprised of a pharmaceutically acceptable caπier and a non-toxic therapeutically effective amount of a compound of Formula (I) as described above, or a pharmaceutically acceptable salt thereof.
Moreover, within this prefeπed embodiment, the invention encompasses a pharmaceutical composition for the prophylaxis or treatment of hyperglycemia and diabetes by the activation of GK, comprising a phannaceutically acceptable carrier and a non-toxic therapeutically effective amount of compound of Formula (I) as described above, or a pharmaceutically acceptable salt thereof.
The invention also provides the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof as a pharmaceutical.
The compounds and compositions ofthe present invention are effective for treating hyperglycemia in mammals such as, for example, humans.
The invention also provides a method of prophylactic or therapeutic treatment of a condition where activation of GK is desirable comprising a step of administering an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
The invention also provides a method of prophylactic or therapeutic treatment of hyperglycemia or diabetes comprising a step of administering an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
The invention also provides a method of prevention of diabetes in a human demonstrating pre-diabetic hyperglycemia or impaired glucose tolerance comprising a step of administering an effective prophylactic amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. The invention also provides the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as a GK activator.
The invention also provides the use of a compound of Fonnula (I), or a pharmaceutically acceptable salt thereof, for the prophylactic or therapeutic treatment of hyperglycemia or diabetes.
The invention also provides the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the prevention of diabetes in a human demonstrating pre-diabetic hyperglycemia or impaired glucose tolerance.
The invention also provides the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the activation of GK.
The invention also provides the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prophylactic or therapeutic treatment of hyperglycemia or diabetes.
The invention also provides the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention of diabetes in a human demonstrating pre-diabetic hyperglycemia or impaired glucose tolerance.
The compounds and compositions ofthe present invention may be optionally employed in combination with one or more other anti-diabetic agents or anti- hyperglycemic agents, which include, for example, sulfonylureas (e.g. glyburide, glirnepiride, glipyride, glipizide, chlorpropamide, gliclazide, glisoxepid, acetohexamide, glibornuride, tolbutamide, tolazamide, carbutamide, gliquidone, glyhexamide, phenbutamide, tolcyclamide, etc.), biguanides (e.g. metformin, phenformin, bufonnin, etc.), glucagon antagonists (e.g. a peptide or non-peptide glucagon antagonist), glucosidase inhibitors (e.g. acarbose, miglitol, etc.), insulin secetagogues, insulin sensitizers (e.g. troglitazone, rosightazone, pioglitazone, etc.) and the like; or anti-obesity agents (e.g. sibutramine, orlistat, etc.) and the like. The compounds and compositions ofthe present invention and the other anti-diabetic agents or anti-hyperglycemic agents may be administered simultaneously, sequentially or separately.
The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids. When the compound ofthe present invention is acidic, its coπesponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases. Salts derived from such inorganic bases include aluminum, ammonium, calcium, cupric, cuprous, ferric, feπous, lithium, magnesium, manganic, manganous, potassium, sodium, zinc and the like salts. Particularly prefeπed are the ammonium, calcium, magnesium, potassium and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, as well as cyclic amines and substituted amines such as naturally occurring and synthetic amines. Other phannaceutically acceptable organic non-toxic bases from which salts can be formed include, for example, arginine, betaine, caffeine, choline, N',N'-dibenzylethylenediamine, diethylamine, 2- diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N- ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like.
When the compound ofthe present invention is basic, its coπesponding salt can be conveniently prepared from phannaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like. Particularly prefeπed are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, methanesulfonic, and tartaric acids.
The pharmaceutical compositions ofthe present invention comprise a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as an active ingredient, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants. The compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, as well as administration through inhaling, although the most suitable route in any given case will depend on the particular host, and nature and severity ofthe conditions for which the active ingredient is being administered. The pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any ofthe methods well known in the art of pharmacy. The pharmaceutical compositions according to the invention are preferably adapted for oral administration.
In practice, the compounds of Formula (I), or pharmaceutically acceptable salts thereof, of this invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional phannaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g. oral or parenteral (including intravenous). Thus, the pharmaceutical compositions ofthe present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount ofthe active ingredient. Further, the compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion, or as a water-in-oil liquid emulsion. In addition to the common dosage forms set out above, the compound represented by Fonnula (I), or a phannaceutically acceptable salt thereof, may also be administered by controlled release means and/or delivery devices. The compositions may be prepared by any ofthe methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.
Thus, the pharmaceutical compositions of this invention may include a pharmaceutically acceptable carrier and a compound of Formula (I), or a pharmaceutically acceptable salt thereof. The compounds of Formula (I), or pharmaceutically acceptable salts thereof, can also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds.
The pharmaceutical compositions of this invention include a phannaceutically acceptable liposomal formulation containing a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
The pharmaceutical carrier employed can be, for example, a solid, liquid, or gas. Examples of solid carriers include lactose, teπa alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Examples of liquid caπiers are sugar syrup, peanut oil, olive oil, and water. Examples of gaseous carriers include carbon dioxide and nitrogen.
In preparing the compositions for oral dosage form, any convenient phannaceutical media may be employed. For example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like may be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used to form oral solid preparations such as powders, capsules and tablets. Because of their ease of administration, tablets and capsules are the prefeπed oral dosage units whereby solid phannaceutical caπiers are employed. Optionally, tablets may be coated by standard aqueous or nonaqueous techniques.
A tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants. Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent or other such excipient. These excipients may be, for example, inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, com starch, or alginic acid; binding agents, for example, starch, gelatin or acacia; and lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer time. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be used.
In hard gelatin capsules, the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. In soft gelatin capsules, the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil. Molded tablets may be made by molding in a suitable machine, a mixture ofthe powdered compound moistened with an inert liquid diluent. Each tablet preferably contains from about 0.05mg to about 5g ofthe active ingredient and each cachet or capsule preferably containing from about 0.05mg to about 5g ofthe active ingredient. For example, a formulation intended for the oral administration to humans may contain from about 0.5mg to about 5g of active agent, compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent ofthe total composition. Unit dosage forms will generally contain between from about lmg to about 2g ofthe active ingredient, typically 25mg, 50mg, lOOmg, 200mg, 300mg, 400mg, 500mg, 600mg, 800mg, or lOOOmg.
Pharmaceutical compositions ofthe present invention suitable for parenteral administration may be prepared as solutions or suspensions ofthe active compounds in water. A suitable surfactant can be included such as, for example, hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.
Pharmaceutical compositions ofthe present invention suitable for injectable use include sterile aqueous solutions or dispersions. Furthermore, the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions. In all cases, the final injectable form must be sterile and must be effectively fluid for easy syringability. The pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.
Pharmaceutical compositions ofthe present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder, or the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a compound of Formula (I), or a pharmaceutically acceptable salt thereof, via conventional processing methods. As an example, a cream or ointment is prepared by admixing hydrophilic material and water, together with about 5wt% to about 10wt% ofthe compound, to produce a cream or ointment having a desired consistency.
Pharmaceutical compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by first admixing the composition with the softened or melted caπier(s) followed by chilling and shaping in molds.
Pharmaceutical compositions of this invention can be in a fonn suitable for inhaled administration. Such administration can be in forms and utilizing carriers described in, for example, 1) Particulate Interactions in Dry Powder Formulations for Inhalation. Xian Zeng et al, 2000, Taylor and Francis, 2) Pharmaceutical Inhalation Aerosol Technology, Anthony Hickey, 1992, Marcel Dekker, 3) Respiratory Dmg Delivery, 1990, Editor: P.R. Byron, CRC Press.
In addition to the aforementioned carrier ingredients, the pharmaceutical compositions described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like. Furthermore, other adjuvants can be included to render the formulation isotonic with the blood ofthe intended recipient. Compositions containing a compound of Formula (I), or pharmaceutically acceptable salts thereof, may also be prepared in powder or liquid concentrate form.
Generally, dosage levels on the order of from about O.Olmg/kg to about 150mg/kg of body weight per day are useful in the treatment ofthe above-indicated conditions, or alternatively about 0.5mg to about lOg per patient per day. For example, diabetes may be effectively treated by the administration of from about 0.01 to lOOmg ofthe compound per kilogram of body weight per day, or alternatively about 0.5mg to about 7g per patient per day.
It is understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity ofthe disease in the particular diabetic patient undergoing therapy. Further, it is understood that the compomids and salts thereof of this invention can be administered at subtherapeutic levels prophylactically in anticipation of a hyperglycemic condition.
The compounds of Formula (I) may exhibit advantageous properties compared to known glucokinase activators, e.g. as illustrated in the assays described herein. In particular compounds ofthe invention may exhibit improved values for Km, Vmax, EC5o, maximum activation (glucose concentration = 5mM), and/or maximum blood glucose reduction on basal blood glucose levels (e.g. in C57BL/6J mice), or other advantageous pharmacological properties, compared to known GK activators
EXPERIMENTAL
In accordance with this invention, the compounds of Formula (la) can be prepared following the protocol illustrated in Scheme 1 below:
SCHEME 1
Figure imgf000022_0001
wherein Q, T, R^R6, m and Δ are as described above, and R11 is Co^alkyl.
The aldehydes II and phenylacetic acids or esters III are commercially available or are readily prepared using known techniques. When Q represents an aromatic or heteroaromatic ring, IV may be prepared by the Perkin reaction (G. Karminski-Zamola et al., Tetrahedron 1982, 38, 1329-1335). In this reaction, II is condensed with the phenylacetic acid III (R11 = Coalkyl) in the presence of a carboxylic acid anhydride, e.g. acetic anhydride, and a tertiary amine base, e.g. triethylamine, at reflux to give the acrylic acid IV. Alternatively, IV may be prepared through the condensation of II and III (R11 = Coalkyl) under the influence of an amine base, such as piperidine, in toluene under reflux (D. Deschenes et al., WO 01/46151). When Q is a heterocyclic ring, the α-carbanion ofthe phenylacetic ester III (R11 = Ci. 4alkyl), generated at -78°C in, for example, tetrahydrofuran, by a strong base, e.g. lithium diisopropylamide, may be condensed with II to give an , ?-unsaturated ester (T. Severin et al. Chem. Ber. 1985, 118, 4760-4773) that may be saponified using, for example, sodium hydroxide (W. L. Corbett et al., WO 01/44216), to produce IV.
The ,/5-unsaturated carboxylic acids IV may be condensed with heteroaromatic amines V, many ofwhich are commercially available, using a variety of coupling conditions, e.g. polymer supported carbodiimide- 1-hydroxybenzotriazole in N,N-dimethylformamide at 20°C (for representative procedures, see http://www.argotech.com/PDF/resins/ps_carbodiimide.pdfand available from Argonaut Technologies, hie, Foster City, California), to give (la).
The compounds of Formula (lb) can be made by the route displayed in Scheme 2 below:
SCHEME 2
Figure imgf000023_0001
wherein Q, T, R^R6 and m are as described above, V is CO Rπ or CO CH2Ph, and X is chloro, bromo, iodo, or -OSO2R12; wherein R11 is as described above and R12 is C1-4alkyl, optionally substituted with one or more fluorines, or optionally substituted aryl.
The halides and sulfonate esters VI are commercially available or are readily prepared using known techniques. These alkylating agents may be reacted with the dianions ofthe phenylacetic acids VII, generated at — 78°C in tetrahydrofuran with >2 equivalents of a strong base, such as lithium diisopropylamide, to generate VIII directly (F. T. Bizzaπo et al., WO 00/58293). Alternatively, the α-carbanion of phenylacetic ester VII, generated at -78°C in tefrahydrofuraii by a strong base, such as lithium bis(trimethylsilyl)amide (L. Snyder et al., J. Org. Chem. 1994, 59, 7033- 7037), can be alkylated by VI to give α-substituted esters. Saponification of these esters, employing, for example, sodium hydroxide in aqueous methanol at 20°C to reflux, leads to the carboxylic acids VIII.
The carboxylic acids VIII may be condensed with heteroaromatic amines V using a variety of coupling conditions, e.g. polymer supported carbodiimide-1- hydroxybenzotriazole in N,N-dimethylformamide at 20°C (for representative procedures, see http://www.argotech.com/PDF/resins/ps_carbodiimide.pdf and available from Argonaut Technologies, Inc., Foster City, California), to give amides (lb). The compound of Formula (lb) has an asymmetric carbon atom which interlinks the amide carbonyl carbon, the aryl ring, and the Q-containing sidechain. In accordance with this invention, the prefeπed stereoconfiguration at the asymmetric centre is (R).
If one desires to isolate the pure (R)- or (S)-stereoisomers ofthe compound of Formula (lb), it is possible to resolve a racemic mixture ofthe chiral carboxylic acid precursor VIII by any conventional chemical means and then condense the enantiopure carboxylic acids with an amine of formula V using a reagent that causes negligible racemisation. By way of illustration, racemic VIII can be condensed with a chiral oxazolidinone derivative (see, for instance, F. T. Bizzaπo et al. WO 00/58293) to generate a mixture of diastereoisomeric imides that are separable by any conventional method, e.g. column chromatography. Hydrolysis ofthe pure imides affords the stereopure (R)- and (S)-carboxylic acids that can then be condensed with heterocyclic amines V, employing a reagent that minimises racemisation ofthe chiral centre, e.g. benzotriazol-l-yloxytris(pyπolidino)phosphonium hexafluorophosphate (I. Coste et al. Tetrahedron Lett. 1990, 31, 205-208), to furnish enantiopure (R)- or (S)-amides of Formula (lb). Alternatively, a racemic mixture of amides of Formula (lb) can be separated by means of chiral high performance liquid chromatography employing a chiral stationary phase which can be purchased from, for example, Daicel Chemical Industries, Ltd, Tokyo, Japan.
Further details for the preparation ofthe compounds of Formula (I) are found in the examples.
The compounds of Formula (I) may be prepared singly or as compound libraries comprising at least 2, for example 5 to 1,000, compounds and more preferably 10 to 100 compounds of Formula (I). Compound libraries may be prepared by a combinatorial "split and mix" approach or by multiple parallel synthesis using either solution or solid phase chemistry, using procedures known to those skilled in the art.
During the synthesis ofthe compounds of Formula (I), labile functional groups in the intermediate compounds, e.g. hydroxy, carboxy and amino groups, may be protected. The protecting groups may be removed at any stage in the synthesis ofthe compounds of Formula (I) or may be present on the final compound of Formula (I). A comprehensive discussion ofthe ways in which various labile functional groups may be protected and methods for cleaving the resulting protected derivatives is given in, for example, Protective Groups in Organic Chemistry, T.W. Greene and P.G.M. Wuts, (1991) Wiley-Interscience, New York, 2nd edition.
Any novel intermediates as defined above are also included within the scope ofthe invention.
According to a further aspect ofthe invention there is provided a compound of Formula (IV) and the use of such compounds in the synthesis of GK activators:
Figure imgf000025_0001
wherein Q, R1, R2, R5, R6, m and Δ are as described for Formula (I).
Preferred compounds of formula (IV) are those wherein:
Q is 4-tetrahydropyranyl;
R1 and R2 are hydrogen;
R5 is SO2R8, or SO2NR9R10;
R6 is hydrogen;
R8 is a C1-3alkyl group, a C3-5cycloalkyl group or a 4-6-membered heterocyclic group;
R9 and R10 are independently C0- alkyl, provided that R9 and R10 are not both hydrogen; m is 0; and
Δ indicates that the double bond has the (E)-configuration.
According to a further aspect ofthe invention there is provided a compound of Formula (VIII) and the use of such compounds in the synthesis of GK activators:
Figure imgf000026_0001
wherein Q, R1, R2, R5, R6 and m are as described for Formula (I).
Prefeπed compounds of formula (VIII) are those wherein:
Q is 4-tetrahydropyranyl;
R1 and R2 are hydrogen;
R5 is SO2R8, or SO2NR9R10;
R6 is hydrogen;
R8 is a C3-5cycloalkyl group or a A- 6-membered heterocyclic group;
R9 and R10 are independently Co^alkyl, provided that R9 and R10 are not both hydrogen; and m is 0.
The preferences for the various substituent groups in the compounds of Formulae (IV) and (VIII) are as described above for the compounds of Formula (I).
Specific compounds of Formulae (IV) and (VIII) include those described in the Preparations.
According to a further aspect ofthe invention there is also provided 5- fluorothiazol-2-ylamine or an amide or acid addition salt thereof, hi particular the invention provides the amides and acid addition salts of this compound. Suitable acid addition salts include those formed with inorganic and organic acids. Such acids include, for example, acetic, trifluoroacetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, hydrofluoric isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, triflic and the like. Particularly prefeπed are the hydrohalide salts especially the hydrochloride. The amides and acid addition salts of 5-fluorothiazol-2-ylamine may be useful as intermediates for the synthesis of compounds of Formula (I) or may themeselves act as GK activators and hence be of use in the prophylactic or therapeutic treatment of hyperglycemia and type II diabetes.
All publications, including, but not limited to, patents and patent application cited in this specification, are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as fully set forth.
Materials and methods
Microwave reactions were performed in a CEM Explorer system at 100W. Column chromatography was carried out on SiO2 (40-63 mesh) unless specified otherwise. LCMS data were obtained employing one of two methods: Method A: Waters Symmetry 3.5 C18 column (2.1 x 30.0mm, flow rate = 0.8mL/min) eluting with a (5% MeCN in H2O)-MeCN solution containing 0.1% HCO2H over 6min and UV detection at 220nm. Gradient information: 0.0-1.2min: 100% (5% MeCN in H2O); 1.2-3.8min: Ramp up to 10% (5% MeCN in H2O)-90% MeCN; 3.8- .4min: Hold at 10% (5% MeCN in H O)-90% MeCN; 4.4-5.5min: Ramp up to 100% MeCN; 5.5- 6.0min: Return to 100% (5% MeCN in H2O). Method B: Phenomenex Mercury Luna 3μ C18 column (2.0 x 10.0mm, flow rate = 1.5mL/min), eluting with a (5% MeCN in H2O)-MeCN solution (4:1 to 1:4) containing 0.1% HCO2H over 2.95min, & employing diode aπay detection. The mass spectra for both Methods A and B were obtained employing an electrospray ionisation source in either the positive (ES+) ion or negative ion (ES~) mode. Atmospheric Pressure Chemical Ionisation (APCI) spectra were obtained on a FinniganMat SSQ 7000C instrument. The syntheses ofthe following compounds have been reported previously: 2-Amino-5-chloro-4- methylthiazole: S. Kyoichi et al. EP 412404; 2-Amino-5-formylthiazole: M. D. Frishberg US Patent No. 4,225,719; 5-Amino-[l,2,4]thiadiazole hydrochloride: Y. Yoshida et al. Bioorg. Med. Chem. 2000, 8, 2317-2335; 2-Chloromethylthiophene: G. Norcini et al. US Patent No. 5,716,943; Ethyl (4-mercaρtoρhenyl)acetate: F. Gadient Ger. Offen. 2442979; Ethyl 4-(methylsulfanylphenyl)acetate: M. Kiuchi et al. J Med. Chem. 2000, 43, 2946-2961; Ethyl (4-propylsulfanylρhenyl)acetate: N. P. Buu-Hoi et al. Chim. Ther. 1967, 2, 39-48; Ethyl (4-[l,2,3]triazol-l-ylphenyl)acetate: G. Biagi et al. Farmaco Ed. Sci. 1988, 43, 597-611; Ethyl (4-[l,2,4]triazol-l-ylρhenyl)acetate: M. Artico et al. Eur. J. Med. Chem. 1992, 27, 219-228; (3-Fluoro-4- methylsulfanylρhenyl)acetic acid: L. B. Snyder and Z. Zheng WO 00/10566; 4- Iodomethyltetrahydropyran: D. J. Anderson et al. WO 95/30670; 4- Iodotetrahydropyran: Heuberger and Owen J Chem. Soc. 1952, 910-913; Methyl (3- bromo-4-methylsulfanylphenyl) acetate: F. T. Bizzarro et al. WO 00/58293; Methyl 4-tert-butoxycarbonylmethylbenzoate: F. Agnelli and G. A. Sulikowski Tetrahedron Lett. 1998, 39, 8807-8810; (4-Methylsulfanyhnethylphenyl)acetic acid: T. Tanaka et al. JP 54079247; (3R)-3-(Tosyloxy)tetrahydrofuran: A. Bouzide et al. Tetrahedron Lett. 2001, 42, 8781-8783; (3S)-3-(Tosyloxy)tetrahydrofuran: F. J. A. Hundscheid et al. Tetrahedron 1987, 43, 5073-5088; 3-(Tosyloxy)oxetane: K. Baum et al. J. Org. Chem. 1983, 48, 2953-2956. (E)-2-Phenyl-3-thiophen-2-yl acrylic acid was purchased from Maybridge (Tintagel, UK).
Abbreviations and acronyms: Ac: Acetyl; z'-Am: Isopentyl; ATP: Adenosine 5 -triphosphate; BOP: Benzotriazol-l-yloxytris(dimethylamino)phosphonimn hexafluorophosphate; «-Bu: «-Butyl; t-Bu: tert-Butyl; Bz: Benzoyl; dba: dibenzylideneacetone; DIPEA: N,N-Diisopropylethylamine; DMAc: N,N- Dimethylacetamide; DME: 1,2-Dimethoxyethane; DMF: N,N-Dimethylformamide; DMPU: l,3-Dimethyl-3,4,5,6-tetrahydro-2(lH)-pyrimidinone; DMSO: Dimethylsulfoxide; DPEPhos: Bis(2-diphenylphosphinophenyl)efher; EDCI: l-(3- Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; Et: Ethyl; FA: Fold activation; GK: Glucokinase; Glc: Glucose; G6P: Glucose-6-phosphate; G6PDΗ: Glucose-6-phosphate dehydrogenase; GST-GK: Glutathione S-transferase- Glucokinase fusion protein; HATU: O-(7-Azabenzotriazol-l-yl)-N,N,N',N- tetramethyluronium hexafluorophosphate; HOBt: 1-Hydroxybenzotriazole; IH: Isohexane; z'-Pr: Isopropyl; LDA: Lithium diisopropylamide; LHMDS: Lithium bis(trimethylsilyl)amide; røCPBA: 3-Chloroperoxybenzoic acid; Me: Methyl; mp: Melting point; ΝADP(H): ?-Nicotinamide adenine dinucleotide phosphate (reduced); NBS: N-Bromosuccinimide; Ph: Phenyl; PS: Polymer supported; Rp-" Retention factor; RT: Retention time; RTA: Retention time with Method A; RTB: Retention time with Method B; RP-HPLC: Reverse phase-high performance liquid chromatography; TBA-OX: Tetrabutylammom'um oxone; TFA: Trifluoroacetic acid; TFAA: Trifluoroacetic anhydride; TFFH: Fluoro-N,N,N'^V'-tetramethylformamidinium hexafluorophosphate; THF: Tetrahydrofuran. Preparation 1: (E)-2-(4-Methanesulfonylρhenyl)-3-thioρhen-3-ylacrylic acid
Figure imgf000029_0001
A mixture of 3-thiophenecarboxaldehyde (1.40mL, 15.0mmol), (4- methanesulfonylphenyl)acetic acid (3.23g, 15.0mmol), and piperidine (0.45mL, 4.5mmol) in PhMe (21mL) was heated under reflux with stirring for 16h. On cooling, the PhMe was decanted off from the oily solid that had settled at the bottom ofthe reaction vessel. This solid was partitioned between IM HCl (60mL) and EtOAc (400mL), then the aqueous phase was extracted further with EtOAc (60mL). The combined organic layers were washed with H2O (60mL), before being shaken with saturated aqueous Na2CO3 (lOOmL). The resulting emulsion was filtered through Celite. The organic layer was extracted further with saturated aqueous Na2CO3 (2 x lOOmL). The combined aqueous layers were washed with Et2O (80mL), before being filtered through Celite and carefully acidified with AcOH to adjust the pH to 4. The off-white precipitate formed was collected, washed thoroughly with H2O, and air dried to furnished the title compound: m/z (ES+) = 634.2 [2M+ NH ]+.
Several other acrylic acids were prepared (TABLE 1) by the piperidine- catalysed condensation of (4-methanesulfonylphenyl)acetic acid with the appropriate heteroaromatic aldehyde as described in Preparation 1.
TABLE 1
Figure imgf000029_0002
Figure imgf000030_0001
Preparation 9: (E)-2-(4-Bromophenyl)-3-furan-2-ylacrylic acid
Figure imgf000030_0002
A mixture of 4-bromophenylacetic acid (12.90g, 60.0mmol), 2- furancarboxaldehyde (6.0mL, 72.0mmol), NΕt3 (12.0mL, 86.4mmol), and Ac O (12.0mL, 127.2mmol) were heated at 140°C (bath) with stirring for l3/4h. The reaction mixture was cooled in an ice bath, before being treated with 2M HCl (30mL) to adjust the pH to 1. A solid precipitated out of solution. This solid was extracted into Et2O (500mL). The Et2O layer was washed with H2O (lOOmL), before being extracted with 5% w/v aqueous Na CO3 solution (5 x lOOmL). The aqueous extracts were washed with Et2O (2 x 50mL), before being carefully acidified with AcOH to pH 6. The cream solid generated was collected, washed with H2O, and recrystaUised from MeOH-H2O to give the title compound: mlz (ES"") = 604.0 [2M+ NH4 .
The Perkin Condensation, using NEt3 and Ac2O, was used to make other acrylic acids (TABLE 2) from the appropriate arylacetic acid and (hetero)aromatic aldehyde as described in Preparation 9.
Figure imgf000031_0001
Preparation 15: Ethyl (4-methanesulfonylphenyl)acetate
Figure imgf000031_0002
SOCl2 (8.2mL, 112.0mmol) was added to a stiπed suspension of (4- methanesulfonylphenyl)acetic acid (20.00g, 93.3mmol) in EtOH (80mL) at-10°C. The mixture was allowed to warm up to 20°C over 16h, then the solvents were removed under reduced pressure. The remainder was dissolved in EtOAc, then the resulting solution was washed with H2O until the pH ofthe aqueous phase was neutral. The EtOAc solution was washed further with saturated aqueous Na2CO3, before being dried (MgSO4). Filtration and solvent evaporation furnished the title compound: mlz (ES+) = 284.1 [M+ MeCN + H]+.
Preparation 16: Ethyl (4-methylsulfanyhnethylphenyl)acetate
Figure imgf000032_0001
(4-Methylsulfanylmethylphenyl)acetic acid (2.00g, 10.2mmol) was esterified as described above in Preparation 15 to give the title compound: mlz (ES"^) = 242.2 [ + NH4]+.
Preparation 17: Ethyl (3 -fluoro-4-methylsulfanylphenyl) acetate
Figure imgf000032_0002
(3-Fluoro-4-methylsulfanylphenyl)acetic acid (7.54g, 37.7mmol) was esterified as described above in Preparation 15 to give the title compound: RTA = 3.62min.
Preparation 18: Ethyl (4-methanesulfinylphenyl)acetate
Figure imgf000032_0003
CPBA (3.82g of 65% pure, 22.2mmol) was added portionwise to a stiπed solution of ethyl 4-(methylsulfanylphenyl)acetate (4.66g, 22.2mmol) in CH2C1 (70mL) while cooling with an ice-H2O bath. The mixture was stiπed for 4d at 20°C, before being quenched with saturated aqueous Na2CO3. The organic layer was separated, washed with saturated aqueous NaHCO3, and dried (MgSO4). Filtration, solvent evaporation, and flash chromatography (IH-EtOAc, 1:1 to 0:1) furnished the title compound: mlz (ES"1 = 227.0 [M+ H]+.
Preparation 19: Ethyl (4-ethanesulfonylphenyl)acetate
Figure imgf000033_0001
Alkylation of ethyl (4-mercaptophenyl)acetate (20g, 102mmol) with Etl (9.8mL, 122mmol), using a similar procedure to that described in Preparation 39, furnished ethyl (4-ethylsulfanylρhenyl)acetate: m/z (ES+) = 225.2 [M+ H]+. Oxidation of this compound (22.6g, lOlmmol) with CPBA (222mmol), employing a protocol similar to that described in Preparation 22, provided the title compound: mlz (ES+) = 298.2 [ + MeCN + H]+.
Preparation 20: Ethyl [4-(propane-l-sulfonyl)phenyl] acetate
Figure imgf000033_0002
Ethyl (4-propylsulfanylphenyl)acetate (20.0g, 83.9mmol) was oxidised with mCPBA (172.0mmol), employing a protocol similar to that described in Preparation 22, to afford the title compound: m/z (ES+) = 312.2 [M+ MeCN + H]+.
Preparation 21: Triphenyl(tetrahydropyran-4-ylmethyl)phosphonium iodide
Figure imgf000033_0003
A stiπed solution of 4-iodomethyltetrahydropyran (3.43g, 15.2mmol) and PPh3 (3.98g, 15.2mmol) in anhydrous MeCN (lOmL) was heated under reflux for 19h. On cooling to 20°C, Et2O (50mL) was added. The precipitate formed was collected, washed with Et2O (150mL), and recrystaUised (MeCN) to give the title compound: m/z (ES+) = 361.2 [M]+.
Preparation 22: 2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)- propionic acid
Figure imgf000033_0004
A stiπed suspension of A1C13 (12.90g, 96.8mmol) in anhydrous CH2C12 (135mL) was treated portionwise at 0°C with ethyl chlorooxoacetate (8.5mL, 76.0mmol). Cyclopropyl phenyl sulfide (lO.OmL, 70.0mmol) was added to the mixture dropwise over lh while maintaining the reaction temperature below 10°C. The mixure was allowed to warm to 20°C, before being stiπed for an additional 70min. Ice cold H2O (35mL) was added on cooling to 0°C, then the mixture was stiπed further for lOmin. The CH2C12 layer was separated, then the aqueous layer was extracted with more CH2C12 (2 x 50mL). The combined organic layers were dried (MgSO4), filtered and concentrated to give ethyl (4-cyclopropylsulfanylphenyl)- oxoacetate: RTB = 1.74min. LHMDS (3.7mL of a 1.0M solution in THF, 3.7mmol) was added to a stiπed suspension of triphenyl(tetrahydropyran-4-ylmethyl)- phosphonium iodide (Preparation 21, 1.82g, 3.7mmol) in anhydrous THF (5.6mL) at 0°C. After lh, a solution of ethyl (4-cyclopropylsulfanylphenyl)oxoacetate (0.78g, 3.1 mmol) in anhydrous THF (4mL) was added over 5min. The mixture was stiπed at 0°C for lh, before being allowed to warm to 20°C over 16h. H O (7mL) was added on cooling down to 0°C. IM HCl was added to adjust the pH to 6, then the mixture was stiπed for lh at 20°C. The THF was removed in vacuo, then Et2O (35mL) was added. The mixture was stiπed for 30min and filtered, washing with Et2O. The aqueous layer was separated and extracted with Et2O (3 x lOmL). The combined organic extracts were washed with brine (20mL), dried, filtered, and concentrated. Flash chromatography (IH-CH2C12, 2:1 to 1:1, followed by THF-CH2C12, 1:99) yielded ethyl 2-(4-cyclopropylsulfanylphenyl)-3-(tetrahydropyran-4-yl)acrylate: m/z (ES+) = 333.2 [M+ H]+. A stiπed solution of this thioether (609mg, 1.83mmol) in CH2C12 (35mL) was treated with a solution of mCPBA (992mg of 65% pure, 3.74mmol) in CH2C12 (15mL). After 16h, saturated aqueous NaHCO3 (25mL) was added, then stirring was continued for 5min. The layers were separated, then the aqueous phase was extracted with CH2C12 (20mL). The combined organic layers were washed with saturated aqueous NaHCO (25mL), H O (25mL), and brine (25mL), before being dried (MgSO ). Filtration and solvent evaporation gave ethyl 2- (4-cyclopropanesulfonylphenyl)-3-(tefrahydropyran-4-yl)acrylate: mlz (ES+) = 382.2 [M+ NH4]+. A solution of this compound (667mg, 1.83mmol) in EtOAc (60mL) was treated with Pd (10% on C, 424mg, 0.39mmol). The reaction mixture was stiπed under a H2 atmosphere for 3d, before being filtered through Celite. The Celite was washed with EtOAc (lOOmL), then the combined filtrates were concentrated to give ethyl 2-(4-cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionate: RF (CH2C12-THF, 30:1) = 0.56. A solution of this ester (664mg, 1.81mmol) in THF- H2O (3:1, 20mL) was stiπed with LiOH-H2O (168mg, 4.00mmol) for 23h. The THF was evaporated off under reduced pressure, then the remainder was diluted with H2O (lOmL). The mixture was washed with Et2O (2 x 20mL), before being acidified with 2M HCl (5mL) to pHl. The remainder was extracted with EtOAc (3 x 20mL). The combined organic extracts were washed with brine (20mL), dried (MgSO4), filtered, and evaporated to give the title compound: mlz (ES+) = 694.4 [2M+ NH ] .
Preparation 23 : (E)-2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4- yl)acrylic acid
Figure imgf000035_0001
Ethyl 2-(4-cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylate (see Preparation 22, 3.44g, 9.44mmol) was saponified, using the procedure described in Preparation 25, to afford the title compound: mlz (ES+) = 673.5 [2M+ H]+.
Preparation 24: (E)-2-(4-Cyclopropanesulfinylphenyl)-3-(tetrahydropyran-4- yl)acrylic acid
Figure imgf000035_0002
Partial oxidation of ethyl 2-(4-cyclopropylsulfanylphenyl)-3-(tetrahydropyran- 4-yl)acrylate (see Preparation 22, 3.14g, 9.44mmol) with wCPBA, employing the protocol described above in Preparation 18, furnished ethyl 2-(4- cyclopropanesulfmylphenyl)-3-(tetrahydropyran-4-yl)acrylate: mlz (ΕS+) = 349.2 [M+ H]+. Saponification of this ester (1.15g, 3.3mmol), using the procedure described in Preparation 25, afforded the title compound: mlz (ES ) = 641.4 [2 + H]+.
Preparation 25: (E)-2-(4-Methanesulfonylphenyl)-3-(tetrahydroρyran-4-yl)acrylic acid
Figure imgf000036_0001
LDA (24mL of a 1.8M solution in n-C7H16-THF-PhEt, 43.3mmol) was added dropwise to a stiπed solution of DMPU (19mL, 153.0mmol) in anhydrous THF (lOOmL) at -78°C. After 30min, a solution of ethyl (4-methanesulfonylphenyl)- acetate (Preparation 15, 5.00g, 20.6mmol) in anhydrous THF (42mL) was added dropwise. The mixture was stiπed further for lh, before being treated dropwise with a solution of tetrahydropyran-4-carboxaldehyde (2.36g, 20.6mmol) in anliydrous THF (25mL). After being allowed to warm up to 20°C over 16h, the reaction was quenched with saturated aqueous NH4C1 (210mL). The THF was removed under reduced pressure, then the remainder was extracted with EtOAc (3 x 250mL). The combined EtOAc extracts were dried (MgSO4), filtered, and concentrated. Column chromatography (IH-EtOAc, 7:3) furnished (E)-ethyl 2-(4-methanesulfonylphenyl)-3- (tetrahydropyran-4-yl)acrylate: mlz (ES+) = 356.2 [M+ NH4]+. A solution of this ester (6.46g, 19.1mmol) in MeOH (30mL) and IM NaOH (40mL, 40.0mmol) was heated under reflux for lh. On cooling, the mixture was washed with EtOAc. The aqueous phase was acidified with IM HCl, before being extracted with EtOAc. The combined organic extracts were dried (MgSO ). Filtration and solvent evaporation afforded the title compound: m/z (ES+) = 621.3 [2M+ H]+.
The acrylic acids listed in TABLE 3 were synthesised employing similar methods to those described in Preparation 25.
TABLE 3
Prep [ Structure Name | mlz (ES
Figure imgf000037_0001
Preparation 30: (E)-3-(Tetrahydropyran-4-yl)-2-(4-[l,2,3]triazol-l-ylphenyl)acrylic acid
Figure imgf000037_0002
NaOΕt (0.63mL of a 0.5M solution in ΕtOH, 0.32mmol) was added dropwise to a stiπed solution of ethyl (4-[l,2,3]triazol-l-ylρhenyl)acetate (730mg, 3.16mmol) and tetrahydropyran-4-carboxaldehyde (396mg, 3.47mmol) in anhydrous DMSO (3mL). The mixture was heated at 80°C for 16h, before being treated with AcOH to adjust the pH to 7. ΕtOAc (30mL) was added, then the solution was washed with H2O (2 x lOmL) and brine (lOmL), before being dried (MgSO4). Filtration, solvent evaporation, and column chromatography (IH-ΕtOAc, 1:1) yielded ethyl 3- (tetrahydropyran-4-yl)-2-(4-[l,2,3]triazol-l-ylρhenyl)acrylate: mlz (ΕS+) = 328.2 [M+ H] . This ester (404mg, 1.23mmol) was saponified as described above in Preparation 25 to give the title compound: mlz (ES+) = 300.2 [M+ H]+. The method detailed in Preparation 30, involving the condensation of a phenylacetic ester with the appropriate aldehyde followed by saponification ofthe intermediate α,y#-unsaturated ester, was employed to prepare the acrylic acids hsted in TABLE 4.
TABLE 4
Figure imgf000038_0001
Preparation 38: 2-(4-Methanesulfonylphenyl)-3-thiophen-2-ylpropionic acid
Figure imgf000039_0001
DMPU (50mL, 413mmol) was added to a solution of LDA (65mL of a 1.8M solution in «-C7Hi6-THF-PhEt, 117mmol) in anhydrous THF (250mL) at -78°C. The mixture was stiπed for lh to generate a cream precipitate. A solution of (4- methanesulfonylphenyl)acetic acid (12.00g, 56mmol) in anhydrous THF (120mL) was added over 20min. More anhydrous THF (30mL) was added, then the thick yellow slurry was stiπed for lh. The mixture was treated with a solution of 2- chloromethylthiophene (7.50g, 57mmol) and PhMe (5.20g, 57mmol) in anhydrous THF (20mL), then stirring was continued at -78°C for 20min. The reaction mixture was then allowed to warm to 20°C over 16h, before being quenched with H2O (500mL). The THF was removed under reduced pressure, then 12M HCl was added to adjust the pH to 2. The mixture was extracted with EtOAc (2 x 300mL), then the extracts were washed with H2O (2 x 200mL) and brine (2 x lOOmL), before being dried (MgSO4). Filtration, solvent evaporation, and column chromatography (TfT- EtOAc, 3:2 containing 0.5% AcOH) furnished the title compound: mlz (ES+) = 638.3 [2M+ NH4]+.
Preparation 39: Ethyl [4-(tetrahydropyran-4-ylsulfanyl)phenyl]acetate
Figure imgf000039_0002
NEt3 (1.3mL, 9.0mmol) and 4-iodotetrahydroρyran (1.93g, 9.0mmol) were added to a stiπed solution of ethyl (4-mercaptophenyl)acetate (1.21g, ό.Ommol) in anhydrous DMF (lOmL) at 0°C. The mixture was allowed to warm to room temperature over 3d, then the solvents were removed under reduced pressure. The residue was partitioned between Et2O (lOOmL) and saturated aqueous NH4C1 (50mL), the aqueous phase being extracted further with Et O (45mL). The combined ethereal extracts were washed with H2O (50mL), H2O-saturated aqueous Na2CO3 (1:1, 50mL), and brine (50mL), before being dried (MgSO4). Filtration, solvent evaporation, and flash chromatography (IH-Et2O, 10:1 to 2:1) afforded the title compound: RF (IH-Et2O, 2:1) = 0.31.
Preparation 40: Ethyl (4-methoxymethylsulfanylphenyl)acetate
Figure imgf000040_0001
This compound was prepared using the procedure described above in Preparation 39: RF (ffl-Et20, 10:1) = 0.19.
Preparation 41 : 2-(4-Methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionic acid
Figure imgf000040_0002
LDA (38.9mL of a 1.8M solution in «-C7H16-THF-PhEt, 70.0mmol) was added to a solution of DMPU (59.3mL, 490.3mmol) in anhydrous THF (150mL) at -78°C. The mixture was stiπed for 30min, before being treated dropwise with a solution of ethyl (4-methanesulfonylphenyl)acetate (Preparation 15, 16.97g, 70.0mmol) in anhydrous THF (50mL). Stirring was continued at -78°C for 45min, then a solution of 4-iodomethyltetrahydropyran (19.00g, 84.0mmol) in anhydrous THF (40mL) was added. The mixture was allowed to warm to 20°C over 16h, before being quenched with IM HCl (70mL). The THF was removed under reduced pressure, then more H2O (40mL) was added and the remainder extracted with EtOAc (2 x 250mL). The EtOAc extracts were dried (MgSO ). Filtration, solvent evaporation, and flash chromatography (IH-EtOAc, 9:1 to 1:1) furnished ethyl 2-(4- methanesulfonylphenyl)-3-(tefrahydropyran-4-yl)'propionate: mlz (ES+) = 698.3 [2M+ Η4]+. A solution of this compound (20.27g, 59.6mmol) in MeOH (lOOmL) and 2M NaOH (62.5mL, 125.0mmol) was heated under reflux for lh. The solvents were removed under reduced pressure, then the remaining solid was triturated with Et2O (5 x lOOmL), before being dissolved in H2O (lOOmL). The aqueous solution was washed with EtOAc (50mL), acidified with 2M HCl to pH 1, and exfracted with EtOAc (2 x IL). After drying (MgSO4), filtration and solvent evaporation gave the title compound: mlz (ES4) = 642.3 [2M+ NH4]+.
Similar approaches to those highlighted by Preparation 41, involving alkylation ofthe appropriate ester with 4-iodomethyltetrahydroρyran followed by hydrolysis ofthe product, were employed to prepare the carboxylic acids shown in TABLE 5.
TABLE 5
Figure imgf000041_0001
Figure imgf000042_0001
Preparation 50: 2-(3-Fluoro-4-methanesulfonylphenyl)-3-(tetrahydropyran-4- yl)propionic acid
Figure imgf000042_0002
A stiπed solution of 2-(3-fluoro-4-methylsulfanylphenyl)-3-(tetrahydropyran- 4-yl)propionic acid (Preparation 47, 598mg, 2.0mmol) in CH2C12 (20mL) was treated with wCPBA (1.15g of 60% pure, 4.0mmol). After 16h, the solution was filtered, then the filtrate was purified by column chromatography (EH-EtOAc-AcOH, 320:80:1 to 80:320:1) to furnish the title compound: mlz (ES+) = 678.3 [2M+ NH4]+.
Preparation 51: 2-(4-Ethylsulfamoylphenyl)-3-(tetrahydropyran-4-yl)propionic acid
Figure imgf000042_0003
Ethyl (4-nitrophenyl)acetate (25.0g, 119.5mmol) was alkylated with 4- iodomethyltetrahydropyran (32.4g, 143.4mmol), according to the protocol described in Preparation 41, to give ethyl 2-(4-nifrophenyl)-3-(tetralιydropyran-4- yl)propionate: o (CDC13): 1.21 (3H, t), 1.25-1.45 (3H, m), 1.55-1.65 (2H, m), 1.70- 1.80 (IH, m), 2.05-2.15 (IH, m), 3.25-3.35 (2H, m), 3.79 (IH, t), 3.90-3.95 (2H, m), 4.10-4.20 (2H, m), 7.49 (2H, d), 8.19 (2H, d). The nitro group of this compound (6.55g, lδ.lmmol) was reduced utilising the procedure described in EXAMPLE 145 to give ethyl 2-(4-aminophenyl)-3-(tetrahydropyran-4-yl)propionate: m/z (ES+) = 278.2 [M+ H]+. This compound (30.5g, 1 lOmmol) was transformed into ethyl 2-(4- chlorosulfonylphenyl)-3-(tefrahydropyran-4-yl)propionate employing the protocol described in Preparation 59. A solution of this sulfonyl chloride (33.6g, 93.2mmol) in anhydrous THF (lOOmL) was added over 30min at 0°C to EtNH2 (116.5mL of a 2.0M solution in THF, 233.0mmol). The mixture was warmed up to 20°C, before being stiπed for 16h. The suspension was filtered through a Celite pad, which was washed with THF (3 x 50mL). The combined THF solutions were concentrated to furnish crude ethyl 2-(4-ethylsulfamoylphenyl)-3-(tetrahydropyran-4-yl)propionate: mlz (ES+) = 370.2 [M+ H]+. Hydrolysis of this ester (33.7g, 91.2mmol), utilising the procedure outlined in Preparation 41, followed by purification via RP-HPLC afforded the title compound: mlz (ES+) = 342.2 [M+ H]+.
Preparation 52: 2-(4-Cyclobutanesulfonylρhenyl)-3-(tetrahydropyran-4-yl)propionic acid
Figure imgf000043_0001
Alkylation of ethyl (4-mercaptophenyl)acetate (9.5g, 48.4mmol) with c-BuBr (7.84g, 58.1mmol), using a similar procedure to that described in EXAMPLE 161, furnished ethyl (4-cyclobutylsulfanylphenyl)acetate: RTA = 4.17min. Oxidation of this compound (18.5g, 73.9mmol) with mCPBA (222mmol), employing a protocol similar to that described in Preparation 22, provided ethyl (4- cyclobutanesulfonylphenyl)acetate: mlz (ES+) = 283.2 [M + H]+. Condensation of this compound (18.84g, 66.7mmol) with tetrahydropyran-4-carboxaldehyde (8.38g, 73.4mmol), utilising the procedure described in Preparation 30, gave ethyl 2-(4- cyclobutanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylate: mlz (ES+) = 396.2 [M+ NH4] . Reduction of this α,/3-unsaturated ester (13.00g, 34.4mmol), using the protocol described in Preparation 22, furnished ethyl 2-(4- cyclobutanesulfonylρhenyl)-3-(tefrahydropyran-4-yl)propionate: mlz (ES+) = 381.2 [M+ H]+. This ester was hydrolysed employing the procedure outlined in Preparation 22 to afford the title compound: mlz (ES+) = 370.2 [M+ NH4]+.
Preparation 53 : (2R)-2-(4-Methanesulfonylphenyl)-3-(tefrahydropyran-4- yl)propionic acid
Figure imgf000044_0001
NEt3 (15.4mL, 1 lOmmol) was added to a stiπed suspension of 2-(4- methanesulfonylphenyl)-3-(tefrahydropyran-4-yl)propanoic acid (Preparation 41, 30.0g, 96.0mmol) in anhydrous THF (300mL) at 0°C. After lOmin, pivaloyl chloride (13.6mL, 1 lOmmol) was added dropwise over 20min and the mixture was stiπed at 0°C for 2h. Meanwhile, «-BuLi (45.3mL of a 2.5M solution in hexanes, 115mmol) was added to a solution of (R)-(+)-4-benzyl-2-oxazolidinone (20.4g, 115mmol) in anhydrous THF (300mL) at -78°C. The mixture was stiπed at -78°C to 20°C over 2h. The solution thus obtained was added dropwise to the abovementioned mixed anhydride solution at -78°C. The reaction was stiπed at -78°C for lh and then at 20°C for 4h, before being treated with H2O (300mL). The THF was removed in vacuo, then the remainder was extracted with EtOAc (3 x 300mL). The combined organic layers were washed with H O, dried (Na2SO4), filtered, and concentrated in vacuo. Chromatographic separation (EtOAc-π-C6H14, 1:2 to 1:1) afforded two products: (1) (4R)-4-benzyl-3-[(2R)-2-[4-(methylsulfonyl)phenyl]-3-(tetrahydro-2H- pyran-4-yl)propanoyl]-l,3-oxazolidin-2-one: mp 139-141°C (from Et2O-TΗF); (2) (4R)-4-benzyl-3-[(2S)-2-[4-(methylsulfonyl)phenyl]-3-(tetrahydro-2H-pyran-4- yl)propanoyl]-l,3-oxazolidin-2-one: mlz (APCI4) = 472 [M+ Η]+. A solution of LiOH (1.5g, 64mmol) and 35% aqueous H2O2 (14.5g, 128mmol) in H2O (400mL) was added dropwise over 40min to a stiπed solution of (4R)-4-benzyl-3-[(2R)-2-[4- (methylsulfonyl)phenyl]-3-(tetrahydro-2H-pyran-4-yl)propanoyl]-l,3-oxazolidin-2- one (15. Ig, 10.9mmol) in TΗF-Η2O (3:1, 1.6L) at 0°C. The reaction was stiπed at 0°C for 1.5h, then the remaining oxidant was destroyed with 10% aqueous Na2SO3. The mixture was washed with Et O (4 x 300mL), acidified with 10% aqueous HCl, and extracted with EtOAc (3 x 200mL). The combined organic layers were washed with brine, dried (Na2SO4), filtered, and concentrated in vacuo. Trituration with Et2O-hexanes gave the title compound: mp 217°C; the absolute configuration was determined by X-ray crystallograpbic analysis. Preparation 54: (2R)-2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4- yl)propionic acid
Figure imgf000045_0001
The title compound ([α]D 20 -48.8 (c = 1.02, CHC13)) was obtained from 2-(4- cyclopropanesulfonylphenyl)-3 -(tefrahydropyran-4-yl)propionic acid (Preparation 22) employing the protocols described in Preparation 53.
Preparation 55: (2R)-2-(4-Ethylsulfamoylphenyl)-3-(tetrahydropyran-4-yl)propionic acid
Figure imgf000045_0002
The title compound was obtained from 2-(4-ethylsulfamoylphenyl)-3- (tetrahydropyran-4-yl)propionic acid (Preparation 51) by employing the protocols described in Preparation 53. It was analysed by chiral HPLC: CHIRAL CEL OJ-Rs (Daicel Chemical Industries, Ltd., Tokyo, Japan), 4.6mm ø x 15cm, CH3CN-0.5M NaClO4 (pH 2.0), 17:83, 0.5mL/min, UV 235nm, 25°C; RT (R) = 43.89min (RT (S) ■■ 38.84min).
Preparation 56: (2R)-2-(4-Cyclobutanesulfonylphenyl)-3-(tetrahydropyran-4- yl)propionic acid
Figure imgf000045_0003
The enantiomerically pure title compound was obtained from 2-(4- cyclobutanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionic acid (Preparation 52) by employing the protocols described in Preparation 53. It was analysed by chiral HPLC: CHIRAL CEL OJ-R® (Daicel Chemical Industries, Ltd., Tokyo, Japan), 4.6mm ø x 15cm, CH3CN-0.5M NaClO4 (pH 2.0), 17:83, 0.5mL/min, UV 235nm, 25°C; RT (R) = 82.69min (RT (S) = 78.63min).
Preparation 57: 2-(4-Methylsulfanyl-3 -nitrophenyl)-3 -(tetrahydropyran-4- yl)propionic acid
Figure imgf000046_0001
(4-Chloro-3-nitrophenyl)acetic acid (lO.OOg, 46.4mmol) was esterified as described above in Preparation 15 to furnish ethyl (4-chloro-3-nitrophenyl)acetate: m/z (ES+) = 285.2 [M+ MeCN + H]+. Alkylation of this ester (10.50g, 43.1mmol), using the protocol described in Preparation 41, yielded ethyl 2-(4-chloro-3- nitrophenyl)-3-(tetrahydropyran-4-yl)propionate: m/z (ES+) = 342.1 [M+ H]+. A solution of this compound (7.42g, 19.7mmol) in DMSO (50mL) was treated with NaSMe (1.52g, 21.6mmol). The mixture was stiπed at 20°C for 5.5h and then at 50°C for 2h, before being poured onto cmshed ice (500mL). After the ice had melted completely, the mixture was partitioned between EtOAc (250mL) and H2O (lOOmL). The aqueous phase was further extracted with EtOAc (4 x 200mL), then the combined organic extracts were washed with brine and dried (MgSO4). Filtration, solvent evaporation, and column chromatography (IH-EtOAc, 7:3) gave ethyl 2-(4- methylsulfanyl-3-nitrophenyl)-3-(tetrahydropyran-4-yl)propionate: mlz (ES4) = 371.0 [M+ NH4]+. This ester (7.48g, 19.2mmol) was hydrolysed with LiOH H2O, as described above in Preparation 22, to furnish the title compound: mlz (ES+) = 343.3 [ + NH4]+.
Preparation 58: 2-(3-Methylsulfanylphenyl)-3-(tetrahydropyran-4-yl)propionic acid
Figure imgf000046_0002
Ethyl (3-nitrophenyl)acetate (11.60g, 55.5mmol) was condensed with tetrahydropyran-4-carboxaldehyde employing the procedure described in Preparation 30 to give ethyl 2-(3-nifrophenyl)-3-(tetrahydropyran-4-yl)acrylate: mlz (ES+) = 628.3 [2M+ NH4]+. A solution of this compound (4.65g, 15.2mmol) in EtOH (80mL) was treated with a sluπy of Pd (10% on C, 49mg, 0.46mmol) in EtOH (lOmL) and H2O (lmL). The mixture was stiπed under a H2 atmosphere for 24h, before being filtered through Celite. The Celite was washed with EtOAc (5 x 50mL), then the combined filtrates were evaporated to give ethyl 2-(3-aminophenyl)-3- (tetrahydropyran-4-yl)propionate: mlz (ES4) = 278.2 [M+ H]+. A solution of this compound (2.77g, lO.Ommol) in DME (lOmL) was added over 30min to a stiπed mixture of z-AmONO (2.0 mL, 15.0mmol) and MeSSMe (9.9mL, 1 lO.Ommol). The temperature was raised to 45°C for 0.5h and then to 85°C for 1.5h. On cooling, the solvents were removed under reduced pressure, then the residue was dissolved in EtOAc (60mL). The EtOAc solution was washed with IM HCl (2 x 20mL), H2O (20mL), and brine (20mL). Filtration, solvent evaporation, and column chromatography (CH2Cl2-Et20, 1:0 to 99:1) afforded ethyl 2-(3-methylsulfanyl- phenyl)-3-(tetrahydropyran-4-yl)propionate: mlz (ES+) = 309.2 [M+ H] . Saponification of this ester with LiOHΗ2O, by the protocol outlined in Preparation 22, furnished the title compound: mlz (ES+) = 561.3 [2M+ H]+.
Preparation 59 : 4-[2-(Tetrahydropyran-4-yl)- 1 -(thiazol-2-ylcarbamoyl)ethyl] - benzenesulfonyl chloride
Figure imgf000047_0001
2-(4-Nitrophenyl)-3-(tetrahydropyran-4-yl)propionic acid (Preparation 46, 10.40g, 37.2mmol) was condensed with thiazol-2-ylamine employing the procedure described in EXAMPLE 65 to afford 2-(4-nitrophenyl)-3-(tefrahydropyran-4-yl)-N- thiazol-2-ylpropionamide: mlz (ES4) = 362.1 [M+ H]+. The nitro group of this compound (6.55g, 18.1mmol) was reduced utilising the procedure described in EXAMPLE 145 to give 2-(4-aminoρhenyl)-3-(tetrahydroρyran-4-yl)-N-thiazol-2-yl- propionamide: mlz (ES4) = 332.1 [M+ H]+. A solution of ΝaΝO2 (2.1 lg, 30.5mmol) in H2O (20mL) was added slowly to a stiπed mixture ofthe above aniline (9.40g, 28.4mmol), 12M HCl (30mL), and H2O (30mL) at 0°C. After lh, the resulting diazonium salt solution was added over 15min to a mixture of CuCl2-2H2O (1.29g, 7.6mmol) in AcOH (64.5mL) and H2O (3.2mL) which had been saturated previously with SO2. The mixture was stiπed for 1.5h, treated with H2O (200mL) and exfracted with EtOAc (300 + 150 mL). The combined EtOAc extracts were washed with H2O (2 x 200mL), filtered, and dried (MgSO4). Filtration and solvent evaporation provided the title compound: mlz (ES4) = 466.1 [M+ MeCN + H]+.
Preparation 60: 4-[l-(5-Chlorothiazol-2-ylcarbamoyl)-2-(tetrahydropyran-4- yl)ethyl]benzenesulfonyl chloride
Figure imgf000048_0001
Using similar procedures to those described in Preparation 59, 2-(4- nitrophenyl)-3-(tetrahydropyran-4-yl)propionic acid (Preparation 46, 9.74g, 34.9mmol) was converted into the title compound: <5H (CDC13): 1.25-1.50 (3H, m), 1.55-1.70 (2H, br), 1.80-1.85 (IH, m), 2.20-2.30 (IH, m), 3.20-3.35 (2H, m), 3.80- 4.00 (3H, m), 7.20 (IH, s), 7.65 (2H, d), 8.00 (2H, d).
Preparation 61: 5-Fluorothiazol-2-ylamine hydrochloride
H.,N-^ 'S -F
\J HCI
NEt3 (63.4mL, 455mmol) was added to a stiπed suspension of 5- bromothiazol-2-ylamine hydrobromide (102.7g, 379mmol) in CH2C1 (1.5L). After lh, TFAA (64.2mL, 455mmol) was added dropwise at 0°C over 15min. The mixture was allowed to warm to 20°C over lh, before being stiπed for an additional 2h. H2O (600mL) was added and the resulting precipitate was collected. The aqueous layer of the filtrate was separated and extracted with CHC13 (3 x 300mL). The combined organic extracts were washed with brine, dried (Na2SO4), filtered and concentrated. The collected precipitate and residual solid were combined and triturated with EtOAc-n-C6H14 to give N-(5-bromothiazol-2-yl)-2,2,2-trifluoroacetamide: <5 (CDCI3): 7.45 (IH, s), 13.05 (IH, br). n-BuLi (253mL of a 1.58M solution in hexanes, 403mmol) was added dropwise over 50min to a stiπed solution ofthe above amide (50.0g, 183mmol) in anhydrous THF (1.3L) at -78°C. After 1.5h, a solution of N-fluorobenzenesulphonimide (86.0g, 275mmol) in anhydrous THF (250mL) was added dropwise over 30min. The mixture was stiπed for 3h, before being warmed up to -30°C. H2O (300mL) was added and the mixture was filtered through a Celite pad. The solid collected and Celite were washed with Et2O (400mL) and H2O (400mL). The organic layer ofthe filtrate was separated and extracted with water (2 x 400mL). The combined aqueous layers were washed with Et2O (400mL), before being acidified to pH 6.5 with 2M HCl and extracted with EtOAc (2 x 400mL). The combined organic extracts were washed with H2O (2 x 400mL) and brine, before being dried (MgSO4), filtered and concentrated. Column chromatography (EtOAc- «-C6H14, 1:3 to 1:2) gave N-(5-fluorothiazol-2-yl)-2,2,2-trifluoroacetamide: δn (CDC13): 7.13 (IH, d). AcCl (12.6mL, 175mmol) was added dropwise to a stiπed solution of this amide (15.7g, 73mmol) in MeOH (300mL) at 0°C. The mixture was stiπed at 20°C for 30min, heated under reflux for lh, and finally concentrated in vacuo. The residual solid was triturated with THF to give the title compound: <5H (D2O): 7.00 (IH, d).
Preparation 62 : 4-[2-(Tetrahydropyran-4-yl)- 1 -(thiazol-2-ylcarbamoyl)ethyl]benzoic acid
Figure imgf000049_0001
Methyl 4-tert-butoxycarbonyhnethylbenzoate (1.71g, 6.84mmol) was alkylated with 4-iodomethyltetrahydropyran (1.86g, 8.21mmol), employing the method described in Preparation 41, to afford methyl 4-[l-tert-butoxycarbonyl-2- (tetrahydropyran-4-yl)ethyl]benzoate: RTA = 3.86min. A solution of this compound (1.37g, 3.94mmol) in CH2C12 (5mL) was treated with TFA-CH2C12 (2:1, 15mL) at 0°C over lOmin. The mixture was stiπed at 20°C for 3h, before being concentrated in vacuo. The residue was freated with PhMe and the solvents were evaporated off under reduced pressure. This process was repeated twice to provide crude methyl 4-[l- carboxy-2-(tetrahydropyran-4-yl)ethyl]benzoate. This carboxylic acid was condensed with thiazol-2-ylamine, utilizing the protocol outlined in EXAMPLE 65, to furnish methyl 4-[2-(tetrahydropyran-4-yl)-l-(thiazol-2-ylcarbamoyl)ethyl]benzoate: mlz (ES4) = 375.2 [M+ H]+. This ester (1.20g, 3.21mmol) was saponified with LiOH-H2O, using the procedure described in Preparation 22, to furnish the title compound: mlz (ES~) = 359.2 [M- H]~.
EXAMPLE 1
(E)-2-(4-Methanesulfonylphenyl)-N-thiazol-2-yl-3-thiophen-3-ylacrylamide
Figure imgf000050_0001
A suspension of PS-carbodiimide (688mg, loading 1.34 mol mg~ , 922 anol), (E)-2-(4-methanesulfonylphenyl)-3-thiophen-3-ylacrylic acid (Preparation 1, 139mg, 450 Λnol), and HOBt (84mg, 622μmόϊ) in anhydrous DMF was stiπed for 15min at 20°C. Thiazol-2-ylamine (32mg, 320 Λnol) was added, then the mixture was stiπed for 40h at 20°C, before being filtered through Celite. The filter cake was washed with DMF (lOmL), EtOAc (20mL), and CH2C12 (20mL). The solutions were combined, the solvents removed under reduced pressure, and the residue dissolved in EtOAc (50mL). The EtOAc solution was washed with saturated aqueous Νa CO (3 x 20mL), H O (20mL), and brine (20mL), before being dried (Na SO4). Filtration, solvent evaporation, and flash chromatography (IH-EtOAc, 3:1 to 1:3) gave the title compound: RTA = 3.43 min; mlz (ES4) = 391.0 [M+ H]+.
The PS-carbodiimide-HOBt-mediated condensation ofthe appropriate carboxylic acid with thiazol-2-ylamine, as outlined in EXAMPLE 1, was also used to synthesise the amides listed in TABLE 6 below.
TABLE 6
Ex I Structure | Name | RT (min) | mlz ES
Figure imgf000051_0001
Figure imgf000052_0001
Figure imgf000053_0001
Figure imgf000054_0001
EXAMPLE 36
(E)-N-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-thiophen-2- ylacrylamide
Figure imgf000055_0001
A solution of (E)-2-(4-methanesulfonylρhenyl)-3-thiophen-2-ylacrylic acid (Preparation 2, 309mg, l.Ommol), HATU (813mg, 2.1mmol), 5-chlorothiazol-2- ylamine hydrochloride (258mg, 1.5mmol), and DIPEA (0.71mL, 4.0mmol) in anhydrous DMF (5mL) was heated under microwave iπadiation with stirring at 60° C for 2min. The solvents were evaporated off under reduced pressure, then the remainder was partitioned between CH2C1 (60mL) and IM HCl (60mL). The organic layer was separated and washed with IM HCl (60mL), H2O (60mL), saturated aqueous Na2CO3 (2 x 60mL), H2O (60mL), and brine (60mL), before being dried (Na2SO4). Filtration, solvent evaporation, and flash chromatography (IH-EtOAc, 4:1 to 2:3) gave the title compound: RTA = 3.77min; mlz (ES4) = 466.1 [M+ MeCN + H]+.
The microwave-mediated condensation ofthe appropriate carboxylic acid with thiazol-2-ylamines, outlined in EXAMPLE 36, was also employed to prepare the amides listed in TABLE 7 below.
TABLE 7
Figure imgf000055_0002
Figure imgf000056_0001
EXAMPLE 44
(E)-2-(4-Bromophenyl)-N-(5-chlorothiazol-2-yl)-3-furan-2-ylacrylamide
Figure imgf000056_0002
A suspension of (E)-2-(4-bromophenyl)-3-furan-2-ylacrylic acid (Preparation 9, 4.10g, H.Ommol) and oxalyl chloride (2.5mL, 28.0mmol) in anhydrous CH C12 (lOOmL) was treated with a catalytic amount of anhydrous DMF (25/ L). The resulting solution was stiπed at 20°C for 4h, then the solvents were removed under reduced pressure. CH C1 (50mL) was added to the residue, then the solvents were evaporated off under reduced pressure to give 2-(4-bromophenyl)-3- furan-2-ylacryloyl chloride as a brown solid. A solution of this acid chloride (343mg, 1.1 mmol) in anhydrous THF (lmL) was added to a solution of 5-chlorothiazol-2- ylamine hydrochloride (171mg, LOmmol) and ΝΕt3 (0.56mL, 4.0mmol) in anhydrous THF (lmL). The suspension was stiπed for 16h at 20°C, then the solvents were removed under reduced pressure. The residue was partitioned between CH2C12 (lOmL) and saturated aqueous NaHCO3 (5mL). The organic layer was washed with H2O (5mL) and brine (5mL), before being concentrated. The resulting solid was recrystaUised from MeOH to furnish the title compound: RT = 4.39min; mlz (ES ) = 410.9 [M+ H]4".
Several other enamides were prepared via the condensation ofthe appropriate acid chloride with heteroaromatic amines as represented by EXAMPLE 44. These compounds are listed in TABLE 8 below.TABLE 8
Figure imgf000057_0001
Figure imgf000058_0001
Figure imgf000059_0002
EXAMPLE 65
2-(4-Methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2-ylpropionamide
Figure imgf000059_0001
EDCI (80mg, 420 anol) and HOBt (56mg, 420/ mol) were added to a stiπed solution of 2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionic acid (Preparation 41, lOOmg, 320 Λnol) in anhydrous DMF (6mL). After 15min, the solution was treated with thiazol-2-ylamine (38mg, 380 mol). The mixture was stiπed at 20°C for 16h, before being concentrated under reduced pressure. The residue was partitioned between CH2C12 and saturated aqueous Νa2CO3. The organic layer was washed with IM HCl and dried (MgSO4). Filtration and solvent evaporation yielded the title compound: RTA = 3.16 min; mlz (ES4) = 436.2 [M+ MeCN + H]+.
The procedure exemplified by the preparation of EXAMPLE 65 was also used to prepare several other amides (TABLE 9).
TABLE 9
Figure imgf000059_0003
Figure imgf000060_0001
O 2004/072031
Figure imgf000061_0001
Figure imgf000062_0001
EXAMPLE 93
(2R)-3-(Tetrahydropyran-4-yl)-2-(4-methanesulfonylphenyl)-N-thiazol-2- ylpropionamide
Figure imgf000063_0001
Method A: To a stiπed solution of PPh3 (3.53g, 13.4mmol) in CH2C12 (70mL) was added NBS (882mg, 10.6mmol) at 0°C. After lOmin, (2R)-2-(4- methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionic acid (Preparation 53, 2.80g, 9.0mmol) was added, then the mixture was stiπed at 0°C for 20 min, and then at 20°C for 30min. Thiazol-2-ylamine (933mg, 9.3mmol) and pyridine (2.2mL, 18.8mmol) were added at 0°C, then the mixture was stiπed at 20°C for 20h. After solvent evaporation, the residue was partitioned between 5% aqueous citric acid (lOOmL) and EtOAc (500mL). The aqueous layer was further exfracted with EtOAc (200mL), then the combined organic layers were washed with H O and brine, before being dried (Na2SO4), filtered, and concentrated in vacuo. Chromatographic purification (CHCl3-MeOH, 99:1) ofthe residue on Chromatorex® NH-DM1020 (Fuji Silysia Chemical, Ltd., Aichi-ken, Japan; See also http://www.fuji-silysia.co.jp/e- fll00dx.htm) gave the title compound: mp 217°C; [α]D 20 -51.5 (c = 1.00, CHC13).
Method B: Racemic 2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)- N-thiazol-2-ylpropionamide (EXAMPLE 65) was separated by chiral stationary phase HPLC. Method: CHIRAL CEL OJ® (Daicel Chemical Industries, Ltd., Tokyo, Japan), 10cm ø x 25cm, MeOH (100%), 189mL/min, UV 285nm, 25°C; RT (S) = 21.7min; RT (R) = 25.4min. Analysis: CHIRAL CEL OJ-R® (Daicel Chemical Industries, Ltd., Tokyo, Japan), 4.6mm ø x 15cm, CH3CΝ-0.5M NaClO4 (pH 2.0), 20:80, 0.5mL/min, UV 225nm, 25°C; RT (S) = 11.53min; RT (R) = 19.30min.
Method A of EXAMPLE 93 was utilised to obtain the compounds listed in TABLE 10 from the appropriate heteroaromatic amine and enantiopure acid.
TABLE 10
Figure imgf000063_0002
Hf
Figure imgf000064_0001
(2R)-2-(4-Cyclopropane- sulfonylphenyl)-N-(3- -52.0 436
102 methyl-[ 1 ,2,4]thiadiazol- (c = 1.00, CHCl3, 25°C) [M+ Hf 5-yl)-3-(tetrahydroρyran-
Figure imgf000065_0001
4-yl)propionamide
Method A of EXAMPLE 93 was also used to prepared the compounds listed in TABLE 11 from the appropriate heteroaromatic amine and enantiopure acid.
TABLE 11
Figure imgf000065_0002
Figure imgf000066_0001
EXAMPLE 114
(E)-2-(4-Cyclopropanesulfonylphenyl)-N-(5-fluoropyridin-2-yl)-3-(tetrahydropyran-
4-yl)acrylamide
Figure imgf000066_0002
TFFH (283mg, 1.07mmol) and DLPEA (373 tmol, 2.14mmol) were added to a stiπed solution of (E)-2-(4-cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4- yl)acrylic acid (Preparation 23, 300mg, 0.89mmol) in anhydrous CH2C12 (18mL). After 30min, the solution was treated portionwise with 2-amino-5-fluoropyridine (200mg, 1.78mmol) over 30min, before being stiπed further for 16h. Solvent evaporation and purification by RP-HPLC furnished the title compound: RTA = 3.34min; mlz (ES4) = 431.2 [M+ H]+.
The procedure exemplified by the preparation of EXAMPLE 114 was also used to prepare several other amides (TABLE 12).
TABLE 12
Figure imgf000067_0001
Figure imgf000068_0001
EXAMPLE 124, EXAMPLE 125, AND EXAMPLE 126
(E)-2-Phenyl-3-(tefrahydropyran-4-yl)-N-thiazol-2-ylacrylamide, (E)-2-(4-
Formylphenyl)-N-(5-formylthiazol-2-yl)-3-(tetrahydropyran-4-yl)acrylamide, and
(E)-N-(5-Formylthiazol-2-yl)-2-phenyl-3-(tetrahydropyran-4-yl)acrylamide
Figure imgf000068_0002
n-BuLi (17mL of a 1.6M solution in hexanes, 27.2mmol) was added to a stiπed solution of (E)-2-(4-bromophenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylacrylamide (EXAMPLE 12, 4.00g, 10.2mmol) in anhydrous THF (lOOmL) at -78°C. After 1 lOmin, the mixture was freated with anhydrous DMF (5mL, 64.6mmol), before being allowed to warm to 20°C over 30min. The reaction was quenched with IM HCl, then the THF was evaporated off under reduced pressure. The aqueous phase was extracted with CH2C12, then the CH2C12 extracts were dried (MgSO4), filtered, and concenfrated. The residue was stiπed with Νa2S2O5 solution. The solid produced was collected and triturated with EtOAc. This material was then suspended in EtOAc, then saturated aqueous NaHCO3 was added with stirring. The layers were separated, then the aqueous phase was extracted with EtOAc and CH2C12. The combined organic layers were dried, filtered, concentrated, and subjected to column chromatography (CH2C12-THF, 93:7), to give EXAMPLE 125 (RTB = 1.30min; mlz (ES4) = 371.2 [M+ H]4) and EXAMPLE 126 (RTB = 1.38min; mlz (ES4) = 343.4 [M+ H]4). The EtOAc washings from the bisulfite addition complex were concentrated, then the residue was subjected to flash chromatography (CH2C12- THF, 24:1 to 93:7) to give EXAMPLE 124 (RTB = 1.39min; mlz (ES4) = 315.3 [M+ H]+) and an additional quantity of EXAMPLE 126.
EXAMPLE 127
2-[2-(4-Methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionylamino]tlιiazole-5- carboxylic acid
Figure imgf000069_0001
Ethyl 2-aminothiazole-5-carboxylate (2.21g, 12.8mmol) was condensed with 2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionic acid (Preparation 41, l.OOg, 3.2mmol), using the procedure described for EXAMPLE 65, to give ethyl 2-[2-(4-methanesulfonylphenyl)-3-(tefrahydropyran-4- yl)propionylamino]thiazole-5-carboxylate: mlz (ES4) = 508.3 [M+ MeCN + H]+. LiOHΗ2O (410mg, 9.8mmol) was added to a solution of this ester (1.44g, 3.1mmol) in THF-H2O (3:1, 30mL). The mixture was stiπed at 20°C for 16h and then at 55°C for 24h. The solvents were removed in vacuo, then the residue was dissolved in H O (50mL). The aqueous solution was washed with EtOAc (20mL), before being acidified to pH 1 with 2M HCl and exfracted with EtOAc (2 x lOOmL). The combined organic extracts were dried (MgSO4), filtered and concentrated to give a solid that was recrystaUised (EtOAc-MeOH) to give the title compound: RTA = 2.95min; mlz (ES+) = 480.2 [M+ MeCN + H]4".
EXAMPLE 128
2-[2-(4-Methanesulfonylphenyl)-3-(tefrahydropyran-4-yl)propionylamino]thiazole-5- carboxylic acid methoxy-methyl-amide
Figure imgf000070_0001
NEt3 (647 μL, 4.64mmol) and BOP (976mg, 2.21mmol) were added to a stiπed solution of 2-[2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4- yl)propionylamino]tlιiazole-5-carboxylic acid (EXAMPLE 127, 968mg, 2.21mmol) in anhydrous DMF (30mL). After 5min, N,O-dimethylhydroxylamine hydrochloride (237mg, 2.43mmol) was added, then the mixture was stiπed at 20°C for 18h. The solvents were removed in vacuo, then the residue was dissolved in EtOAc (75mL). The EtOAc solution was washed with saturated aqueous Νa2CO (40mL), 2M HCl (40mL), and brine (40mL), before being dried (MgSO4). Filtration and solvent evaporation provided the title compound: RTB = 1.27min; m/z (ES4) = 482.0 [M+ H]+.
EXAMPLE 129
2-[2-(4-Methanesulfonylphenyl)-3-(tefrahydropyran-4-yl)propionylamino]thiazole-5- carboxylic acid methylamide
Figure imgf000070_0002
2-[2-(4-Methanesulfonylphenyl)-3-(tetrahydropyran-4- yl)propionylamino]thiazole-5-carboxylic acid (EXAMPLE 127, 399mg, 0.91mmol) was condensed with MeNH ΗCl in the presence of NEt3, utilising the general procedure described in EXAMPLE 65, to give the title compound: RTA = 2.82min; m/z (ES4) = 452.3 [M+ H]4".
EXAMPLE 130
(E)-2-[2-(4-Methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acryloylamino]thiazole-
5-carboxylic acid methylamide
Figure imgf000071_0001
Ethyl 2-aminothiazole-5-carboxylate (0.73g, 4.26mmol) was condensed with (E)-2-(4-methanesulfonylphenyl)-3-(tefraliydropyran-4-yl)acrylic acid (Preparation 25, 0.33g, 1.07mmol), using the procedure described in EXAMPLE 65, to give (E)-ethyl 2-[2-(4-methanesulfonylphenyl)-3- (tefrahydropyran-4-yl)acryloylamino]thiazole-5-carboxylate: mlz (ΕS ) = 465.3 [M+ H]+. This ester (0.50g, 1.07mmol) was saponified, employing the protocol described in EXAMPLE 127, to furnish (E)-2-[2-(4-methanesulfonylphenyl)-3- (tefrahydropyran-4-yl)acryloylamino]thiazole-5-carboxylic acid: mlz (ΕS-) = 435.2 [M- H]~. Utilising the approach described in EXAMPLE 129, this acid (0.16g, 0.37mmol) was transformed into the title compound: RTA = 2.87min; mlz (ES4) = 450.2 [M+ H]4".
EXAMPLE 131 AND EXAMPLE 132
N-(5-Formylthiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4- yl)propionamide andN-(5-Hydroxymethylthiazol-2-yl)-2-(4-methanesulfonylphenyl)-
3 -(tetrahydropyran-4-yl)propionamide
Figure imgf000071_0002
DLBAL (2.45mL of a 1.5M solution in PhMe, 3.68mmol) was added dropwise to a stiπed solution of ethyl 2-[2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4- yl)propionylamino]thiazole-5-carboxylate (see EXAMPLE 127, 1.72g, 3.68mmol) in anhydrous CH2C12 (50mL) at -78°C. After 50min, more DLBAL (2.0mL of a 1.5M solution in PhMe, 3.00mmol) was added. The mixture was stiπed further for 70min, before being quenched with MeOH (3mL) and IM HCl (3mL). On warming to 20°C, more IM HCl (20mL) was added. The organic phase was separated, dried (MgSO4), filtered, and concenfrated, before being purified by column chromatography (LΗ- EtOAc, 1:9 to 0:1, then MeOH:EtOAc, 1:9) to give the title aldehyde (RTA = 2.97min; mlz (ES4) = 464.2 [M+ MeCN + H]4) and the title alcohol (RTA = 2.56min; rø/z (ES+) = 425.3 [M+ H]4).
EXAMPLE 133
N-(5-Cyanothiazol-2-yl)-2-(4-cyclopropanesulfonylphenyl)-3-(tefrahydropyran-4- yl)propionamide
Figure imgf000072_0001
A stiπed solution of 2-(4-cyclopropanesulfonylphenyl)-N-(5-formylthiazol-2- yl)-3-(tetrahydropyran-4-yl)propionamide (EXAMPLE 86, 369mg, 0.82mmol) in pyridine (1.53mL) was treated with H2ΝOH-HCl (63mg, 0.91mmol) at 0°C. The mixture was stiπed at 20°C for 3h, before being warmed up to 60°C and treated with Ac2O (155 L, 1.65mmol). After 3h, the mixture was cooled to 20°C, before being concentrated in vacuo and treated with CH2C12 (6mL) and H2O (6mL). The aqueous phase was acidified to pH 3 with 10% aqueous citric acid. The organic layer was separated, then the aqueous layer was further extracted with CH C12 (2 x lOmL). The combined organic extracts were dried (MgSO ), filtered, and concentrated to give a residue that was purified by column chromatography (IH-EtOAc, 1 :3) to furnish the title compound: RTA = 3.40min; mlz (ES4) = 487.4 [M+ MeCN + H]4".
EXAMPLE 134
N-(5-Cyanothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4- yι)propionamide
Figure imgf000072_0002
The procedure described in EXAMPLE 133 was employed to convert N-(5- foπnylthiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4- yl)propionamide (EXAMPLE 131, 200mg, 0.47mmol) into the title compound: RTA
= 3.14min; mlz (ES4") = 461.3 [M+ MeCΝ + H]4". EXAMPLE 135
Methyl {2-[2-(4-methanesulfonylphenyl)-3-(tetrahydroρyran-4-yl)propionylamino]- thiazol-5-ylmethyl} carbamate
Figure imgf000073_0001
(NH4)2CO3 (2.25g, 34.1mmol) was added to a stiπed solution of N-(5- formylthiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4- yl)proρionamide (EXAMPLE 131, 125mg, 0.3mmol) in MeOH (15mL). After 16h at 20°C, the mixture was concentrated, then the residue was partitioned between CH2C12 and H2O. The organic layer was washed with Νa2CO3 and 2M HCl, before being dried (MgSO4). Filtration, solvent evaporation, and column chromatography (EtOAc) furnished the title compound: RTA = 1.07min; mlz (ES4") = 482.3 [M+ H]4".
EXAMPLE 136
(E)-3-(l-Formylpiperidin-4-yl)-2-(4-methanesulfonylphenyl)-N-thiazol-2- ylacrylamide
Figure imgf000073_0002
(E)-tert-Butyl 4-[2-carboxy-2-(4-methanesulfonylphenyl)vinyl]piperidine- 1 - carboxylate (Preparation 35, 3.17g, 7.7mmol) was condensed with thiazol-2-ylamine (2.32g, 23.2mmol), employing the procedure described in EXAMPLE 65, to give (E)-tert-butyl 4-[2-(4-methanesulfonylphenyl)-2-(thiazol-2- ylcarbamoyl)vinyl]piperidine-l -carboxylate: mlz (ES4) = 492.2 [M+ H]4". TFA (20mL) was added to a stiπed solution ofthe abovementioned carbamate (1.40g, 2.8mmol) in CH2C12 (20mL). After 2h, the solution was concentrated in vacuo. The residue was dissolved in H2O, then the solution was washed with EtOAc. The aqueous layer was concentrated to furnish the trifluoroacetate salt of (E)-2-(4- methanesulfonylphenyl)-3-piρeridin-4-yl-N-thiazol-2-ylacrylamide: mlz (ES4) = 392.1 [M+ H]4". A stiπed solution of imidazole (102mg, 1.5mmol) in anhydrous DMF (lmL) was treated with Me3SiCl (114//L, 0.9mmol). After 20min, the above trifluoroacetate salt (150mg, 0.3mmol) was added. The mixture was stiπed for 16h, before being partitioned between CH2C12 and IM HCl. The organic layer was dried (MgSO4), filtered, concenfrated, and flash chromatographed (EtOAc-MeOH, 97:3 to 19:1). Recrystallisation (EtOAc) ofthe residue gave the title compound: RTA = 3.05min; mlz (ES+) = 420.2 [M+ H]+.
EXAMPLE 137 AND EXAMPLE 138
(E)-2-(4-Methanesulfonylphenyl)-3-(l-oxohexahydro-lλ4-thiopyran-4-yl)-N-thiazol-
2-ylacrylamide and (E)-3-(l,l-Dioxohexahydro-lλ6-thiopyran-4-yl)-2-(4- methanesulfonylphenyl)-N-thiazol-2-ylacrylamide
Figure imgf000074_0001
røCPBA (71mg of 86% pure, AlQμmoϊ) was added to a stiπed solution of (E)- 2-(4-methanesulfonylphenyl)-3-(tefrahydrothiopyran-4-yl)-N-thiazol-2-ylacrylamide (EXAMPLE 71, 96mg, 230 flnol) in CH2C12 (5mL). After 2h, the reaction mixture was quenched with saturated aqueous Νa2CO3 solution. The organic layer was washed with saturated aqueous NaHCO3, before being dried (MgSO4). Filtration, solvent evaporation, and flash chromatography (EtOAc then CH2Cl2-MeOH, 19:1) gave EXAMPLE 138 (RTA = 3.12min; mlz (ES4") = 482.2 [M+ MeCN + H]+) and EXAMPLE 137 (RTA = 2.95min; mlz (ES4) = 425.1 [M+ H]+).
EXAMPLE 139 AND EXAMPLE 140
(E)-N-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(l -oxohexahydro- 1 λ4- thiopyran-4-yl)acrylamide and (E)-N-(5-Chlorothiazol-2-yl)-3-(l,l-dioxohexahydro- lλ6-thiopyran-4-yl)-2-(4-methanesulfonylphenyl)acrylamide
Figure imgf000075_0001
Incomplete oxidation of (E)-N-(5-chlorothiazol-2-yl)-2-(4- methanesulfonylphenyl)-3-(tetrahydrothiopyran-4-yl)acrylamide (EXAMPLE 72), employing the procedure described above' for EXAMPLE 137 and EXAMPLE 138, furnished EXAMPLE 139 (RTB = 1.36min; m/z (ES+) = 458.9 [M+ H]4) and EXAMPLE 140 (RTB = 1.48min; m/z (ES4) = 515.9 [M+ MeCΝ + H]4).
EXAMPLE 141 AND EXAMPLE 142
2-(3-Fluoro-4-methanesulfinylphenyl)-3-(tefrahydropyran-4-yl)-N-thiazol-2- ylpropionamide and 2-(3-Fluoro-4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-
N-thiazol-2-ylpropionamide
Figure imgf000075_0002
Incomplete oxidation of 2-(3-fluoro-4-methylsulfanylphenyl)-3- (tetrahydropyran-4-yl)-N-thiazol-2-ylpropionamide (EXAMPLE 85, 350mg, 0.92mmol) with 1.5 equiv of mCPBA, employing the procedure described above for EXAMPLE 137 and EXAMPLE 138, furnished EXAMPLE 141 (RTA = 3.06min; mlz (ES+) = 397.1 [M+ H]4) and EXAMPLE 142 (RTA = 3.12min; m/z (ES4") = 413.1 [M+ H]4").
EXAMPLE 143
N-(5-Bromothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4- yl)propionamide
Figure imgf000075_0003
A solution of 2-(4-methanesulfonylρhenyl)-3-(tetrahydropyran-4-yl)-N- thiazol-2-ylproρionamide (EXAMPLE 65, 202mg, 510//mol), BS (91mg, 5l0μmol), and Bz2O2 (6mg, 26μ ol), in CC (2mL) was heated to reflux for 16h. After removal ofthe solvent, the residue was partitioned between EtOAc (30mL) and H2O (30mL). The organic extracts were washed with saturated aqueous ΝH C1 (30mL), before being dried (MgSO4). Filtration, solvent evaporation, and flash chromatography (CH2Cl2-EtOAc, 2:3) gave the title compound: RTA = 3.50min; mlz (ES4) = 516.2 [M + MeCN + H]4".
EXAMPLE 144
(E)-2-(4-Hydroxyphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2-ylacrylamide
Figure imgf000076_0001
BBr3 (2.5mL of a 1.0M solution in CH2C12, 2.5mmol) was added to a stiπed solution of (E)-2-(4-methoxyphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylacrylamide (EXAMPLE 13, 340mg, 984 mιol) in anhydrous CH2C12 (20mL) at -78°C. After lh, the mixture was allowed to warm to 20°C over a period of 24h. CH2C12 (lOOmL) was added, then the mixture was washed with H2O (20mL) and brine (20mL), before being dried (MgSO ). Filtration, solvent evaporation, and column chromatography (CH2Cl2-MeOH, 50:1) furnished the title compound: RTB = 1.27min; mlz (ES4") = 331.0 [M+ H]4".
EXAMPLE 145
(E)-2-(4-Methanesulfonylaminophenyl)-3-(tefrahydropyran-4-yl)-N-thiazol-2- ylacrylamide
Figure imgf000076_0002
A stiπed suspension of (E)-2-(4-nitrophenyl)-3-(tefrahydropyran-4-yl)-N- thiazol-2-ylacrylamide (EXAMPLE 81, 1.54g, 4.0mmol) in EtOH (54mL) and THF (3 lmL) was treated with H2O (13mL), saturated aqueous NH4CI (13mL), and Fe powder (1.49g, 26.7mmol). After 4.5h at 20°C, the reaction mixture was filtered through Celite, washing with CH2C12. The combined filtrates were concenfrated and the residue was dissolved in CH2C12. The CH2C12 solution was washed with H2O and dried (MgSO4). Filtration, solvent evaporation, and column chromatography (EtOAc-MeOH, 19:1) gave (E)-2-(4-aminophenyl)-3-(tetraliydiOpyran-4-yl)-N- thiazol-2-ylacrylamide: mlz (ES4) = 330.1 [M+ H]+. A stiπed solution of this compound (104mg, 291 mιol) in anhydrous CH2C12 (4mL) was treated with MeSO2Cl (90 L, 1 65 μmoϊ) and pyridine (94 L, 1 l65μmoϊ). After 16h, the mixture was diluted with CH2C12 (25mL), before being extracted twice with 2M ΝaOH. The combined aqueous extracts were washed with Et2O, before being acidified with 12M HCl to pHl and extracted twice with CH C12. The combined organic extracts were washed with brine and dried (MgSO4). Filtration and solvent evaporation afforded the title compound: RTB = 1.26min; mlz (ES4") = 408.0 [M+ H]+.
EXAMPLE 146
3-(Tetrahydropyran-4-yl)-2-[4-(tetralιydropyran-4-ylmethylsulfanyl)phenyl]-N- thiazol-2-ylpropionamide
Figure imgf000077_0001
A solution of 2-(4-methoxymethylsulfanylphenyl)-3 -(tefrahydropyran-4-yl)-N- thiazol-2-ylpropionamide (EXAMPLE 77, 1.29g, 3.28mmol) in THF (50mL) was added to a stiπed solution of AgΝO3 (0.59g, 3.28mmol) in EtOH (85mL) at 40°C. The mixture was protected from light and stiπed at 40°C for 21h. The solvents were evaporated off under reduced pressure, then the remaining solid was triturated with /-PrOH (60mL), THF (60mL), and Et2O (60mL). After air-drying, the solid was stiπed vigorously with CH2C12 (200mL) and 6M HCl (82mL) for 4h under Ar. The layers were separated, then the aqueous phase was exfracted with CH2C12 (2 x lOOmL). The combined organic extracts were filtered through Celite, washed with brine (lOOmL) and dried (MgSO4). Filtration and solvent evaporation furnished 2-(4- mercaptophenyl)-3-(tefrahydropyran-4-yl)-N-thiazol-2-ylpropionamide: mlz (ES4") = 349.2 [M + H]+. NEt3 (0.14mL, 1006 mol) and a solution of 4- iodomethyltetrahydropyran (151 mg, 668 moι) in anhydrous DMF (3mL) were added to a stiπed solution of this benzenethiol (197mg, 565μmol) in anhydrous DMF (7mL) at 0°C. The mixture was warmed to 20°C, before being stiπed for 16h. The solvents were evaporated off under reduced pressure, then the residue was partitioned between CH2C12 (25mL) and 2% aqueous citric acid (lOmL). The aqueous layer was exfracted with CH2C12 (lOmL), then the combined organic layers were washed with H2O (lOmL), saturated aqueous Na2CO3 (lOmL), H2O (lOmL), and brine (lOmL). After drying (MgSO4), filtration and solvent evaporation gave a residue that was subjected to flash chromatography (IH-EtOAc, 3:1 to 0:1) to furnish the title compound: RTA = 3.61min; m/z (ES4) = 447.3 [M+ H]4".
EXAMPLE 147
2-[4-(Pyridin-3-ylsulfanyl)phenyl]-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide
Figure imgf000078_0001
A solution of Pd2dba3 (18mg, 20 mol) and DPEPhos (24mg, 45/ xoT) in anhydrous PhMe (4mL) was stiπed at 20°C for 3min. 3-Iodopyridine (107mg, 522 jmol), 2-(4-mercaptophenyl)-3 -(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide (see EXAMPLE 146, 173mg, 500 tmol), and t-BuOK (65mg, 579 mol) were added, then the mixture was heated at 105°C (bath) for 2.5h. On cooling to 20°C, the mixture was diluted with CH2C12 (lOmL) and filtered through Celite, washing with CH2C12 (5mL) and EtOAc (lOmL). Solvent evaporation and flash chromatography (IH-EtOAc, 3:1 to 0:1) afforded the title compound: RTB = 1.37min; m/z (ES4") = 426.0 [M+ H]4".
EXAMPLE 148
3-(Tetrahydropyran-4-yl)-2-[4-(tetrahydropyran-4-ylmethanesulfonyl)phenyl]-N- thiazol-2-ylpropionamide
Figure imgf000079_0001
A stiπed solution of 3-(tefrahydropyran-4-yl)-2-[4-(tetrahydropyran-4- ylmethylsulfanyl)phenyl]-N-thiazol-2-ylpropionamide (EXAMPLE 146, 146mg, 327/tmol) in CH2C12 (7mL) was freated with a solution of mCPBA (186 mg of 65% pure, 690 anol) in CH2C12 (7mL). After 4d, saturated aqueous Νa2CO3 (lOmL) was added, then the mixture was stiπed vigorously for 5min. The aqueous phase was extracted with CH2C12 (lOmL), then the combined organic exfracts were washed with saturated aqueous Na2CO3 (lOmL), H2O (lOmL), and brine (lOmL), before being dried (MgSO4). Filtration, solvent evaporation, and flash chromatography (EtOAc) provided the title compound: RTA = 3.26min; mlz (ES4) = 479.3 [M+ H]+.
Several other sulfones were prepared by the oxidation ofthe appropriate thioether (TABLE 13) using the protocol described in EXAMPLE 148.
TABLE 13
Figure imgf000079_0002
[A] RT employing Method A. [B] RT employing Method B.
The compounds listed in TABLE 14 were prepared from 2-(4- mercaptophenyl)-3-(tefrahydropyran-4-yl)-N-thiazol-2-ylpropionamide (see EXAMPLE 146) by combining the procedures used to make EXAMPLES 146 and 148.
TABLE 14
Figure imgf000080_0001
Figure imgf000081_0002
[A] RT employing Method A. [B] RT employing Method B.
EXAMPLE 161
2-[4-(Oxetane-3-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide
Figure imgf000081_0001
A mixture of 2-(4-mercaptophenyl)-3-(tefrahydropyran-4-yl)-N-thiazol-2- ylpropionamide (see EXAMPLE 146, 349mg, Ommol), K2CO3 (152mg, l.lmmol), Νal (150mg, LOmmol), and 3-(tosyloxy)oxetane (274mg, 1.2mmol) in anhydrous DMAc (20mL) was heated for 2h at 130°C. The solvent was evaporated off under reduced pressure, then the residue was partitioned between CH2C12 (75mL) and 2% aqueous citric acid (20mL). The organic layer was washed with H2O (20mL), saturated aqueous Νa2CO3 (20mL), and brine (20mL), before being dried (MgSO ). Filtration and solvent evaporation afforded 2-[4-(oxetan-3-ylsulfanyl)phenyl]-3- (tetrahydropyran-4-yl)-N-thiazol-2-ylpropionamide: mlz (ES+) = 405.2 [M+ H]4". This thioether was oxidised employing the protocol outlined in EXAMPLE 148 to give the title compound: RTA = 3.04min; mlz (ES4) = 437.2 [M+ H]4".
The compounds listed in TABLE 15 were synthesized employing the protocols described in EXAMPLE 161.
TABLE 15
Figure imgf000081_0003
Figure imgf000082_0002
EXAMPLE 165
2-[4-(2-Oxopropane-l-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide
Figure imgf000082_0001
Reaction of 2-(4-mercaptophenyl)-3-(tefrahydropyran-4-yl)-N-thiazol-2- ylpropionamide (see EXAMPLE 146, 363mg, 1.04mmol) with chloroacetone (90 L, 1. lOmmol), employing a procedure similar to that described in EXAMPLE 146, fuπιished 2-[4-(2-oxopropylsulfanyl)phenyl]-3-(tefralιydropyraιι-4-yl)-N-thiazol-2- ylpropionamide: m/z (ES4) = 405.3 [M+ H]4". TBA-OX (2.46g, 2.44mmol) was added to a stiπed solution ofthe abovementioned thioether (399mg, 0.99mmol) in CH2C12 (20mL). After 19h, the reaction mixture was freated with more TBA-OX (0.97g, 0.96mmol). An additional quantity of TBA-OX (1.09g, 1.07mmol) was added 20h later, then the mixture was stiπed further for 3d. Solvent evaporation and flash chromatography (IH-EtOAc, 3:2 to 0:1) afforded the title compound: RTA = 3.12min; mlz (ES4") = 437.2 [M+ H]4".
The compounds listed in TABLE 16 were obtained from 2-(4- mercaptophenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2-ylpropionamide (see EXAMPLE 146) by combining the procedure used to make EXAMPLE 147 with that used to prepare EXAMPLES 141 and 142. TABLE 16
Figure imgf000083_0001
EXAMPLE 171
2-(3-Amino-4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide
Figure imgf000083_0002
2-(4-Methylsulfanyl-3-nitrophenyl)-3-(tefrahydropyran-4-yl)-N-thiazol-2- ylpropionamide (EXAMPLE 80, 5.84g, 13.2mmol) was oxidized with røCPBA following the procedure described in EXAMPLE 148 to give 2-(4-methanesulfonyl- 3-nifrophenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2-ylpropionamide: mlz (ES ) = 481.1 [M+ MeCΝ + H]4". This compound (520mg, 1.2mrnol) was reduced, employing the procedure described in EXAMPLE 145, to give the title compound: RTA = 2.95min; mlz (ES4) = 426.1 [M+ ΝH4 .
EXAMPLE 172
2-(3-Chloro-4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide
Figure imgf000084_0001
A solution of ΝaΝO2 (34mg, 498 mol) in H2O (0.8mL) was added to a solution of 2-(3-amino-4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol- 2-ylpropionamide (EXAMPLE 171, 200mg, 488/mιoI) in 6M HCl (1.6mL) at 0°C. The reaction was stiπed at 0°C for 35min, before being added slowly to a stiπed mixture of Cu powder (80mg, 1.26mmol) and 12M HCl (0.8mL) at 0°C. The temperature was increased to 20°C, then stirring was continued for lh. The mixture was then heated at 60°C for lh, before being cooled down to 20°C and extracted with CH C12 (3 x 15mL). The organic extracts were dried (MgSO4), filtered, and concentrated to give a residue that was purified by RP-HPLC to furnish the title compound: RTA = 3.17min; mlz (ES+) = 429.2 [M+ H]4".
EXAMPLE 173
2-[4-(Mo holine-4-sulfonyl)phenyl]-3-(tetralιydropyran-4-yl)-N-thiazol-2-yl- propionamide
Figure imgf000084_0002
ΝEt3 (120μL, 868 mol) and morpholine (76μL, 868 mιol) were added to a stiπed solution of 4-[2-(tetrahydropyran-4-yl)-l-(thiazol-2- ylcarbamoyl)ethyl]benzenesulfonyl chloride (Preparation 59, 300mg, 723 mol) in anhydrous DMF (4mL). After lOmin, the solvents were removed in vacuo, then the residue was taken up in CH2C12 (50mL). The CH2C12 solution was washed with H2O (20mL), IM HCl (20mL), H2O (20mL), saturated aqueous Na2CO3 (20mL), and brine (20mL), before being dried (MgSO4). Filtration, solvent evaporation, and recrystallisation (CH2C12-IH) gave the title compound: RTA = 3.15min; mlz (ES4) = 466.1 [M+ H]+.
The sulfonamides listed in TABLE 17 were synthesised by employing protocols similar to those described in EXAMPLE 173.
TABLE 17
Figure imgf000085_0001
Figure imgf000086_0001
Figure imgf000087_0001
Figure imgf000088_0002
EXAMPLE 198
N-(5-Chlorotln^ol-2-yl)-2-[4-(piperazine-l-sulfonyl)phenyl]-3-(tetrahydropyran-4- yl)propionamide
Figure imgf000088_0001
ΝEt3 (278 μL, 2.0mmol) and tert-butyl piperazine-1 -carboxylate (373mg, 2.0mmol) were added to a stiπed solution of 4-[l-(5-chlorothiazol-2-ylcarbamoyl)-2- (tetrahydropyran-4-yl)ethyl]benzenesulfonyl chloride (Preparation 60, 449mg, LOmmol) in anhydrous DMAc (4mL). The mixture was stiπed for 16h, then the solvents were removed in vacuo. The residue was dissolved in EtOAc (50mL) to give a solution that was washed with H2O (15mL), saturated aqueous Na2CO3 (15mL), and brine (15mL), before being dried (MgSO4). Filtration, solvent evaporation, and column chromatography (IH-EtOAc, 7:3 to 1:1) gave tert-butyl 4-{4-[l-(5- chlorothiazol-2-ylcarbamoyl)-2-(tetrahydropyran-4- yl)ethyl]benzenesulfonyl}piperazine-l-carboxylate: mlz (ES+) = 599.5 [M+ H]+. A solution of this compound (189mg, 316/anol) in CH2C12-TFA (1:1, 7mL) was stiπed for lh. The solvents were evaporated off under reduced pressure, then the residue was triturated with Et2O. The product was collected, washed with Et2O, and air-dried to furnish the trifluoroacetate salt ofthe title compound: RTA = 2.64min; mlz (ES ) = 499.3 [M+ H]+.
The compounds listed in TABLE 18 were synthesized as their trifluoroacetate salts employing the procedures described in EXAMPLE 198.
TABLE 18
Figure imgf000089_0002
EXAMPLE 201
N-Ethyl-4-[2-(tefrahydropyran-4-yl)-l-(thiazol-2-ylcarbamoyl)ethyl]benzamide
Figure imgf000089_0001
4-[2-(Tefrahydropyran-4-yl)- 1 -(thiazol-2-ylcarbamoyl)ethyl]benzoic acid (Preparation 62, 150mg, 420 mol) was condensed with EtΝH2ΗCl in the presence of DIPEA, utilising the general procedure described in EXAMPLE 65, to give the title compound: RTA = 2.97min; m/z (ES4) = 388.3 [M+ H]4".
1H NMR data for several Examples are catalogued in TABLE 19.
TABLE 19
Ex Solvent δa
Figure imgf000090_0001
The following compounds may also be synthesised using the procedures described above:
2-(3-Chloro-4-methanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3- (tefrahydropyran-4-yl)propionamide;
2-(4-Methanesulfonyl-3-trifluoromethylphenyl)-N-(5-fluorothiazol-2-yl)-3- (tefrahydropyran-4-yl)ρropionamide; and
2-(3,4-Dichlorophenyl)-N-(5-fluorothiazol-2-yl)-3-(tefrahydropyran-4- yl)propionamide.
ASSAYS
In vitro GK activity
Using a protocol similar to that described in WO 00/58293, GK activity was assayed by coupling the production of G6P by GST-GK to the generation of ΝADPH with G6PDH as the coupling enzyme. The GK assay was performed at 30°C in a flat bottom 96-well assay plate from Costar with a final incubation volume of 100 L. The assay buffer contained: 25mM Hepes buffer (pH 7.4), 12.5mM KCI, 5mM D-Glc, 5mM ATP, 6.25mM NADP, 25mM MgCl2, ImM dithiothreitol, test compound or 5% DMSO, 3.0unit/mL G6PDH, and OAμUmL GST-GK, derived from human liver GK. ATP, G6PDH, and NADP were purchased from Roche Diagnostics. The other reagents were >98% pure and were purchased from Kanto Chemicals. The test compounds were dissolved in DMSO, before being added to the assay buffer without ATP. This mix was preincubated in the temperature controlled chamber of a SPECTRAmax 250 microplate spectrophotometer (Molecular Devices Corporation, Sunnyvale, CA) for lOmin, then the reaction was started by the addition of 10 L ATP solution.
After starting the reaction, the increase in optical density (OD) at 340nm was monitored over a lOmin incubation period as a measure of GK activity. Sufficient GST-GK was added to produce an increase in OD 40 over the lOmin incubation period in wells containing 5% DMSO, but no test compound. Preliminary experiments established that the GK reaction was linear over this period of time, even in the presence of activators that produced a 8-fold increase in GK activity. The GK activity in control wells was compared with the activity in wells containing test GK activators. The compound concentrations that produced a 50% increase in GK activity (i.e. FA1.5) were calculated. GK activators achieved FA1.5 at < 30 .
The above EXAMPLES 1-201 produced EC50s ranging from 0.1 to 32.6/ with max FAs from 1.6 to 8.7.
The following compounds did not achieve FA1.5 at <30μM and hence are not prefeπed compounds ofthe invention:
2-(4-Bromophenyl)-3-furan-2-yl-N-[l,3,4]thiadiazol-2-yl-acrylamide;
3-Furan-2-yl-2-(4-methoxyphenyl)-N-(4-trifluoromethyl-thiazol-2- yl)acrylamide;
N-(5-Bromothiazol-2-yl)-3-furan-2-yl-2-(3-methoxyphenyl)acrylamide;
N-(5-Chlorothiazol-2-yl)-3-furan-2-yl-2-(3-methoxyphenyl)acrylamide;
4-[2-(Tefrahydropyran-4-yl)-l-(thiazol-2-ylcarbamoyl)ethyl]benzoic acid;
N-Methyl-4-[2-(tefrahydropyran-4-yl)- 1 -(thiazol-2- ylcarbamoyl)ethyl]benzamide; N,N-Dimethyl-4-[2-(tetrahydropyran-4-yl)-l-(thiazol-2- ylcarbamoyl)ethyl]benzamide;
2-(4-Aminophenyl)-N-(5-chlorothiazol-2-yl)-3-(tetrahydropyran-4-yl)- propionamide;
N-(5-Dimethylaminomethylthiazol-2-yl)-2-(4-methanesulfonylphenyl)-3- (tefrahydropyran-4-yl)propionamide;
N-(5-Chlorobenzooxazol-2-yl)-2-(4-methanesulfonylphenyl)-3- (tefrahydropyran-4-yl)propionamide;
2-(4-Methanesulfonylphenyl)-N-(l-methyl-lH-benzoimidazol-2-yl)-3- (tefrahydropyran-4-yl)propionamide;
N-(lH-Benzoimidazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tefrahydropyran- 4-yl)-propionamide;
N-Isoquinolin- 1 -yl-2-(4-methanesulfonylphenyl)-3 -(tetrahydropyran-4-yl)- propionamide;
N-Isoquinolin-3-yl-2-(4-methanesulfonylphenyl)-3-(tefrahydropyran-4-yl)- propionamide;
3-[2-(Tefrahydropyran-4-yl)-l-(thiazol-2-ylcarbamoyl)ethyl]benzoic acid;
3-[2-(Tetrahydropyran-4-yl)-l-(thiazol-2-ylcarbamoyl)ethyl]-N-thiazol-2-yl- benzamide;
3-[2-(Tefrahydropyran-4-yl)- 1 -(thiazol-2-ylcarbamoyl)ethyl]benzoic acid methyl ester;
2-(4-Mercaptophenyl)-3-(tefrahydro-pyran-4-yl)-N-thiazol-2-yl-propionamide;
2-(4-Aminophenyl)-3-(tetrahydro-pyran-4-yl)-N-thiazol-2-yl-propionamide;
2-[2-(4-Methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionylamino]- thiazole-4-carboxylic acid;
4-[2-(Tefrahydropyran-4-yl)-l-(thiazol-2-ylcarbamoyl)ethyl]benzamide;
2-(3-Cyclopropanesulfonylaminophenyl)-3-(tetrahydropyran-4-yl)-N-thiazol- 2-yl-propionamide;
2- [2-(4-Methanesulfonylphenyl)-3 -(tefraliydropyran-4-yl)propionylamino] - thiazole-4-carboxylic acid ethyl ester;
2-[2-(4-Methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-propionylamino]- thiazole-5-carboxylic acid ethyl ester;
2-(3-Methanesulfonylammophenyl)-3-(tefrahydropyran-4-yl)-N-thiazol-2-yl- propionamide; 2-(4-Methanesulfonylρhenyl)-3-(tetrahydropyran-4-yl)-N-(5- trifluoromethylthiazol-2-yl)-propionamide;
2-(4-Cyanophenyl)-3-(tetrahydroρyran-4-yl)-N-thiazol-2-yl-propionamide;
2-(4-Dimethylaminomethylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2-yl- acrylamide;
2-(4-Methylaminomethylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2-yl- acrylamide;
2-[2-(4-Carboxyphenyl)-3-(tetrahydropyran-4-yl)acryloylamino]-thiazole-5- carboxylic acid;
N-[5-(4-Ethylpiperazine-l-carbonyl)thiazol-2-yl]-2-phenyl-3- (tefrahydropyran-4-yl)acrylamide;
N- [5-(4-Methylpiperazine- 1 -carbonyl)thiazol-2-yl] -2-phenyl-3- (tefrahydropyran-4-yl)acrylamide;
2-[2-Phenyl-3-(tetrahydro-ρyran-4-yl)acryloylamino]thiazole-5-carboxylic acid (2-dimethylaminoethyl)amide;
2-(4-Methanesulfonylphenyl)-4-(tetrahydropyran-4-yl)-N-thiazol-2-yl- butyramide;
2-(4-Methanesulfonylphenyl)-4-(tefrahydropyran-4-yl)-but-2-enoic acid thiazol-2-ylamide;
2-(4-Acetylaminophenyl)-N-(5-chlorothiazol-2-yl)-3-(tetrahydropyran-4- yl)acrylamide;
N-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-piperidin-4-yl- acrylamide;
2-(4-Methanesulfonylphenyl)-3-piperidin-4-yl-N-thiazol-2-yl-acrylamide;
2-(4-Aminophenyl)-3-(tetrahydro-pyran-4-yl)-N-thiazol-2-yl-acrylamide;
2-(4-Aminophenyl)-N-(5 -chloro-thiazol-2-yl)-3 -(tefrahydro-pyran-4- yl)acrylamide;
2-(4-Methanesulfonylphenyl)-3-ρiperidin-l-yl-N-thiazol-2-yl-propionamide;
2-(4-Methanesulfonylphenyl)-3-(3-methylthiophen-2-yl)-N-thiazol-2-yl- acrylamide;
2-(4-Methanesulfonylphenyl)-3-pyridin-3-yl-N-thiazol-2-yl-acrylamide;
2-(3 -Bromophenyl)-N-(5 -chlorothiazol-2-yl)-3 -thiophen-2-yl-acrylamide;
2-(3 -Bromophenyl)-N-thiazol-2-yl-3 -thiophen-2-yl-acrylamide;
N-(4,5-Dimethylthiazol-2-yl)-2-phenyl-3-thiophen-2-yl-acrylamide; N-(5-Chlorothiazol-2-yl)-2-phenyl-3-thiophen-2-yl-acrylamide; N-(5-Methylthiazol-2-yl)-2-phenyl-3-thiophen-2-yl-acrylamide; 2-(4-Bromophenyl)-N-pyrazin-2-yl-3-thiophen-2-yl-acrylamide; 3-Furan-2-yl-2-(3-methoxyphenyl)-N-thiazol-2-yl-acrylamide; 2-(4-Bromophenyl)-N-(5-bromopyridm-2-yl)-3-furan-2-yl-acrylamide; N-(5-Bromothiazol-2-yl)-2-(4-cyanophenyl)-3-phenyl-acrylamide; 2-(4-Cyanophenyl)-3-phenyl-N-[l,3,4]thiadiazol-2-yl-acrylamide; 2-(4-Cyanophenyl)-3-furan-2-yl-N-[l,3,4]thiadiazol-2-yl-acrylamide; 2-(4-Cyanophenyl)-3-phenyl-N-thiazol-2-yl-acrylamide; 3-Furan-2-yl-2-(3-methoxyphenyl)-N-pyridin-2-yl-acrylamide; 2-(4-Bromophenyl)-N-(4,5-dimethylthiazol-2-yl)-3-thiophen-2-yl-acrylamide; 2-(4-Bromophenyl)-N-pyridin-2-yl-3-thiophen-2-yl-acrylamide; 2-(4-Bromophenyl)-N-pyrimidin-4-yl-3-thiophen-2-yl-acrylamide; 2-(4-Bromophenyl)-3-thiophen-2-yl-N-(4-trifluoromethyl-thiazol-2-yl)- acrylamide;
N-(5-Bromopyridin-2-yl)-3-furan-2-yl-2-(4-methoxyphenyl)acrylamide;
3-Furan-2-yl-2-(4-methoxyphenyl)-N-pyrimidin-4-yl-acrylamide;
N-(5-Bromotlfrazol-2-yl)-3-furan-2-yl-2-(4-methoxyphenyl)acrylamide;
N-(5-ChlorotMazol-2-yl)-3-furan-2-yl-2-(4-methoxyphenyl)acrylamide;
N-BerιzotMazol-2-yl-3-furan-2-yl-2-(4-methoxyphenyl)acrylamide;
N-Benzothiazol-2-yl-2-(4-bromophenyl)-3-thiophen-2-yl-acrylamide;
3-Furan-2-yl-2-(4-methoxyphenyl)-N-[l,3,4]thiadiazol-2-yl-acrylamide;
2-(4-Bromophenyl)-N-(5 -bromopyridin-2-yl)-3 -thiophen-2-yl-acrylamide; and
N-(4,5-Dimethylthiazol-2-yl)-3-furan-2-yl-2-(4-methoxyphenyl)acrylamide.
In vivo GK activity
Following an 18h fasting period, C57BL/6 J mice were dosed orally via gavage with GK activator at 50mg/kg body weight. Blood Glc determinations were made 5 times during the 6h post-dose study period.
Mice (n = 5) were weighed and fasted for 18h before oral treatment. GK activators were dissolved in the Gelucire vehicle reported in WO 00/58293 (EtOH:Gelucire44/14:PEG400q.s. 4:66:30 v/v/v) at a concentration of 13.3mg/mL. Mice were dosed orally with 7.5mL formulation per kg of body weight to equal a 50mg/kg dose. Immediately prior to dosing, a pre-dose (time zero) blood Glc reading was acquired by snipping off a small portion ofthe animals' tails (<lmm) and collecting 15 L blood for analysis. After GK activator freatment, further blood Glc readings were taken at 1, 2, 4, and 6h post-dose from the same tail wound. Results were interpreted by comparing the mean blood Glc values of 5 vehicle freated mice with the 5 GK activator treated mice over the 6h study duration. Compounds are considered active when they exhibit a statistically significant decrease in blood Glc compared to vehicle for 2 consecutive assay time points.
Several ofthe GK activators exemplified above showed strong GK activator effects in vivo when administered orally following the abovementioned protocol.

Claims

WHAT IS CLAIMED IS:
1. A compound of Formula (I)
Figure imgf000096_0001
(I) or a pharmaceutically acceptable salt thereof, wherein:
Q is an aryl, a 5- or 6-membered heteroaryl, or a 4-8-membered heterocyclic ring;
T together with the -N=C- to which it is attached forms a heteroaryl ring, or a heterocyclic ring where the N=C bond is the only site of unsaturation;
R and R each independently are hydrogen, hydroxy, halogen, cyano, nitro, vinyl, ethynyl, methoxy, OCFnH3_n, -N(C0-4alkyl)(C0-4alkyl), CHO, or C1-2alkyl optionally substituted with 1-5 independent halogen, hydroxy, cyano, methoxy, -N(Co-2alkyl)(Co_2alkyl), SOCH3, or SO2CH3 substituents; or R1 and R2 together form
1 9 a carbocyclic or heterocyclic ring; or R and R may be taken together to represent an oxygen atom attached to the ring via a double bond;
R3 and R4 each independently are hydrogen, halogen, OCFnH _n, methoxy, CO2R77, cyano, nitro, CHO, CONR99R100, CON(OCH3)CH3, or C1-2alkyl, heteroaryl, or C3_7cycloalkyl optionally substituted with 1-5 independent halogen, hydroxy, cyano, methoxy, -NHCO2CH3, or -N(Co-2alkyl)(C0_2alkyl) substituents; or R3 and R4 together form a 5-8-membered aromatic, heteroaromatic, carbocyclic, or heterocyclic ring;
R and R each independently are hydrogen, hydroxy, halogen, cyano, nitro, CO2R7, CHO, COR8, C(OH)R7R8, C(=NOR7)R8, CONR9R10, SR7, SOR8, SO2R8, SO2NR9R10, CH2NR9R10, NR9R10, ^Co^alky SO^8, NHCOR7, or C1-4alkyl group, C2-4alkenyl group, C2-4alkynyl group, Cι-4alkoxy group, aryl group, or heteroaryl group, wherein any group optionally is substituted with 1-6 independent halogen, cyano, nifro, hydroxy, C1--2alkoxy, -N(C0-2alkyl)(Co_2alkyl), Cι_2alkyL CFnH3_„, aryl, heteroaryl, -COC^alkyl, -CON(C0-2alkyl)(C0-2alkyl), SCH3, SOCH3, SO2CH3, or -SO2N(Co-2alkyl)(Co-2alkyl) substituents; or R5 and R6 together form a 5-8- membered carbocyclic or heterocyclic ring;
R7 and R77 each independently are hydrogen, or C1-4alkyl group, C2-4alkenyl group, C2-4alkynyl group, C3-7cycloalkyl group, aryl group, heteroaryl group, or 4-7- membered heterocyclic group, wherein any group optionally is substituted with 1-6 independent halogen, cyano, nitro, hydroxy, d-2alkoxy, -N(C0_ alkyl)(Co-2alkyl), C1_ alkyl, C _7cycloalkyl, 4-7-membered heterocyclic ring, CFnH3_n, aryl, heteroaryl, CO2H, -COCi_2al yl, -CON(Co-2alkyl)(C0_2alkyl), SOCH3, SO2CH3, or -SO2N(Co-2alkyl)(Co-2alkyl) substituents;
R8 is C1-4alkyl group, C2-4alkenyl group, C - alkynyl group, C3-7cycloalkyl group, aryl group, heteroaryl group, or 4-7-membered heterocyclic group, wherein any group optionally is substituted with 1-6 independent halogen, cyano, nitro, hydroxy, C1_2alkoxy, -N(C0_ alkyl)(C0_2alkyl), Coalkyl, C3_7cycloalkyl, 4-7- membered heterocyclic ring, CFnH3_n, aryl, heteroaryl, CO2H, CO -^alkyl, -CON(Co-2alkyl)(Co_2alkyl), SOCH3, SO2CH3, or -SO2N(C0_2alkyl)(C0_2alkyl) substituents;
R9, R10, R99, and R100 each independently are hydrogen, or C1-4alkyl group, C - cycloalkyl group, aryl group, heteroaryl group, or 4-7-membered heterocyclic group, wherein any group optionally is substituted with 1-6 independent halogen, cyano, nitro, hydroxy, C^alkoxy, -N(C0_2alkyl)(Co_2alkyl), Coalkyl, C3_ 7cycloalkyl, 4-7-membered heterocyclic ring, CFnH3_n, aryl, heteroaryl, CO -^alkyl, -CON(C0_2alkyl)(Co-2alkyl), SOCH3, SO2CH3, or -SO2N(Co-2alkyl)(C0-2alkyl) substituents; or R9 and R10 or R99 and R100 together form a 6-8-membered heterobicyclic ring system or a 4-8-membered heterocyclic ring which optionally is substituted with 1-2 independent Coalkyl, CH2OCH3, COC0_2alkyl, hydroxy, or SO2CH3 substituents; n is 1, 2 or 3; m is O or 1; and the dotted line together with the solid line forms an optional double bond, and A indicates that the double bond has the (E)-configuration.
2. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the dotted line together with the solid line forms a double bond.
3. A compound according to claim 1, or a phannaceutically acceptable salt thereof, wherein the dotted line together with the solid line forms a single bond.
4. A compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein the dotted line together with the solid line forms a single bond, and the absolute configuration at the asymmetric centre αto the amide carbonyl carbon is (R).
5. A compound according to any one ofthe preceding claims, wherein m is 0.
6. The compound according to any one ofthe preceding claims, or a pharmaceutically acceptable salt thereof, wherein Q is thienyl, furyl, thiazolyl, pyridyl, tetrahydropyranyl, piperidinyl, tefrahydrothiopyranyl, 1-oxo- tetrahydrothiopyranyl or 1,1-dioxo-tetrahydrothiopyranyl.
7. A compound according to claim 6, or a pharmaceutically acceptable salt thereof, wherein Q is 4-tefrahydropyranyl.
8. The compound according to any one ofthe preceding claims, or a pharmaceutically acceptable salt thereof, wherein the group of formula
Figure imgf000098_0001
is thiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, pyrimidinyl, pyrazinyl, or pyridyl.
9. A compound according to claim 8, or a pharmaceutically acceptable salt thereof, wherein the group of formula
Figure imgf000099_0001
is 2-pyr azinyl or 2-thiazolyl.
10. A compound according to claim 9, or a phannaceutically acceptable salt thereof, wherein the group of formula
Figure imgf000099_0002
is 2-thiazolyl, R3 is 5-fluoro and R is hydrogen.
11. A compound according to any one ofthe preceding claims, or a pharmaceutically acceptable salt thereof, wherein R3 and R4 are independently selected from hydrogen, halogen, and methyl.
12. A compound according to any one ofthe preceding claims, or a pharmaceutically acceptable salt thereof, wherein R5 is SOR8, SO2R8, or SO2NR9R10.
13. A compound according to any one ofthe preceding claims, or a pharmaceutically acceptable salt thereof, wherein R8 is C1-4alkyl or C3_7cycloalkyl.
14. A compound according to any one ofthe preceding claims, or a pharmaceutically acceptable salt thereof, wherein R5 is SO C3- cycloalkyl.
15. A compound according to any one ofthe preceding claims, or a pharmaceutically acceptable salt thereof, wherein R6 is hydrogen.
16. A compound selected from:
(E)-2-(4-Methanesulfonylphenyl)-N-thiazol-2-yl-3-tliiophen-3-ylacrylamide; (E)-2-(4-Methanesulfonylphenyl)-N-thiazol-2-yl-3-thiophen-2-ylacrylamide; (E)-3-Furan-2-yl-2-(4-methanesulfonylphenyl)-N-thiazol-2-ylacrylamide; (E)-2-(4-Methanesulfonylphenyl)-3,N-bistbiazol-2-ylacrylamide; (E)-2-(4-Methanesulfonylphenyl)-3-(5-methylthiophen-2-yl)-N-thiazol-2- ylacrylamide;
(E)-3-(5-Chlorothiophen-2-yl)-2-(4-methanesulfonylρhenyl)-N-thiazol-2- ylacrylamide;
(E)-2-(4-Methanesulfonylphenyl)-3-thiazol-5-yl-N-thiazol-2-ylacrylamide;
2-(4-Methanesulfonylphenyl)-N-thiazol-2-yl-3-thiophen-2-ylpropionamide;
2-(4-Cyclopropanesulfonylphenyl)-3-(tefrahydropyran-4-yl)-N-tl'iiazol-2- ylpropionamide;
2-(4-Cyclopropanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3- (tetrahydropyran-4-yl)propionamide;
N-(5-Fluorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tefrahydropyran-4- yl)propionamide;
(E)-2-(4-Bromophenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2-ylacrylamide;
(E)-2-(4-Methoxyphenyl)-3-(tefrahydropyran-4-yl)-N-thiazol-2-ylacrylamide;
(E)-3-(Tefrahydropyran-4-yl)-N-thiazol-2-yl-2-(4-[ 1 ,2,4]triazol- 1 - ylphenyl)acrylamide;
(E)-3-(Tetrahydrothiopyran-4-yl)-N-thiazol-2-yl-2-(4-[ 1 ,2,4]triazol- 1 - ylphenyl) acrylamide;
(E)-3-(Tefrahydropyran-4-yl)-N-thiazol-2-yl-2-(4-[ 1 ,2,3]triazol- 1 - ylphenyl)acrylamide;
3-(Tefrahydropyran-4-yl)-N-thiazol-2-yl-2-(4- trifluoromethylsulfanylphenyl)propionamide;
2-(4-Methylsulfanylmethylphenyl)-3-(tefrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-(4-Methanesulfonylphenyl)-N-(lH-pyrazol-3-yl)-3-(tefraliydropyran-4- yl)propionamide;
2-(4-Methanesulfonylphenyl)-N-pyridin-2-yl-3-(tefrahydropyran-4- yl)proρionamide;
2-(4-Methanesulfonylphenyl)-N-pyrimidin-4-yl-3-(tetrahydropyran-4- yl)propionamide;
N-(4,5-Dihy<irothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran- 4-yl)propionamide; N-(lH-Imidazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4- yl)propionamide;
N-Benzothiazol-2-yl-2-(4-methanesulfonylphenyl)-3-(tefrahy(hOpyran-4- yl)propionamide;
2-(4-Methanesulfonylphenyl)-3-(tefrahydropyran-4-yl)-N-[l,3,4]thiadiazol-2- ylpropionamide;
2-(4-Methanesulfonylphenyl)-N-(3-methyl-[l,2,4]thiadiazol-5-yl)-3- (tefrahydropyran-4-yl)propionamide;
N-(5-Fluoropyridin-2-yl)-2-(4-methanesulfonylphenyl)-3-(tefrahydropyran-4- yl)propionamide;
2-(4-Methanesulfonylphenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4- yl)propionamide;
2-(4-Methanesulfonylphenyl)-N-(5-methylthiazol-2-yl)-3-(tetrahydropyran-4- yl)propionamide;
2-(4-Methanesulfonylphenyl)-N-(4-methylthiazol-2-yl)-3-(tetrahydropyran-4- yl)propionamide;
2-(4-Cyclopropanesulfonylphenyl)-N-(3-methyl-[l,2,4]thiadiazol-5-yl)-3- (tefrahydropyran-4-yl)propionamide;
2-(4-Cyclopropanesulfonylphenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4- yl)propionamide;
2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-N- [ 1 ,2,4]thiadiazol-5-ylpropionamide;
(E)-2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylacrylamide;
, 2-(4-Methanesulfonylphenyl)-N-(5-nifrothiazol-2-yl)-3-(tetrahydropyran-4- yl)propionamide;
(E)-N-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-thiophen-2- ylacrylamide;
(E)-N-(5-Chloro-4-methylthiazol-2-yl)-2-(4-methanesulfonylphenyl)-3- thiophen-2-ylacrylamide;
(E)-N-(5-Chlorothiazol-2-yl)-3-furan-2-yl-2-(4- methanesulfonylphenyl)acrylamide;
(E)-N-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-thiophen-3- ylacrylamide; (E)-N-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylρhenyl)-3-ρyridin-3- ylacrylamide;
N-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-thiophen-2- ylpropionamide;
N-(5-Chloro-4-methylthiazol-2-yl)-2-(4-methanesulfonylphenyl)-3- (tefrahydropyran-4-yl)propionamide;
(E)-N-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-thiazol-5- ylacrylamide;
(E)-2-(4-Bromophenyl)-N-(5-chlorotWazol-2-yl)-3-furan-2-ylacrylamide;
(E)-2-(4-Bromophenyl)-3-furan-2-yl-N-pyrimidin-4-ylacrylamide;
(E)-2-(4-Bromophenyl)-N-(5-bromothiazol-2-yl)-3-furan-2-ylacrylamide;
(E)-2-(4-Bromophenyl)-3-furan-2-yl-N-thiazol-2-ylacrylamide;
(E)-2-(4-Bromophenyl)-3-furan-2-yl-N-(5-methylthiazol-2-yl)acrylamide;
(E)-N-Benzothiazol-2-yl-2-(4-bromophenyl)-3-furan-2-ylacrylamide;
(E)-2-(4-Bromophenyl)-N-(4,5-dimethylthiazol-2-yl)-3-furan-2-ylacrylamide;
(E)-2-(4-Bromophenyl)-N-(5-bromothiazol-2-yl)-3-thiophen-2-ylacrylamide;
(E)-2-(4-Bromophenyl)-N-thiazol-2-yl-3-thiophen-2-ylacrylamide;
(E)-2-(4-Bromophenyl)-N-[l,3,4]thiadiazol-2-yl-3-thiophen-2-ylacrylamide;
(E)-2-(4-Bromophenyl)-N-(5-methylthiazol-2-yl)-3-thiophen-2-ylacrylamide;
(E)-2-(4-Bromophenyl)-N-(5-chlorothiazol-2-yl)-3-thiophen-2-ylacrylamide;
(E)-3-Furan-2-yl-2-(4-methoxyphenyl)-N-thiazol-2-ylacrylamide;
(E)-3-Furan-2-yl-2-(4-methoxyphenyl)-N-(5-methylthiazol-2-yl)acrylamide;
(E)-N-(5-Chlorothiazol-2-yl)-2-(4-nitrophenyl)-3-thiophen-2-ylacrylamide;
(E)-N-(5-Bromothiazol-2-yl)-2-(4-nitrophenyl)-3-thiophen-2-ylacrylamide;
(E)-2-(4-Νitrophenyl)-N-thiazol-2-yl-3-thiophen-2-ylacrylamide;
(E)-N-(5-Bromothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-thiophen-2- ylacrylamide;
(E)-2-(4-Cyanophenyl)-N-thiazol-2-yl-3-thiophen-2-ylacrylamide;
(E)-N-(5-Chlorothiazol-2-yl)-2-(4-cyanophenyl)-3-thiophen-2-ylacrylamide;
(E)-N-(5-Chlorothiazol-2-yl)-2-(4-cyanophenyl)-3-phenylacrylamide;
2-(4-Methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2-yl- propionamide;
(E)-2-Phenyl-N-thiazol-2-yl-3-thiophen-2-ylacrylamide;
(E)-2-Phenyl-N-[ 1 ,3,4]thiadiazol-2-yl-3-thiophen-2-ylacrylamide; (E)-2-(4-Methanesulfonylphenyl)-3-(tefrahydropyran-4-yl)-N-thiazol-2- ylacrylamide;
(E)-N-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylρhenyl)-3- (tetrahydropyran-4-yl)acrylamide;
(E)-N-(5-Bromofhiazol-2-yl)-2-(4-methanesulfonylphenyl)-3- (tetrahydropyran-4-yl)acrylamide;
(E)-2-(4-Methanesulfonylphenyl)-3-(tetrahydrothiopyran-4-yl)-N-thiazol-2- ylacrylamide;
(E)-N-(5-Chlorofhiazol-2-yl)-2-(4-methanesulfonylphenyl)-3- (tefrahydrothiopyran-4-yl)acrylamide;
(E)-N-(5-Chloro-4-methylthiazol-2-yl)-2-(4-methanesulfonylphenyl)-3- (tetrahydrothiopyran-4-yl)acrylamide;
(E)-2-(4-Methanesulfinylphenyl)-3-(tefrahydrothiopyran-4-yl)-N-thiazol-2- ylacrylamide;
(E)-N-(5-Chlorothiazol-2-yl)-2-(4-methanesulfmylphenyl)-3- (tetrahydrothiopyran-4-yl)acrylamide;
N-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tefrahydropyran-4- yl)propionamide;
2-(4-Methoxymethylsulfanylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
3-(Tetrahydropyran-4-yl)-2-[4-(tefrahydropyran-4-ylsulfanyl)phenyl]-N- thiazol-2-ylpropionamide;
2-(3 -Methylsulfanylphenyl)-3 -(tefrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-(4-Methylsulfanyl-3-nitrophenyl)-3-(tefrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
(E)-2-(4-Νitrophenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2 -ylacrylamide;
(E)-N-(5-Chlorothiazol-2-yl)-2-(4-nitrophenyl)-3-(tefrahydroρyran-4- yl)acrylamide;
(E)-2-(4-Methylsulfanylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylacrylamide;
(E)-N-(5-Chlorothiazol-2-yl)-2-(4-methylsulfanylphenyl)-3-(tetrahydropyran- 4-yl)acrylamide; 2-(3-Fluoro-4-methylsulfanylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-(4-Cyclopropanesulfonylphenyl)-N-(5-formylthiazol-2-yl)-3- (tetrahydropyran-4-yl)propionamide;
(E)-N-(5-Chlorothiazol-2-yl)-2-(4-cyclopropanesulfmylphenyl)-3- (tefrahydropyran-4-yl)acrylamide;
(E)-2-(4-Cyclopropanesulfinylphenyl)-3-(tefrahydropyran-4-yl)-N-thiazol-2- ylacrylamide;
2-(3-Bromo-4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-(4-Εthanesulfonylphenyl)-N-(3-methyl-[l,2,4]thiadiazol-5-yl)-3- (tetrahydropyran-4-yl)propionamide;
2-(4-Ethylsulfamoylphenyl)-N-pyrimidin-4-yl-3-(tefrahydropyran-4- yl)propionamide;
2-(4-Ethylsulfamoylphenyl)-N-pyrazin-2-yl-3-(tefrahydropyran-4- yl)propionamide
(2R)-3-(Tetrahydropyran-4-yl)-2-(4-methanesulfonylphenyl)-N-thiazol-2- ylpropionamide;
(2R)-2-(4-Cyclopropanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3- (tefrahydropyran-4-yl)propionamide;
(2R)-N-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3- (tetrahydropyran-4-yl)propionamide;
(2R)-N-(5-Fluorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3- (tetrahydropyran-4-yl)propionamide;
(2R)-2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydiOpyran-4-yl)-N- [ 1 ,2,4]thiadiazol-5-ylpropionamide;
(2R)-2-(4-Cyclopropanesulfonylphenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4- yl)propionamide;
(2R)-N-(5-Fluoropyridin-2-yl)-2-(4-methanesulfonylphenyl)-3- (tetrahydropyran-4-yl)propionamide;
(2R)-2-(4-Cyclopropanesulfonylphenyl)-N-(5-fluoropyridin-2-yl)-3- (tetrahyάjOpyran-4-yl)propionamide;
(2R)-2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide; (2R)-2-(4-Cyclopropanesulfonylphenyl)-N-(3-methyl-[l,2,4]thiadiazol-5-yl)- 3 -(tefrahydropyran-4-yl)proρionamide;
(2R)-2-(4-Cyclobutanesulfonylphenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4- yl)propionamide;
(2R)-2-(4-Cyclobutanesulfonylphenyl)-N-pyrimidin-4-yl-3-(tetrahydropyran- 4-yl)propionamide;
(2R)-2-(4-Cyclobutanesulfonylphenyl)-N-isoxazol-3-yl-3-(tetrahydropyran-4- yl)propionamide;
(2R)-2-(4-Cyclobutanesulfonylphenyl)-N-(l-methyl-lH-pyrazol-3-yl)-3- (tetrahydropyran-4-yl)propionamide;
(2R)-2-(4-Cyclobutanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3- (tetrahydropyran-4-yl)propionamide;
(2R)-2-(4-Ethylsulfamoylphenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-yl)- propionamide;
(2R)-2-(4-Ethylsulfamoylphenyl)-N-pyrimidin-4-yl-3-(tetrahydropyran-4-yl)- propionamide;
(2R)-2-(4-Ethylsulfamoylphenyl)-N-pyridin-2-yl-3-(tetrahydropyran-4-yl)- propionamide;
(2R)-2-(4-Ethylsulfamoylphenyl)-N-(l-methyl-lH-pyrazol-3-yl)-3- (tetrahydropyran-4-yl)propionamide;
(2R)-2-(4-Ethylsulfamoylphenyl)-N-(3-methyl-[l,2,4]thiadiazol-5-yl)-3- (tetrahydropyran-4-yl)propionamide;
(2R)-2-(4-Ethylsulfamoylphenyl)-N-(6-methoxypyrimidin-4-yl)-3- (tetrahydropyran-4-yl)propionamide;
(E)-2-(4-Cyclopropanesulfonylphenyl)-N-(5-fluoropyridin-2-yl)-3- (tefrahydropyran-4-yl)acrylamide;
(E)-2-(4-Cyclopropanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3- (tetrahydropyran-4-yl)acrylamide;
2-(3-Fluoro-4-methanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3- (tetrahydropyran-4-yl)propionamide;
(E)-N-(5-Fluorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3- (tetrahydropyran-4-yl)acrylamide;
(E)-2-(4-Εthanesulfonylphenyl)-N-pyrimidin-4-yl-3-(tefrahydroρyran-4- yl)acrylamide; (E)-2-(4-Ethanesulfonylphenyl)-N-isoxazol-3-yl-3-(tefrahydroρyran-4- yl)acrylamide;
(E)-N-(5-Fluorothiazol-2-yl)-2-[4-(propane-l-sulfonyl)phenyl]-3- (tetrahydroρyran-4-yl)acrylamide;
(E)-2-[4-(Troρane-l-sulfonyl)ρhenyl]-N-pyrimidin-4-yl-3-(tetrahydropyran-4- yl)acrylamide;
(E)-N-(3-Methyl-[l,2,4]thiadiazol-5-yl)-2-[4-(propane-l-sulfonyl)phenyl]-3- (tetrahydropyran-4-yl)acrylamide;
(E)-N-( 1 -Methyl- lH-ρyrazol-3 -yl)-2-[4-(ρropane- 1 -sulfonyl)phenyl] -3- (tetrahydropyran-4-yl)acrylamide;
(E)-2-Phenyl-3-(tefrahydropyran-4-yl)-N-thiazol-2-ylacrylamide;
(E)-2-(4-Formylphenyl)-N-(5-foπnyltlιiazol-2-yl)-3-(tetrahydropyran-4- yl)acrylamide;
(E)-N-(5-Formylthiazol-2-yl)-2-phenyl-3-(tetrahydropyran-4-yl)acrylamide;
2-[2-(4-Methanesulfonylphenyl)-3-(tefrahydroρyran-4- yl)propionylamino]thiazole-5-carboxylic acid;
2-[2-(4-Methanesulfonylphenyl)-3-(tetrahydropyran-4- yl)propionylamino]thiazole-5-carboxylic acid methoxy-methyl-amide;
2-[2-(4-Methanesulfonylphenyl)-3-(tefrahydropyran-4- yl)propionylamino]thiazole-5-carboxylic acid methylamide;
(E)-2-[2-(4-Methanesulfonylphenyl)-3-(tetrahydropyran-4- yl)acryloylamino]thiazole-5-carboxylic acid methylamide;
N-(5-Fomiyltliiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4- yl)propionamide;
N-(5-Ηydroxymethylthiazol-2-yl)-2-(4-methanesulfonylphenyl)-3- (tetrahydropyran-4-yl)ρropionamide;
N-(5-Cyanothiazol-2-yl)-2-(4-cyclopropanesulfonylphenyl)-3- (tefrahydropyran-4-yl)ρropionamide;
N-(5-Cyanothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4- yl)propionamide;
Methyl {2-[2-(4-methanesulfonylphenyl)-3-(tefrahydropyran-4- yl)propionylamino] -thiazol-5-yhnethyl} carbamate;
(E)-3-(l-Formylpiperidin-4-yl)-2-(4-methanesulfonylphenyl)-N-thiazol-2- ylacrylamide; (E)-2-(4-Methanesulfonylphenyl)-3-(l-oxohexahydro-lλ4-thiopyran-4-yl)-N- thiazol-2-ylacrylamide;
(E)-3-( 1 , 1 -Dioxohexahydro- 1 λ6-thiopyran-4-yl)-2-(4- methanesulfonylphenyl)-N-thiazol-2-ylacrylamide;
(E)-N-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylρhenyl)-3-(l- oxohexahydro- 1 λ4-thiopyran-4-yl)acrylamide;
(E)-N-(5-Chlorothiazol-2-yl)-3-(l,l-dioxohexahydro-lλ6-thiopyran-4-yl)-2- (4-methanesulfonylphenyl)acrylamide;
2-(3-Fluoro-4-methanesulfinylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-(3-Fluoro-4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
N-(5-Bromothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4- yl)propionamide;
(E)-2-(4-Hycfroxyphenyl)-3-(tetralιydropyran-4-yl)-N-thiazol-2-ylacrylamide;
(E)-2-(4-Methanesulfonylaminophenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylacrylamide;
3-(Tefrahydropyran-4-yl)-2-[4-(tetrahydropyran-4-ylmethylsulfanyl)phenyl]- N-thiazol-2-ylpropionamide;
2-[4-(Pyridin-3-ylsulfanyl)phenyl]-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
3-(Tetrahydropyran-4-yl)-2-[4-(tefrahydropyran-4-ylmethanesulfonyl)phenyl]- N-thiazol-2-ylpropionamide;
2-(4-Methoxymethanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-[4-(Tefrahydropyran-4-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-N-thiazol- 2-ylpropionamide;
2-[4-(Pyridine-3-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-(3-Methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-(4-Cyclopropylmetfranesulfonylphenyl)-3-(tefrahydropyran-4-yl)-N-thiazol- 2-ylpropionamide; 2-[4-(Pyridin-3-ylmethanesulfonyl)phenyl]-3-(tefrahydropyran-4-yl)-N- thiazol-2-ylpropionamide;
2-[4-(Propane-l-sulfonyl)phenyl]-3-(tefrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-(4-Ethanesulfonylphenyl)-3-(tefrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-(4-Cyanomethanesulfonylphenyl)-3-(tefrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-[4-([l,2,4]Oxadiazol-3-ylmethanesulfonyl)phenyl]-3-(tetrahydropyran-4-yl)- N-thiazol-2-ylpropionamide;
2-[4-([l,3]Dioxolan-2-ylmethanesulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-N- thiazol-2-ylpropionamide;
2-[4-(Propane-2-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-[4-(Oxetane-3-sulfonyl)phenyl]-3-(tefrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-[4-((3S)-Tefrahydrofuran-3-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-N- thiazol-2-ylpropionamide;
2-[4-((3R)-Tefrahydrofuran-3-sulfonyl)phenyl]-3-(tefrahydropyran-4-yl)-N- thiazol-2-ylpropionamide;
2-(4-Cyclobutanesulfonylphenyl)-3-(tetraliydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-[4-(2-Oxopropane- 1 -sulfonyl)phenyl] -3 -(tefrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-[4-(Pyridine-2-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-[4-(Pyridine-2-sulfinyl)phenyl]-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-[4-( yrazine-2-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-[4-(Pyrazine-2-sulfinyl)phenyl]-3-(tefrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-[4-(Pyrimidine-5-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide; 2-(3-Amino-4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-(3-Chloro-4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-[4-(Morpholine-4-sulfonyl)phenyl]-3-(tefrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-(4-Sulfamoylphenyl)-3-(tefrahydropyran-4-yl)-N-thiazol-2-ylpropionamide;
2-(4-Methylsulfamoylphenyl)-3-(tetrahydroρyran-4-yl)-N-thiazol-2- ylpropionamide;
2-(4-Dimethylsulfamoylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-[4-(4-Methylpiperazine-l-sulfonyl)phenyl]-3-(tefrahydropyran-4-yl)-N- thiazol-2-ylpropionamide;
2-{4-[(Pyridin-2-ylmethyl)sulfamoyl]phenyl}-3-(tetrahydropyran-4-yl)-N- thiazol-2-ylpropionamide;
2-{4-[(Pyridin-3-ylmethyl)sulfamoyl]phenyl}-3-(tetrahydropyran-4-yl)-N- thiazol-2-ylpropionamide;
3 -(Tetrahydropyran-4-yl)-2- {4- [(tetrahydrop yran-4- ylmethyl)sulfamoyl]phenyl}-N-thiazol-2-ylpropionamide;
2-{4-[(Tetrahydrofuran-2-ylmethyl)sulfamoyl]phenyl}-3-(tetrahydropyran-4- yl)-N-thiazol-2-ylpropionamide;
3-(Tefrahydropyran-4-yl)-N-thiazol-2-yl-2-[4-(thiomorpholine-4- sulfonyl)phenyl]propionamide;
2-[4-(Azetidine-l-sulfonyl)phenyl]-3-(tefrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-[4-([l,4]Oxazepane-4-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-N-thiazol- 2-ylpropionamide;
2-(4-Cyclopropylsulfamoylphenyl)-3-(tefrahydropyran-4-yl)-N-tliiazol-2- ylpropionamide;
2-[4-(Cyclopropylmethylsulfamoyl)phenyl]-3-(tefrahydropyran-4-yl)-N- thiazol-2-ylpropionamide;
3-(Tetrahydropyran-4-yl)-N-thiazol-2-yl-2-{4-[(thiophen-2- ylmethyl)sulfamoyl]phenyl}propionamide; 2-[4-((lS,4S)-2-Oxa-5-azabicyclo[2.2.1]heptane-5-sulfonyl)phenyl]-3- (tetrahydropyran-4-yl)-N-thiazol-2-ylpropionamide;
2-(4-Ethylsulfamoylphenyl)-3-(tefrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-[4-(4-Methyl-[l,4]diazepane-l-sulfonyl)phenyl]-3-(tefrahydropyran-4-yl)- N-thiazol-2-ylpropionamide;
2-[4-((2R)-2-Methoxymethylpyπolidine-l-sulfonyl)phenyl]-3- (tetrahydropyran-4-yl)-N-thiazol-2-ylpropionamide;
3-(Tefrahydropyran-4-yl)-2-[4-(tefrahydroρyran-4-ylsulfamoyl)phenyl]-N- thiazol-2-ylpropionamide;
2-[4-(Imidazole-l-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
N-(5-Chlorothiazol-2-yl)-2-[4-(2-dimethylaminoethylsulfamoyl)phenyl]-3- (tetrahydropyran-4-yl)propionamide;
N-(5-Chlorothiazol-2-yl)-2-[4-(3-hydroxyazetidine-l-sulfonyl)phenyl]-3- (tetrahydropyran-4-yl)ρropionamide;
N-(5-Chlorothiazol-2-yl)-2-[4-((3S)-3 -hydroxypyπolidine- 1 -sulfonyl)phenyl] - 3-(tetrahydropyran-4-yl)propionamide;
N-(5-Chlorothiazol-2-yl)-2-[4-(4-methylpiperazine- 1 -sulfonyl)phenyl] -3 - (tefrahydropyran-4-yl)propionamide;
N-(5-Chlorothiazol-2-yl)-2-[4-(piperazine-l-sulfonyl)phenyl]-3- (tefrahydropyran-4-yl)propionamide;
N-(5-Chlorothiazol-2-yl)-2-[4-(2-methylaminoethylsulfamoyl)phenyl]-3- (tetrahydropyran-4-yl)propionamide;
2-[4-(2-Aminoethylsulfamoyl)phenyl]-N-(5-chlorothiazol-2-yl)-3- (tetrahydroρyran-4-yl)propionamide;
N-Ethyl-4-[2-(tetrahydropyran-4-yl)- 1 -(thiazol-2- ylcarbamoyl)ethyl]benzamide;
2-(3 -Chloro-4-methanesulfonylphenyl)-N-(5 -fluorothiazol-2-yl)-3 - (tefrahydropyran-4-yl)ρropionamide;
2-(4-Methanesulfonyl-3-trifluoromethylphenyl)-N-(5-fluoiOthiazol-2-yl)-3- (tefrahydropyran-4-yl)propionamide; and
2-(3,4-Dichlorophenyl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4- yl)propionamide; or a pharmaceutically acceptable salt thereof.
17. A compound selected from:
(E)-2-(4-Methanesulfonylphenyl)-N-thiazol-2-yl-3-thiophen-2-ylacrylamide; (E)-3-Furan-2-yl-2-(4-methanesulfonylphenyl)-N-thiazol-2-ylacrylamide; 2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-(4-Cyclopropanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3- (tetrahydropyran-4-yl)propionamide;
(E)-3 -(Tefrahydropyran-4-yl)-N-thiazol-2-yl-2-(4-[ 1 ,2,4]triazol- 1 - ylphenyl)acrylamide;
(E)-3-(Tefrahydrothiopyran-4-yl)-N-thiazol-2-yl-2-(4-[l,2,4]triazol-l- ylphenyl)acrylamide;
(E)-3-(Tefrahydropyran-4-yl)-N-thiazol-2-yl-2-(4-[l,2,3]triazol-l- ylphenyl)acrylamide;
N-Benzothiazol-2-yl-2-(4-methanesulfonylphenyl)-3-(tefrahydropyran-4- yl)propionamide;
2-(4-Cyclopropanesulfonylphenyl)-N-(3-methyl-[l,2,4]thiadiazol-5-yl)-3- (tefrahydropyran-4-yl)propionamide;
2-(4-Cyclopropanesulfonylphenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4- yl)propionamide;
2-(4-Cyclopropanesulfonylphenyl)-3-(tefrahydropyran-4-yl)-N- [l,2,4]thiadiazol-5-ylpropionamide;
(E)-2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylacrylamide;
(E)-N-(5-Chloro-4-methylthiazol-2-yl)-2-(4-methanesulfonylphenyl)-3- thiophen-2-ylacrylamide;
(E)-2-(4-Methanesulfonylphenyl)-3-(tefrahydropyran-4-yl)-N-thiazol-2- ylacrylamide;
(E)-N-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3- (tefrahydropyran-4-yl)acrylamide;
(E)-N-(5 -Bromothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3 - (tetrahydropyran-4-yl)acrylamide; (E)-2-(4-Methanesulfonylphenyl)-3-(tefrahydrothiopyran-4-yl)-N-thiazol-2- ylacrylamide;
(E)-N-(5 -Chlorothiazol-2-yl)-2-(4-methanesulfonylρhenyl)-3 - (tetrahydrothiopyran-4-yl)acrylamide;
(E)-N-(5-Chlorothiazol-2-yl)-2-(4-methanesulfinylphenyl)-3- (tetrahydrothiopyran-4-yl)acrylamide;
2-(4-Methoxymethylsulfanylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
(E)-2-(4-Νitrophenyl)-3-(tefrahydropyran-4-yl)-N-thiazol-2-ylacrylamide;
(E)-N-(5-Chlorothiazol-2-yl)-2-(4-nitrophenyl)-3-(tefrahydropyran-4- yl)acrylamide;
(E)-2-(4-Methylsulfanylphenyl)-3-(tetraliydropyran-4-yl)-N-thiazol-2- ylacrylamide;
(E)-N-(5-Chlorothiazol-2-yl)-2-(4-methylsulfanylphenyl)-3-(tetrahydropyran- 4-yl)acrylamide;
(E)-N-(5-Chlorothiazol-2-yl)-2-(4-cyclopropanesulfinylphenyl)-3- (tetrahydropyran-4-yl)acrylamide;
(E)-2-(4-Cyclopropanesulfinylphenyl)-3-(tefrahydropyran-4-yl)-N-thiazol-2- ylacrylamide;
(2R)-2-(4-Cyclopropanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3- (tetrahydropyran-4-yl)propionamide;
(2R)-2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-N- [ 1 ,2,4]thiadiazol-5-ylpropionamide;
(2R)-2-(4-Cyclopropanesulfonylphenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4- yl)propionamide;
(2R)-2-(4-Cyclopropanesulfonylphenyl)-N-(5-fluoropyridin-2-yl)-3- (tetrahydropyran-4-yl)propionamide;
(2R)-2-(4-Cyclopropanesulfonylphenyl)-3-(tetralιydropyran-4-yl)-N-thiazol-2- ylpropionamide;
(2R)-2-(4-Cyclopropanesulfonylphenyl)-N-(3-methyl-[l,2,4]thiadiazol-5-yl)- 3 -(tetrahydropyran-4-yl)propionamide;
(2R)-2-(4-Cyclobutanesulfonylphenyl)-N-pyrazin-2-yl-3-(tefrahydropyran-4- yl)propionamide; (2R)-2-(4-Cyclobutanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3- (tetrahydropyran-4-yl)propionamide;
(E)-2-(4-Cyclopropanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3- (tefrahydropyran-4-yl)acrylamide;
(E)-N-(5-Fluorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3- (tetrahydropyran-4-yl)acrylamide;
(E)-2-(4-Methanesulfonylaminophenyl)-3-(tefrahydropyran-4-yl)-N-thiazol-2- ylacrylamide;
2-[4-(Pyridin-3-ylsulfanyl)phenyl]-3-(tefraliydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-(4-Methoxymethanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-[4-(Tefrahy<fropyran-4-sulfonyl)phenyl]-3-(tefrahyoh-opyraιι-4-yl)-N-thiazol- 2-ylpropionamide;
2-[4-(Pyridine-3-sulfonyl)phenyl]-3-(tefralιydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-(4-Cyclopropylmethanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol- 2-ylpropionamide;
2-[4-([l,2,4]Oxadiazol-3-ylmethanesulfonyl)phenyl]-3-(tefrahydropyran-4-yl)- N-thiazol-2-ylpropionamide;
2-[4-([l,3]Dioxolan-2-ylmethanesulfonyl)phenyl]-3-(tefrahydropyran-4-yl)-N- thiazol-2-ylpropionamide;
2-[4-(Oxetane-3-sulfonyl)phenyl]-3-(tefrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-[4-((3S)-Tetrahydrofuran-3-sulfonyl)phenyl]-3-(tefralιydropyran-4-yl)-N- thiazol-2-ylpropionamide;
2-[4-((3R)-Tetrahydrofuran-3-sulfonyl)phenyl]-3-(tefrahydropyran-4-yl)-N- thiazol-2-ylpropionamide;
2-(4-Cyclobutanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-[4-(2-Oxopropane-l-sulfonyl)phenyl]-3-(tefrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-(4-Methylsulfamoylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide; 2-(4-Dimethylsulfamoylphenyl)-3-(tefrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-[4-(4-Methylpiperazine-l-sulfonyl)phenyl]-3-(tefrahydropyran-4-yl)-N- thiazol-2-ylpropionamide;
2-{4-[(Pyridin-2-ylmethyl)sulfamoyl]phenyl}-3-(tetrahydropyran-4-yl)-N- thiazol-2-ylpropionamide;
2-{4-[(Pyridin-3-ylmethyl)sulfamoyl]phenyl}-3-(tefrahydropyran-4-yl)-N- thiazol-2-ylpropionamide;
2-[4-(Azetidine-l-sulfonyl)phenyl]-3-(tefrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-(4-Cyclopropylsulfamoylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-[4-(Cyclopropylmethylsulfamoyl)phenyl]-3-(tetrahydropyran-4-yl)-N- thiazol-2-ylpropionamide;
3-(Tetrahydropyran-4-yl)-N-thiazol-2-yl-2-{4-[(thiophen-2- ylmethyl)sulfamoyl]phenyl}propionamide;
2-[4-((lS,4S)-2-Oxa-5-azabicyclo[2.2.1]heptane-5-sulfonyl)phenyl]-3- (tetrahydropyran-4-yl)-N-thiazol-2-ylpropionamide;
2-(4-Ethylsulfamoylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
2-[4-(4-Methyl-[l,4]diazepane-l-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)- N-thiazol-2-ylpropionamide;
2-[4-(hnidazole-l-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-N-thiazol-2- ylpropionamide;
N-(5-Chlorothiazol-2-yl)-2-[4-(2-dimethylaminoethylsulfamoyl)phenyl]-3- (tefrahydropyran-4-yl)propionamide; and
N-(5-Chlorothiazol-2-yl)-2-[4-(piperazine-l-sulfonyl)phenyl]-3- (tefrahydropyran-4-yl)propionamide; or a phannaceutically acceptable salt thereof.
18. A compound selected from:
(2R)-2-(4-Cyclobutanesulfonylphenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4- yl)propionamide; and (2R)-2-(4-Cyclobutanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3- (tetrahydropyran-4-yl)propionamide; or a pharmaceutically acceptable salt thereof.
19. (2R)-2-(4-Cyclopropanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3- (tetrahydropyran-4-yl)propionamide, or a pharmaceutically acceptable salt thereof.
20. (2R)-2-(4-Cyclopropanesulfonylphenyl)-N-pyrazin-2-yl-3- (tetrahydropyran-4-yl)propionamide, or a pharmaceutically acceptable salt thereof.
21. (E)-N-(5-Fluorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3- (tetrahydropyran-4-yl)acrylamide, or a pharmaceutically acceptable salt thereof.
22. A compound of Formula (I):
Figure imgf000115_0001
(I) or a pharmaceutically acceptable salt thereof, wherein: Q is 4-tetrahydropyranyl;
T together with the -Ν=C- to which it is attached forms a 2-pyrazinyl or 2- thiazolyl ring;
R1 and R2 are hydrogen;
R3 and R4 each independently are hydrogen or fluoro;
R3 is SO2R8, or SO2NR 9yRr 1ι0υ;. R6 is hydrogen; R8 is a C3-5cycloalkyl group or a 4-6-membered heterocyclic group, and, in addition, when the dotted line together with the solid line forms a double bond R8 may be a C1-3alkyl group;
R9 and R10 are independently Cα^alkyl, provided that R9 and R10 are not both hydrogen; m is 0; and the dotted line together with the solid line forms an optional double bond, and Δ indicates that the double bond has the (E)-configuration.
23. A compound of Formula (I):
Figure imgf000116_0001
(I) or a pharmaceutically acceptable salt thereof, wherein:
Q is 4-tetrahydropyranyl;
T together with the -N=C- to which it is attached forms a 2-pyrazinyl or 2- thiazolyl ring;
R and R are hydrogen;
R3 and R4 each independently are hydrogen or fluoro;
R5 is SO2R8;
R6 is hydrogen;
R is a C3-4cycloalkyl group and, in addition, when the dotted line together with the solid line forms a double bond R8 may be a C1-3alkyl group; m is 0; and the dotted line together with the solid line forms an optional double bond, and A indicates that the double bond has the (E)-configuration.
24. A pharmaceutical composition comprising a compound according to any of claims 1 to 23, or a pharmaceutically acceptable salt thereof, and a phannaceutically acceptable caπier.
25. A method of prophylactic or therapeutic freatment of a condition where activation of GK is desirable comprising a step of administering an effective amount of a compound according to any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof.
26. A method of prophylactic or therapeutic freatment of hyperglycemia or diabetes comprising a step of administering an effective amount of a compound according to any of claims 1 to 23, or a phannaceutically acceptable salt thereof.
27. The method according to claim 26 wherein the compound according to any one of claims 1 to 23 is admimstered in combination with one or more other anti- hyperglycemic agents or anti-diabetic agents.
28. A method of prevention of diabetes in a human demonstrating pre- diabetic hyperglycemia or impaired glucose tolerance comprising a step of administering an effective prophylactic amount of a compound according to any of claims 1 to 23, or a phannaceutically acceptable salt thereof.
29. A process for the preparation of a compound of Formula (la)
Figure imgf000117_0001
(la) said process comprising a step ofthe condensation of a compomid of Formula (TV):
Figure imgf000118_0001
with a compound of Formula (V):
Figure imgf000118_0002
V wherein Q, T, R ,ι to R , m and Δ are as defined in claim 1.
30. A process for the preparation of a compound of Formula (lb)
Figure imgf000118_0003
(lb) said process comprising a step ofthe condensation of a compound of Formula (VIII):
Figure imgf000119_0001
with a compound of Foπnula (V):
Figure imgf000119_0002
V wherein Q, T, R ,1 t.o τ Rι6 and m are as defined in claim 1.
31. A compound of formula (IV) :
Figure imgf000119_0003
wherein Q is 4-tefrahydropyranyl;
R1 and R2 are hydrogen;
R3 is SO2Rδ, or SO2NR 9yπRl0. R6 is hydrogen; is a C1-3alkyl group, a C3-5cycloalkyl group or a 4-6-membered heterocyclic group;
R9 and R10 are independently Co-^alkyl, provided that R9 and R10 are not both hydrogen; m is 0; and
Δ indicates that the double bond has the (E)-configuration.
32. A compound of Fonnula (IV) selected from:
(E)-2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydroρyran-4-yl)acrylic acid; (E)-2-(4-Cyclopropanesulfinylphenyl)-3-(tetrahydropyran-4-yl)acrylic acid; (E)-2-(4-Methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylic acid; (E)-2-(4-Εthanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylic acid; and (E)-2-[4-(Propane-l-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)acrylic acid.
33. A compound of formula ( VIII) :
Figure imgf000120_0001
Q is 4-tetrahydropyranyl;
R and R are hydrogen;
R5 is SO2R8, or SO2NR9R10;
R6 is hydrogen;
R is a C -5cycloalkyl group or a 4-6-membered heterocyclic group;
R and R .10 are independently Co-4alkyl, provided that R and R 10 are not both hydrogen; and m is 0.
34. A compound of Formula (VIII) selected from:
2-(4-Cyclopropanesulfonylρhenyl)-3-(tetrahydropyran-4-yl)-propionic acid;
2-(4-Methoxymethanesulfanylphenyl)-3-(tefrahydropyran-4-yl)-propionic acid;
2-(4-Ethylsulfamoylphenyl)-3 -(tefrahydropyran-4-yl)propionic acid;
2-(4-Cyclobutanesulfonylphenyl)-3-(tetrahydroρyran-4-yl)propionic acid;
(2R)-2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionic acid;
(2R)-2-(4-Ethylsulfainoylphenyl)-3-(tefrahydropyran-4-yl)propionic acid; and (2R)-2-(4-Cyclobutanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionic acid.
35. 5-Fluorothiazol-2-ylamine or an amide or acid addition salt thereof.
PCT/US2004/003968 2003-02-11 2004-02-10 Phenylacetamides and their use as glucokinase modulators WO2004072031A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
AU2004212500A AU2004212500B2 (en) 2003-02-11 2004-02-10 Phenylacetamides and their use as glucokinase modulators
SI200430768T SI1594867T1 (en) 2003-02-11 2004-02-10 Phenylacetamides and their use as glucokinase modulators
NZ541759A NZ541759A (en) 2003-02-11 2004-02-10 Phenylacetamides and their use as glucokinase modulators
JP2006503482A JP4757188B2 (en) 2003-02-11 2004-02-10 Tri (cyclo) substituted amide compounds
DK04707845T DK1594867T3 (en) 2003-02-11 2004-02-10 Phenylacetamides and their use as glucokinase modulators
KR1020057014855A KR101120916B1 (en) 2003-02-11 2004-02-10 Phenylacetamides and their use as glucokinase modulators
EP04707845A EP1594867B1 (en) 2003-02-11 2004-02-10 Phenylacetamides and their use as glucokinase modulators
CA002515670A CA2515670A1 (en) 2003-02-11 2004-02-10 Phenylacetamides and their use as glucokinase modulators
DE602004012969T DE602004012969T2 (en) 2003-02-11 2004-02-10 PHENYLACETAMIDES AND THEIR USE AS GLUCOCINASE MODULATORS
CN200480009651.1A CN1809561B (en) 2003-02-11 2004-02-10 Phenylacetamides and their use as glucokinase modulators
MXPA05008406A MXPA05008406A (en) 2003-02-11 2004-02-10 Phenylacetamides and their use as glucokinase modulators.
BR0407139-5A BRPI0407139A (en) 2003-02-11 2004-02-10 Tri (Cycle) Replaced Amide Compounds
EA200501095A EA012700B1 (en) 2003-02-11 2004-02-10 Phenylacetamides and their use as glucokinase modulators
IL169954A IL169954A (en) 2003-02-11 2005-07-28 Tricyclo substituted amide compounds, process for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for the treatment of a condition where activation of gk is desirable
HR20050687A HRP20050687A2 (en) 2003-02-11 2005-08-01 Tri(ciclo) substituted amide compounds
NO20053742A NO20053742L (en) 2003-02-11 2005-08-04 Tri (cyclo) -substituted amide compounds

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US44668303P 2003-02-11 2003-02-11
US60/446,683 2003-02-11
US49443403P 2003-08-11 2003-08-11
US60/494,434 2003-08-11
US51280003P 2003-10-20 2003-10-20
US60/512,800 2003-10-20

Publications (3)

Publication Number Publication Date
WO2004072031A2 true WO2004072031A2 (en) 2004-08-26
WO2004072031A3 WO2004072031A3 (en) 2004-12-02
WO2004072031A8 WO2004072031A8 (en) 2005-10-06

Family

ID=32872762

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/003968 WO2004072031A2 (en) 2003-02-11 2004-02-10 Phenylacetamides and their use as glucokinase modulators

Country Status (26)

Country Link
US (2) US7214681B2 (en)
EP (2) EP2168962A3 (en)
JP (1) JP4757188B2 (en)
KR (1) KR101120916B1 (en)
AR (1) AR043157A1 (en)
AT (1) ATE391718T1 (en)
AU (1) AU2004212500B2 (en)
BR (1) BRPI0407139A (en)
CA (1) CA2515670A1 (en)
CY (1) CY1110254T1 (en)
DE (1) DE602004012969T2 (en)
DK (1) DK1594867T3 (en)
EA (1) EA012700B1 (en)
ES (1) ES2303628T3 (en)
HR (1) HRP20050687A2 (en)
IL (1) IL169954A (en)
MA (1) MA27708A1 (en)
MX (1) MXPA05008406A (en)
MY (1) MY145590A (en)
NO (1) NO20053742L (en)
NZ (1) NZ541759A (en)
PL (1) PL378117A1 (en)
PT (1) PT1594867E (en)
SI (1) SI1594867T1 (en)
TW (1) TWI314553B (en)
WO (1) WO2004072031A2 (en)

Cited By (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1549626A1 (en) * 2002-10-03 2005-07-06 Novartis AG Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
WO2005095417A1 (en) * 2004-04-02 2005-10-13 Novartis Ag Thiazolopyridine derivates, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
WO2005103021A1 (en) * 2004-04-21 2005-11-03 Prosidion Limited Tri(cyclo) substituted amide compounds
WO2006016178A1 (en) * 2004-08-12 2006-02-16 Prosidion Limited Enantioselective process
WO2006016174A1 (en) * 2004-08-12 2006-02-16 Prosidion Limited Fluorination process of protected aminothiazole
US7199140B2 (en) 2001-06-26 2007-04-03 Astrazeneca Ab Vinyl phenyl derivatives as GLK activators
WO2007041366A1 (en) 2005-09-30 2007-04-12 Novartis Ag Sulfonamide derivatives as glycokinase activators useful in the treatment of type 2 diabetes
WO2007039177A2 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
WO2007051847A1 (en) * 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides as glucokinase modulators
WO2007051846A1 (en) * 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
WO2007051845A1 (en) * 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
WO2007061923A2 (en) * 2005-11-18 2007-05-31 Takeda San Diego, Inc. Glucokinase activators
US7230108B2 (en) 2002-11-19 2007-06-12 Astrazeneca Ab Quinoline derivatives as glucokinase ligands
WO2007041365A3 (en) * 2005-09-30 2007-06-21 Novartis Ag 3-cyclyl-2- (4-sulfamo yl-phenyl) -n-cyclyl-propionamide derivatives useful in the treatment of impaired glucose tolerance and diabetes
WO2007089512A1 (en) * 2006-01-27 2007-08-09 Array Biopharma Inc. Glucokinase activators
WO2007128761A2 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Uses of dpp-iv inhibitors
WO2008005914A2 (en) * 2006-07-06 2008-01-10 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
WO2008017381A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
WO2008043492A1 (en) * 2006-10-09 2008-04-17 Clariant Finance (Bvi) Limited Method for producing alkaline (meth)acrylamides
WO2008012227A3 (en) * 2006-07-24 2008-05-15 Hoffmann La Roche Pyrazoles as glucokinase activators
WO2008078674A1 (en) 2006-12-25 2008-07-03 Kyorin Pharmaceutical Co., Ltd. Glucokinase-activating substance
DE102007005045A1 (en) 2007-01-26 2008-08-07 Sanofi-Aventis New phenothiazine derivative for use in preparing medicine for blood sugar lowering and for treatment of diabetes, nicotine dependence, alcohol dependence, central nervous system disorders, schizophrenia, and Alzheimer's disease
WO2009021740A2 (en) 2007-08-15 2009-02-19 Sanofis-Aventis Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
WO2009091014A1 (en) 2008-01-18 2009-07-23 Astellas Pharma Inc. Phenyl acetamide derivative
WO2009091634A1 (en) * 2008-01-15 2009-07-23 Eli Lilly And Company Crystalline 2-(4-cyclopropanesulphonyl-phenyl)-n-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide
WO2009127546A1 (en) 2008-04-16 2009-10-22 F. Hoffmann-La Roche Ag Pyrrolidinone glucokinase activators
WO2009133687A1 (en) 2008-04-28 2009-11-05 杏林製薬株式会社 Cyclopentylacrylic acid amide derivative
WO2009139438A1 (en) * 2008-05-15 2009-11-19 田辺三菱製薬株式会社 Process for production of optically active carboxylic acid
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
US7709505B2 (en) 2002-11-19 2010-05-04 Astrazeneca Ab Benzofuran derivatives, process for their preparation and intermediates thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US7750020B2 (en) 2004-04-02 2010-07-06 Novartis Ag Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of Type 2 diabetes
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
EP2308840A1 (en) 2005-06-30 2011-04-13 Prosidion Limited GPCR agonists
WO2011058193A1 (en) 2009-11-16 2011-05-19 Mellitech [1,5]-diazocin derivatives
US8008332B2 (en) 2006-05-31 2011-08-30 Takeda San Diego, Inc. Substituted indazoles as glucokinase activators
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
US8063079B2 (en) 2008-12-19 2011-11-22 Eli Lilly And Company Cyclopropyl compounds
US8067612B2 (en) 2006-10-09 2011-11-29 Clariant Finance (Bvi) Limited Method for producing bisbenzoxazoles
US8067635B2 (en) 2006-10-09 2011-11-29 Clariant Finance (Bvi) Limited Method for producing tertiary amides of alkylphenyl carboxylic acids
WO2011157682A1 (en) 2010-06-17 2011-12-22 F. Hoffmann-La Roche Ag 3-oxo-3,9-dihydro-1h-chromeno[2,3-c]pyrroles as glucokinase activators
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2011161030A1 (en) 2010-06-21 2011-12-29 Sanofi Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators
EP2402327A1 (en) 2010-06-29 2012-01-04 Advinus Therapeutics Private Limited Acetamide compounds as glucokinase activators, their process and medicinal applications
WO2012004269A1 (en) 2010-07-05 2012-01-12 Sanofi (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals
WO2012004270A1 (en) 2010-07-05 2012-01-12 Sanofi Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament
US8101785B2 (en) 2006-10-09 2012-01-24 Clariant Finance (Bvi) Limited Method for producing fatty acid alkanol amides
WO2012010413A1 (en) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament
US8124617B2 (en) 2005-09-01 2012-02-28 Takeda San Diego, Inc. Imidazopyridine compounds
WO2012051450A1 (en) 2010-10-13 2012-04-19 Takeda Pharmaceutical Company Limited Method of making azaindazole derivatives
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
US8222416B2 (en) 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
WO2012120051A1 (en) 2011-03-08 2012-09-13 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
WO2012120050A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120058A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8563730B2 (en) 2008-05-16 2013-10-22 Takeda San Diego, Inc. Pyrazole and fused pyrazole glucokinase activators
WO2014050084A1 (en) 2012-09-26 2014-04-03 興和株式会社 Novel phenylacetamide compound and pharmaceutical containing same

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0514147A (en) * 2004-08-12 2008-05-27 Prosidion Ltd compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, methods of prophylactic or therapeutic treatment of a condition where gk activation is desirable, prophylactic or therapeutic treatment of hyperglycemia or diabetes, and prevention of diabetes in a human demonstrating hyperglycemia. pre-diabetic or impaired glucose tolerance, and process for preparing the compound
US7514439B2 (en) 2005-07-11 2009-04-07 Mitsubishi Tanabe Pharma Corporation Oxime derivative and preparations thereof
EP2105435A4 (en) * 2007-01-10 2011-06-15 Mitsubishi Tanabe Pharma Corp Hydrazone derivative
EP2116533B1 (en) * 2007-03-07 2013-07-10 Kyorin Pharmaceutical Co., Ltd. Glucokinase activator
DE102008017216B4 (en) 2008-04-04 2013-08-14 Clariant International Ltd. Continuous process for the preparation of fatty acid amides
DE102009031059A1 (en) 2009-06-30 2011-01-05 Clariant International Ltd. Apparatus for continuously carrying out chemical reactions at high temperatures
DE102009042523B4 (en) 2009-09-22 2012-02-16 Clariant International Ltd. Apparatus and method for the continuous performance of heterogeneously catalyzed chemical reactions at high temperatures
DE102009042522A1 (en) 2009-09-22 2011-04-07 Clariant International Ltd. Continuous transesterification process
US8877794B2 (en) * 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
DE102010056564A1 (en) 2010-12-30 2012-07-05 Clariant International Limited Hydroxyl groups and ester-bearing polymers and processes for their preparation
DE102010056565A1 (en) 2010-12-30 2012-07-05 Clariant International Ltd. Process for modifying hydroxyl-bearing polymers

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046768A (en) * 1976-06-17 1977-09-06 Velsicol Chemical Corporation 1-Thiazolyl-5-pyridylcarbonyloxyimidazolidinones
WO2001012189A1 (en) * 1999-08-12 2001-02-22 Pharmacia Italia S.P.A. 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
WO2002008209A1 (en) * 2000-07-20 2002-01-31 F. Hoffmann-La Roche Ag Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators
WO2003095438A1 (en) * 2002-04-26 2003-11-20 F. Hoffmann-La Roche Ag Substituted phenylacetamides and their use as glucokinase activators
WO2004063179A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Substituted arylcyclopropylacetamides as glucokinase activators

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US219887A (en) * 1879-09-23 Improvement in wooden printing-types
US320050A (en) * 1885-06-16 Geoege t
PT1169312E (en) * 1999-03-29 2005-01-31 Hoffmann La Roche GLYCOCINASE ACTIVATORS
US6610846B1 (en) * 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
US6353111B1 (en) * 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
CN1176915C (en) * 2000-05-03 2004-11-24 霍夫曼-拉罗奇有限公司 Alkynyl phenyl heteroaromatic glucokinase activators
CA2407428C (en) 2000-05-03 2010-02-02 F. Hoffmann-La Roche Ag Hydantoin-containing glucokinase activators
US6489485B2 (en) * 2000-05-08 2002-12-03 Hoffmann-La Roche Inc. Para-amine substituted phenylamide glucokinase activators
JP3839723B2 (en) * 2000-05-08 2006-11-01 エフ．ホフマン−ラ ロシュ アーゲー Substituted phenylacetamide and its use as a glucokinase activator
WO2001085707A1 (en) * 2000-05-08 2001-11-15 F. Hoffmann-La Roche Ag Para-amine substituted phenylamide glucokinase activators
US6369232B1 (en) * 2000-08-15 2002-04-09 Hoffmann-La Roche Inc. Tetrazolyl-phenyl acetamide glucokinase activators
ES2256340T3 (en) * 2000-12-06 2006-07-16 F. Hoffmann-La Roche Ag FUSIONED HETEROAROMATIC ACTIVATORS OF GLUCOQUINASA.
US6433188B1 (en) * 2000-12-06 2002-08-13 Wendy Lea Corbett Fused heteroaromatic glucokinase activators
US6482951B2 (en) * 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
SE0102299D0 (en) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102300D0 (en) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (en) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
JP2005526702A (en) 2001-12-03 2005-09-08 ノボ　ノルディスク　アクティーゼルスカブ Use of a glucokinase activator for the treatment of type 2 diabetes in combination with a glucagon antagonist
US6911545B2 (en) * 2001-12-19 2005-06-28 Hoffman-La Roche Inc. Crystals of glucokinase and methods of growing them
JP2005518391A (en) 2001-12-21 2005-06-23 ノボ　ノルディスク　アクティーゼルスカブ Amide derivatives as GK activators
EP1496052B1 (en) 2002-03-26 2009-08-05 Banyu Pharmaceutical Co., Ltd. Novel aminobenzamide derivative
AU2003235307A1 (en) 2002-05-16 2003-12-02 Banyu Pharmaceutical Co., Ltd. Crystal of glucokinase protein, and method for drug design using the crystal
MXPA05000130A (en) 2002-06-27 2005-02-17 Novo Nordisk As Aryl carbonyl derivatives as therapeutic agents.
EP1549626A1 (en) 2002-10-03 2005-07-06 Novartis AG Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046768A (en) * 1976-06-17 1977-09-06 Velsicol Chemical Corporation 1-Thiazolyl-5-pyridylcarbonyloxyimidazolidinones
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
WO2001012189A1 (en) * 1999-08-12 2001-02-22 Pharmacia Italia S.P.A. 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
WO2002008209A1 (en) * 2000-07-20 2002-01-31 F. Hoffmann-La Roche Ag Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators
WO2003095438A1 (en) * 2002-04-26 2003-11-20 F. Hoffmann-La Roche Ag Substituted phenylacetamides and their use as glucokinase activators
WO2004063179A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Substituted arylcyclopropylacetamides as glucokinase activators

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 55, no. 8, 17 April 1961 (1961-04-17), Columbus, Ohio, US; SAIKACHI H ET AL: "Syntheses of furan derivatives. XXVII. 2-Phenyl-3-(5-nitro-2-furyl)acrylic acid, 2-phenyl-5-(5-nitro-2-furyl)-2,4- pentadienoic acid, an their amides"column 7380 XP002284123 & YAKUGAKU ZASSHI, vol. 80, 1960, pages 1584-1588, *
DATABASE CAPLUS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002284124 retrieved from STN Database accession no. 1964:4864 & MNDZHOYAN A L ET AL: "Effect of organic acids of pyridyl and thiazolylamides on certain memners of coli-typhosal, staphylococcal, streptococcal groups and on acid-resistant mycobacteria" BIOL. SVOISTVA KHIM. SOEDIN., AKAD. NAUK ARM. SSR, INST. TONKOI ORGAN. KHIM., no. 1, 1962, pages 219-233, *
DATABASE CAPLUS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002284125 retrieved from STN Database accession no. 1958:25545 & MNDZHOYAN A L ET AL: "Amides of the pyridine and thiazole series" IZVEST. AKAD. NAUK ARMYAN. S.S.R., SER. KHIM. NAUK, vol. 10, 1957, pages 143-156, *
DATABASE CHEMCATS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002284126 retrieved from STN Database accession no. 2002:273644 & "Enamine Product Listing (Catalog)" 15 November 2001 (2001-11-15), ENAMINE , KIEV (UKRAINE) *
KASCHERES A ET AL: "Reaction of diphenylcyclopropenone with 2-aminopyridines. Synthetic and mechanistic implications" JOURNAL OF ORGANIC CHEMISTRY, vol. 40, no. 10, 16 May 1975 (1975-05-16), pages 1440-1444, XP002284121 *
KASCHERES A ET AL: "Reaction of diphenylcyclopropenone with 2-aminothiazoles and related compounds" HETEROCYCLES, vol. 22, no. 11, 1984, pages 2529-2540, XP008031620 *

Cited By (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199140B2 (en) 2001-06-26 2007-04-03 Astrazeneca Ab Vinyl phenyl derivatives as GLK activators
US7812167B2 (en) 2002-10-03 2010-10-12 Novartis, Ag Substituted (thiazol-2-yl)-amides or sulfonamides as glucokinase activators useful in the treatment of type 2 diabetes
EP1549626A1 (en) * 2002-10-03 2005-07-06 Novartis AG Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
US7230108B2 (en) 2002-11-19 2007-06-12 Astrazeneca Ab Quinoline derivatives as glucokinase ligands
US7709505B2 (en) 2002-11-19 2010-05-04 Astrazeneca Ab Benzofuran derivatives, process for their preparation and intermediates thereof
US7750020B2 (en) 2004-04-02 2010-07-06 Novartis Ag Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of Type 2 diabetes
JP2007530631A (en) * 2004-04-02 2007-11-01 ノバルティス アクチエンゲゼルシャフト Thiazolopyridine derivatives, pharmaceutical compositions containing the same and methods of treating glucokinase-mediated conditions
WO2005095417A1 (en) * 2004-04-02 2005-10-13 Novartis Ag Thiazolopyridine derivates, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
AU2005229415B2 (en) * 2004-04-02 2009-05-14 Novartis Ag Thiazolopyridine derivatives, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
WO2005103021A1 (en) * 2004-04-21 2005-11-03 Prosidion Limited Tri(cyclo) substituted amide compounds
EA012204B1 (en) * 2004-04-21 2009-08-28 Прозидион Лимитед Tri(cyclo) substituted amide compounds
WO2006016174A1 (en) * 2004-08-12 2006-02-16 Prosidion Limited Fluorination process of protected aminothiazole
WO2006016178A1 (en) * 2004-08-12 2006-02-16 Prosidion Limited Enantioselective process
EP2308840A1 (en) 2005-06-30 2011-04-13 Prosidion Limited GPCR agonists
US8124617B2 (en) 2005-09-01 2012-02-28 Takeda San Diego, Inc. Imidazopyridine compounds
WO2007039177A2 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
AU2006297127B2 (en) * 2005-09-30 2011-09-29 Novartis Ag 3-cyclyl-2- (4-sulfamo yl-phenyl) -n-cyclyl-propionamide derivatives useful in the treatment of impaired glucose tolerance and diabetes
EP2298779A1 (en) * 2005-09-30 2011-03-23 Novartis AG Sulfonamide derivatives as glycokinase activators useful in the treatment of type 2 diabetes
US7795257B2 (en) 2005-09-30 2010-09-14 Novartis Ag Organic compounds
WO2007041366A1 (en) 2005-09-30 2007-04-12 Novartis Ag Sulfonamide derivatives as glycokinase activators useful in the treatment of type 2 diabetes
EP2554540A3 (en) * 2005-09-30 2013-05-22 Novartis AG 3-Cyclyl-2-(4-sulfamoyl-phenyl)-n-cyclyl-propionamide derivatives useful in the treatment of impaired glucose tolerance and diabetes
WO2007041365A3 (en) * 2005-09-30 2007-06-21 Novartis Ag 3-cyclyl-2- (4-sulfamo yl-phenyl) -n-cyclyl-propionamide derivatives useful in the treatment of impaired glucose tolerance and diabetes
US8252931B2 (en) 2005-09-30 2012-08-28 Novartis Ag Thiazolo[5,4-B]pyridine glucokinase activators
JP2009510111A (en) * 2005-09-30 2009-03-12 ノバルティス アクチエンゲゼルシャフト Sulfonamide derivatives as glucokinase activators useful in the treatment of type 2 diabetes
JP2009510110A (en) * 2005-09-30 2009-03-12 ノバルティス アクチエンゲゼルシャフト 3-cyclyl-2- (4-sulfamoyl-phenyl) -N-cyclyl-propionamide derivatives useful for the treatment of impaired glucose tolerance and diabetes
WO2007051846A1 (en) * 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
WO2007051845A1 (en) * 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
WO2007051847A1 (en) * 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides as glucokinase modulators
WO2007061923A3 (en) * 2005-11-18 2007-11-01 Takeda San Diego Inc Glucokinase activators
WO2007061923A2 (en) * 2005-11-18 2007-05-31 Takeda San Diego, Inc. Glucokinase activators
WO2007089512A1 (en) * 2006-01-27 2007-08-09 Array Biopharma Inc. Glucokinase activators
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
EP2351568A2 (en) 2006-05-04 2011-08-03 Boehringer Ingelheim International GmbH Uses of dpp-iv inhibitors
WO2007128761A2 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Uses of dpp-iv inhibitors
US8008332B2 (en) 2006-05-31 2011-08-30 Takeda San Diego, Inc. Substituted indazoles as glucokinase activators
US8394843B2 (en) 2006-05-31 2013-03-12 Takeda California, Inc. Substituted isoindoles as glucokinase activators
WO2008005914A3 (en) * 2006-07-06 2009-04-02 Bristol Myers Squibb Co Novel glucokinase activators and methods of using same
US8153677B2 (en) 2006-07-06 2012-04-10 Bristol-Myers Squibb Company Substituted pyrazolylamide compounds useful as glucokinase activators
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
US7888504B2 (en) 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
US8614332B2 (en) 2006-07-06 2013-12-24 Bristol-Myers Squibb Company Substituted pyrazolylamides useful as glucokinase activators
WO2008005914A2 (en) * 2006-07-06 2008-01-10 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
US7935699B2 (en) 2006-07-24 2011-05-03 Hoffmann-La Roche Inc. Pyrazole glucokinase activators
EP2261216A2 (en) * 2006-07-24 2010-12-15 F. Hoffmann-La Roche AG Pyrazoles as glucokinase activators
WO2008012227A3 (en) * 2006-07-24 2008-05-15 Hoffmann La Roche Pyrazoles as glucokinase activators
JP2009544648A (en) * 2006-07-24 2009-12-17 エフ．ホフマン−ラ ロシュ アーゲー Pyrazoles as glucokinase activators
EP2261216A3 (en) * 2006-07-24 2011-12-14 F. Hoffmann-La Roche AG Pyrazoles as glucokinase activators
WO2008017381A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
US8101785B2 (en) 2006-10-09 2012-01-24 Clariant Finance (Bvi) Limited Method for producing fatty acid alkanol amides
US9039870B2 (en) 2006-10-09 2015-05-26 Clariant Finance (Bvi) Limited Method for producing alkaline (meth)acrylamides
WO2008043492A1 (en) * 2006-10-09 2008-04-17 Clariant Finance (Bvi) Limited Method for producing alkaline (meth)acrylamides
US8067635B2 (en) 2006-10-09 2011-11-29 Clariant Finance (Bvi) Limited Method for producing tertiary amides of alkylphenyl carboxylic acids
US8067612B2 (en) 2006-10-09 2011-11-29 Clariant Finance (Bvi) Limited Method for producing bisbenzoxazoles
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
WO2008078674A1 (en) 2006-12-25 2008-07-03 Kyorin Pharmaceutical Co., Ltd. Glucokinase-activating substance
DE102007005045A1 (en) 2007-01-26 2008-08-07 Sanofi-Aventis New phenothiazine derivative for use in preparing medicine for blood sugar lowering and for treatment of diabetes, nicotine dependence, alcohol dependence, central nervous system disorders, schizophrenia, and Alzheimer's disease
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
WO2009021740A2 (en) 2007-08-15 2009-02-19 Sanofis-Aventis Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
WO2009091634A1 (en) * 2008-01-15 2009-07-23 Eli Lilly And Company Crystalline 2-(4-cyclopropanesulphonyl-phenyl)-n-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide
WO2009091014A1 (en) 2008-01-18 2009-07-23 Astellas Pharma Inc. Phenyl acetamide derivative
EP2236498A1 (en) * 2008-01-18 2010-10-06 Astellas Pharma Inc. Phenyl acetamide derivative
US8329707B2 (en) 2008-01-18 2012-12-11 Astellas Pharma Inc. Substituted pyrazine compounds
EP2236498A4 (en) * 2008-01-18 2012-02-22 Astellas Pharma Inc Phenyl acetamide derivative
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
WO2009127546A1 (en) 2008-04-16 2009-10-22 F. Hoffmann-La Roche Ag Pyrrolidinone glucokinase activators
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
US8946440B2 (en) 2008-04-28 2015-02-03 Kyorin Pharmaceutical Co., Ltd. Cyclopentylacrylamide derivative
US9452977B2 (en) 2008-04-28 2016-09-27 Kyorin Pharmaceutical Co., Ltd. Cyclopentylacrylamide derivative
WO2009133687A1 (en) 2008-04-28 2009-11-05 杏林製薬株式会社 Cyclopentylacrylic acid amide derivative
WO2009139438A1 (en) * 2008-05-15 2009-11-19 田辺三菱製薬株式会社 Process for production of optically active carboxylic acid
US9139598B2 (en) 2008-05-16 2015-09-22 Takeda California, Inc. Glucokinase activators
US8563730B2 (en) 2008-05-16 2013-10-22 Takeda San Diego, Inc. Pyrazole and fused pyrazole glucokinase activators
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8063079B2 (en) 2008-12-19 2011-11-22 Eli Lilly And Company Cyclopropyl compounds
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011058193A1 (en) 2009-11-16 2011-05-19 Mellitech [1,5]-diazocin derivatives
US8765728B2 (en) 2009-11-16 2014-07-01 Mellitech [1,5]-diazocin derivatives
US8222416B2 (en) 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
WO2011157682A1 (en) 2010-06-17 2011-12-22 F. Hoffmann-La Roche Ag 3-oxo-3,9-dihydro-1h-chromeno[2,3-c]pyrroles as glucokinase activators
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2011161030A1 (en) 2010-06-21 2011-12-29 Sanofi Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators
EP2402327A1 (en) 2010-06-29 2012-01-04 Advinus Therapeutics Private Limited Acetamide compounds as glucokinase activators, their process and medicinal applications
WO2012004270A1 (en) 2010-07-05 2012-01-12 Sanofi Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament
WO2012004269A1 (en) 2010-07-05 2012-01-12 Sanofi (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals
WO2012010413A1 (en) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament
WO2012051450A1 (en) 2010-10-13 2012-04-19 Takeda Pharmaceutical Company Limited Method of making azaindazole derivatives
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120051A1 (en) 2011-03-08 2012-09-13 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
WO2012120050A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120058A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2014050084A1 (en) 2012-09-26 2014-04-03 興和株式会社 Novel phenylacetamide compound and pharmaceutical containing same
US9242978B2 (en) 2012-09-26 2016-01-26 Kowa Company, Ltd. Phenylacetamide compound and pharmaceutical containing same
JPWO2014050084A1 (en) * 2012-09-26 2016-08-22 興和株式会社 Novel phenylacetamide compound and pharmaceutical containing the same

Also Published As

Publication number Publication date
EP2168962A2 (en) 2010-03-31
DE602004012969D1 (en) 2008-05-21
MA27708A1 (en) 2006-01-02
JP4757188B2 (en) 2011-08-24
TWI314553B (en) 2009-09-11
DE602004012969T2 (en) 2009-06-18
EP1594867B1 (en) 2008-04-09
TW200505881A (en) 2005-02-16
NO20053742L (en) 2005-08-29
EP2168962A3 (en) 2010-04-07
ATE391718T1 (en) 2008-04-15
JP2006517590A (en) 2006-07-27
CA2515670A1 (en) 2004-08-26
ES2303628T3 (en) 2008-08-16
US20040181067A1 (en) 2004-09-16
US20070281946A1 (en) 2007-12-06
KR101120916B1 (en) 2012-04-12
KR20060058049A (en) 2006-05-29
MXPA05008406A (en) 2006-02-17
MY145590A (en) 2012-02-29
WO2004072031A3 (en) 2004-12-02
EP1594867A2 (en) 2005-11-16
PL378117A1 (en) 2006-03-06
WO2004072031A8 (en) 2005-10-06
CY1110254T1 (en) 2015-01-14
NZ541759A (en) 2009-02-28
PT1594867E (en) 2008-06-03
AU2004212500B2 (en) 2010-06-24
EA200501095A1 (en) 2006-04-28
SI1594867T1 (en) 2008-10-31
HRP20050687A2 (en) 2006-02-28
US7582632B2 (en) 2009-09-01
IL169954A (en) 2010-12-30
BRPI0407139A (en) 2006-02-07
US7214681B2 (en) 2007-05-08
AU2004212500A1 (en) 2004-08-26
EA012700B1 (en) 2009-12-30
DK1594867T3 (en) 2008-07-21
AR043157A1 (en) 2005-07-20

Similar Documents

Publication Publication Date Title
WO2004072031A2 (en) Phenylacetamides and their use as glucokinase modulators
JP2006517590A5 (en)
NZ550567A (en) Tri(cyclo) substituted amide compounds
JP4621198B2 (en) Tri (cyclo) substituted amide glucokinase activating compound
EP1789396A1 (en) Substituted phenylacetamides and their use as glucokinase activators
CN101027295A (en) Chemical compounds and pharmaceutical compositions containing them for the treatment of inflammatory disorders
AU2003292229A1 (en) 5-substituted-pyrazine or pyridine glucokinase activators
CA2720343A1 (en) Heterocyclic derivative and use thereof
EP1921074A1 (en) Thiazole derivative
CN1809561B (en) Phenylacetamides and their use as glucokinase modulators
HUT76482A (en) Novel 5-(3-aryl-prop-2-ynyl)-5-(arylsulfonyl and arylthio)thiazolidine-2,4-diones and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 169954

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 200506130

Country of ref document: ZA

Ref document number: P20050687A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 840/MUMNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200501095

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/008406

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2515670

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004212500

Country of ref document: AU

Ref document number: 541759

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 378117

Country of ref document: PL

Ref document number: 2006503482

Country of ref document: JP

Ref document number: 1020057014855

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2004212500

Country of ref document: AU

Date of ref document: 20040203

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004212500

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004707845

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1200501259

Country of ref document: VN

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 35/2004 UNDER (22) REPLACE "03 FEBRUARY 2004 (03.02.2004)" BY "10 FEBRUARY 2004 (10.02.2004)"

WWE Wipo information: entry into national phase

Ref document number: 20048096511

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2004707845

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0407139

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 1020057014855

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 156/MUMNP/2008

Country of ref document: IN